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Obesity and diabetes are major public health concerns that contribute to 
cardiovascular disease, hypertension, and stroke. It is now widely accepted that chronic 
inflammation is an important element of pathogenic mechanisms linking obesity to 
diabetes. Moreover, clinical and experimental evidence has established the mitogen-
activated protein kinase (MAPK) signaling pathway as a pivotal mediator during 
inflammatory stress in coupling obesity to insulin resistance (IR). While numerous 
studies have examined the upstream kinase activation of MAPKs, few have examined 
mechanisms that dephosphorylate, and thus, deactivate these pathways, potentially 
affording protection against adipose tissue (AT) inflammation and obesity-induced IR. 
Data presented in this dissertation demonstrate that several MAPK-specific dual-
specificity phosphatases (DUSPs) are induced in AT under conditions of genetic and 
diet-induced obesity that is associated with increased inflammation and IR. While AT is 
composed of multiple cell types, evidence suggests an essential role for preadipocytes 
(PAs) and adipocytes (ADs) in the development of AT inflammation and IR. Therefore, 
we further report phenotypic differences in DUSP expression where four of the ten 
MAPK-specific DUSPs are more abundant in PAs compared to ADs while two of the ten 
DUSPs are more abundant in ADs compared to PAs, suggesting a regulatory role for 
these phosphatases that is cell type specific. Moreover, phenotypic differences were 
observed regarding MAPK signaling and DUSP expression in PAs and ADs exposed to 
TNFα-mediated inflammatory stress, where ERK, JNK, and p38 phosphorylation was 
markedly elevated and transient in PAs while ERK and JNK phosphorylation was 
prolonged in ADs concomitant with the phenotypic differences in inducible DUSPs. As 
 
 
induction of DUSPs in PAs kinetically mirrored MAPK dephosphorylation, we further 
show that de novo mRNA synthesis was essential for MAPK dephosphorylation, 
suggesting a role for inducible DUSPs in the modulation of MAPK signaling. Based on 
these data, we present empirical evidence that DUSP knockdown markedly increased 
the magnitude and duration of ERK, JNK, and p38 phosphorylation in response to 
inflammatory stress, subsequently elevating MAPK-dependent pro-inflammatory 
cytokine and chemokine gene expression. Collectively, these findings demonstrate an 
essential role for DUSPs in the timely modulation of MAPK signaling, highlighting 
prospective therapeutic targets linking obesity with metabolic inflammatory diseases. 
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CHAPTER I 
INTRODUCTION 
Significance of Research 
Obesity and diabetes mellitus are major public health concerns that lead to 
cardiovascular disease, hypertension, and stroke. Globally, obesity rates are expected to 
increase from 1.6 billion to 2.3 billion, while deaths due to diabetes are expected to jump 
by over 80% in developed countries between 2006 and 2015. As the prevalence and 
costs of obesity and diabetes rise, improved therapeutic strategies that target these 
diseases will be crucial for future generations. Early evidence established a critical role 
for inflammation in the coupling of obesity to insulin resistance (IR), ultimately 
contributing to diabetes. It has been further determined that the mitogen-activated 
protein kinase (MAPK) signaling pathway plays a central role in linking inflammatory 
stress to obesity-induced IR. Numerous studies have examined the role of upstream 
kinases that phosphorylate and thus activate MAPK signaling, yet a critical gap exists in 
the literature, as few studies have examined mechanisms that dephosphorylate (i.e., 
deactivate) this pathway, potentially providing protection from obesity-induced IR. 
Collectively, the proposed research is significant, as it will advance our understanding of 
how phosphatases can modulate or even control MAPK signaling, establishing a 
platform for the identification of new therapeutic targets for the treatment of obesity-
induced IR. The objective of this dissertation is to determine the mechanistic role of 
MAPK-specific dual-specificity phosphatases (DUSPs) on the timely modulation of 
MAPK dephosphorylation and its biological consequences in adipocytes under 
2 
 
conditions of differentiation and inflammatory stress. The literature relevant to this 
research project is reviewed below.  
 
Review of Literature 
Obesity and Diabetes. The World Health Organization (WHO) Expert 
Consultation on Obesity forewarned the global community in 1997 of the emerging 
overweight and obesity epidemic currently afflicting many nations worldwide. Moreover, 
the expert panel warned that lack of action would result in epidemic increases of many 
non-communicable diseases.  Since that time, global populations have seen a pandemic 
rise of overweight and obesity, with over 1 billion adults (age 15+) overweight and 400 
million obese or having a body mass index (BMI) of 30 kg/m2 or greater (1). Concomitant 
with these statistics, prevalence rates for obese individuals in the United States are 
continually increasing with one in three people classified as obese. More alarming is the 
racial division seen in the United States, where half of African American and Hispanic 
adults are obese (1-6). Correspondingly, the clinical manifestations related to obesity 
(e.g., diabetes and heart disease) have risen, decreasing an individual’s quality of life 
while pushing the health care system to its limits with current medical costs estimated at 
well over $140 billion/year (1,3). 
Similar to obesity, diabetes is a major cause of morbidity and mortality 
contributing to rising health care costs and a poor quality of life. While diabetes mellitus 
consists of a group of chronic metabolic conditions characterized by elevated blood 
glucose levels via the body’s inability to produce or respond to insulin, or both, 90-95% 
of diabetes burden in the United States is due to type 2 diabetes (7-9). Type 2 diabetes 
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generally begins as IR, eventually producing a hyperinsulinemic and hyperglycemic state 
that subsequently leads to pancreatic -cell failure and/or exhaustion, ultimately 
decreasing insulin secretion. It is currently estimated that over 20 million people in the 
United States have diabetes, with 1.5 million new cases of diabetes diagnosed each 
year (7-10). Moreover, it has been estimated that some 12 million people in the United 
States are pre-diabetic (i.e., fasting blood glucose (FBG) of 100-125 mg/dL). These 
individuals have elevated blood glucose levels but do not meet the diagnostic criteria for 
diabetes (i.e., FBG>126 mg/dL). In addition to the sharp rise in diabetes prevalence over 
the last two decades, it is expected that global incidence rates of type 2 diabetes will 
double to 350 million cases by 2030 as the population ages and obesity rates continue 
to climb for adults and children (7-11).  
While the precise link between obesity and its associated type 2 diabetes remain 
poorly understood, evidence supports a casual role for excess fat mass and IR (12-15). 
Increased adiposity in humans and animals highly correlates to decreased insulin 
signaling and the development of diabetes (15-17), whereas fat mass loss reduces type 
2 diabetes and premature mortality rates (18-22). Unfortunately, few individuals (~10%) 
who lose weight keep it off (19,20,23). Therefore, research is clearly needed to delineate 
effective strategies for the treatment and prevention of obesity and associated type 2 
diabetes. However, socioeconomic and molecular complexities in studying obesity and 
diabetes impede these research efforts. Furthermore, while evidence supports a role for 
obesity in the development of diabetes, this association appears highly dependent on 
genetics and/or environment, as many obese subjects do not progress to the diabetic 
state (14,15,18-20,23-26) Nonetheless, research over the past several years has 
implicated adipose tissue (AT) as a central mediator of whole-body glucose homeostasis 
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in normal and diseased states, altering our view of the adipocyte from that of a mere 
storage depot for lipid (23).  
Adipose tissue as an endocrine organ. AT is an innervated connective tissue 
composed of distinct cell types: preadipocytes (PAs), mature adipocytes (ADs), and 
macrophages, among others, that contribute to AT function. Classically, it is understood 
that AT plays an essential role in the storage and release of fatty acids during periods of 
caloric abundance and restriction. In addition, AT provides insulation and padding to the 
body. While the role for AT as an energy source has been known for centuries, the idea 
that it acts in an endocrine manner, to centrally regulate energy expenditure and food 
intake, was not developed until 1953 (27). Since that time, studies involving genetically 
obese (ob/ob) and diabetic (db/db) mice demonstrated that a circulating factor, absence 
in ob/ob and ineffective in db/db mice was involved in obesity, diabetes, hyperphagia, 
and reduced physical activity (28). However, it was not until 1994 that this lipostatic 
signal known as leptin, an adipocyte-specific protein essential for whole-body energy 
homeostasis, was identified and AT recognized as an endocrine organ (29). Not long 
after, studies demonstrated that injection of ob/ob mice with leptin reduced food intake, 
body weight, and fat mass while maintaining lean body mass. In addition, these mice 
had increases in energy expenditure and restored euglycemia, confirming a role for 
leptin as a mediator of energy intake and storage (30,31). 
It is now well established that AT secretes various bioactive peptides or proteins, 
collectively termed ‘adipokines,’ that play a key role in energy metabolism, vascular 
homeostasis, and immunity (Fig.1.1). Moreover, studies demonstrate that most 
adipokines are dysregulated in obesity and type 2 diabetes (17,32). For example, 
circulating levels of the pro-inflammatory cytokine tumor necrosis factor α (TNFα) are 
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elevated in AT of obese individuals (33). In contrast, anti-inflammatory or insulin-
sensitizing adipokines like adiponectin (Fig.1.1) are markedly attenuated with obesity 
(32,34). While the didactic view that some adipokines exhibit beneficial versus 
deleterious effects is an oversimplification of a complex process, it appears that 
dysregulation of adipocyte-derived proteins may play a significant role in the 
pathogenesis of diabetes with increased adiposity. Moreover these early studies led to 
well established understanding that AT is a dynamic endocrine organ, critical for 
regulating metabolism in health and disease. 
Inflammation, obesity, and insulin resistance. The identification that IR 
occurred in response to infections such as sepsis provided some of the first associations 
between IR and the immune response (35,36). Since then, it has been demonstrated 
that many inflammatory diseases such as HIV, hepatitis C, and rheumatoid arthritis 
promote IR (37-39). Treatment with the anti-inflammatory drug salicylate improved 
insulin sensitivity in patients, laying an early foundation that inflammation plays a key 
role in the pathogenesis of diabetes (40,41).  
Around the same time as the discovery of leptin, Hotamisligil et al. (42) provided 
the first molecular link between inflammation and obesity with the observation that the 
inflammatory cytokine TNF is overexpressed in AT of rodent models of obesity. Others 
have since shown that TNF is overexpressed in AT and muscle of obese humans 
(43,44), while circulating levels of TNFα fall after weight loss (45). Subsequently, TNF 
administration in cell culture or to whole animals inhibits insulin action (46-49), while 
ablation of this cytokine or its receptors in obese animals improves insulin sensitivity (50-
53). These studies clearly illustrate the importance of TNF as a master ‘adipo-cytokine’ 
linking obesity to IR. Since the initial discovery of TNF, other inflammatory mediators 
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(e.g., MCP-1 and IL-6) have been identified that increase with obesity and have been 
shown to play a causal role in the development of IR, establishing the well accepted 
paradigm that obesity is a chronic condition of low-grade inflammation (44).   
Similar to TNFα, monocyte chemoattractant protein-1 (MCP-1)/ chemokine (C-C 
motif) ligand 2 (CCL2) is elevated in AT of animal and human obesity (54-56). MCP-1 
and its cognate receptor CCR2 are required for macrophage infiltration into AT. 
Macrophage infiltration and inflammatory gene expression are markedly reduced with 
weight loss in obese subjects (54,55). Mice deficient in MCP-1 or CCR2 have less 
macrophage accumulation, a lower inflammatory gene profile, and improved insulin 
sensitivity on a high fat diet compared to wild-type counterparts (57,58). In contrast, 
transgenic mice expressing MCP-1 have the reverse phenotype (57). Similarly, diet-
induced obese (DIO) mice treated with a CCR2 antagonist presented with less adipose 
macrophage accumulation and improved hyperglycemia (58). Furthermore, in vitro 
treatment of 3T3-L1 ADs with MCP-1 attenuated insulin-stimulated glucose uptake and 
expression of key adipogenic genes (59). While MCP-1 appears essential for obesity-
induced IR, it has become increasingly clear that other CC chemokines (e.g., CCL3, 
CCL8, CCL9) are upregulated in genetic and diet-induced obesity models (56). As 
recent evidence demonstrates that AT inflammation is derived from activated AT 
macrophages (60), adipocyte-secreted chemokines may play a key role in the early 
development of adipose inflammation.   
Inflammatory cells of AT. The initiation and maintenance of immunity is energy 
demanding and inefficient during periods of energy deficit or starvation (49,61). For 
example, it has been reported that fever increases energy demand by 7-13%, per 1°C 
(e.g., 98.6°F to 100.4°F) increase in temperature. Increased energy consumption 
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associated with fever approximates energy costs of a 70 kg man walking 27 miles 
(49,61-64). Thus, evolutionary pressures to survive would have favored the co-
development of organ systems and signaling pathways that mediate this process. 
Evidence for this evolutionary development have been observed in lower organisms, 
such as Drosophila melanogaster, in which the fat body controls immune and metabolic 
responses (65), and higher organisms where immune cells reside alongside other cell 
types including ADs (49). Regarding integration of metabolic and immune responses, 
cells within AT show evidence of co-evolutionary development and coordination. In 
particular, PAs, ADs, and macrophages share many functions, as they all secrete 
cytokines and can be activated by pathogens such as lipopolysaccharide (LPS) and fatty 
acids via toll-like receptors (44,49,66). Moreover, traits primarily attributed to 
macrophages, phagocytosis and expression of membrane-bound NADPH oxidases, 
have also been shown in PAs (67), while transcriptional profiling suggests macrophages 
and PAs are genetically related (67,68). While studies suggest that PAs are more 
inflammatory than ADs (66) and that PAs can trans-differentiate into macrophage-like 
cells (67,68), there is also extensive overlap between insulin-responsive ADs and 
macrophages regarding inflammation (e.g., TNFα, IL-6, PAI-1) and metabolic regulation 
(e.g., PPARγ, carnitine acetyltransferase, FABP4) (49). Thus, periods of chronic 
overnutrition may tip the balance, reactivating the primordial inflammatory potential of AT 
as observed with increased expression of TNFα and other pro-inflammatory cytokines in 
obese individuals.     
AT cross-talk. As co-evolutionary development and coordinated efforts between 
ADs and macrophages would have allowed Paleolithic man to store excess nutrients for 
time of energy deprivation and to mount a potent immune response against infection, 
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modern man has seen dramatic dietary and lifestyle changes that may convert this 
beneficial interaction into a pathological relationship (49). Collectively, evidence suggest 
that cross-talk in AT (Fig.1.2) during times of nutrient overload contributes to adipocyte 
dysregulation and obesity-induced IR. In particular, evidence demonstrates that both 
PAs and hypertrophied ADs secrete increased amounts of MCP-1 (59) that results in 
macrophage infiltration of obese mice and humans (16,69). Consistent with this, 
macrophage accumulation in AT of lean individuals (5-10%) is substantially less than 
that of obese patients, where macrophages can make up to 50% of the total number of 
cells within AT (60). Thus, increased secretion of MCP-1 and/or other chemokines from 
ADs may initiate the pro-inflammatory state (17). This appears evident as fractionation of 
AT from DIO mice demonstrates that chemokine expression is primarily secreted from 
isolated ADs (56). Subsequently, macrophages and to a lesser extent ADs secrete the 
pro-inflammatory cytokine TNFα (33,70) that has been shown to induce inflammatory 
gene expression, increase fatty acid release, and inhibit insulin signaling in ADs (17,42). 
Moreover, increasing evidence demonstrates that AT sits at the nexus of whole-body IR, 
as increased fatty acid release and decreased triglyceride storage during periods of 
chronic, low-grade inflammation directly contribute to skeletal muscle IR (17).   
Inflammatory signaling. Metabolic effects of inflammatory mediators have been 
primarily attributed to two major inflammatory signaling pathways, that of nuclear factor-
kappa B (NF-B) and MAPK signaling pathways involving extracellular signal-regulated 
protein kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 (17,71). These signaling 
pathways are activated in AT in response to inflammatory stimulation and serve as 
mediators of localized IR through transcriptional mechanisms involving adipocyte gene 
expression as well as the expression and secretion of other pro-inflammatory molecules 
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(49,71). In addition to nuclear events involving c-Jun/AP-1 mediated gene expression, 
MAPK activity has also been linked to cytosolic suppression of proximal insulin signaling 
through IRS-1 and PI3K/AKT disruption demonstrating that compartmentalized signaling 
events can impact different properties of AT dysfunction (71-74). 
At the molecular level, insulin binds to and activates its tyrosine kinase 
transmembrane insulin receptor. Once activated, the insulin receptor will phosphorylate 
select tyrosine residues on downstream targets including the family of insulin receptor 
substrate (IRS) proteins (i.e., IRS-1, -2, -3, and -4). Tyrosine phosphorylated IRS-1 
activates the phosphatidylinositol 3-kinase (PI3K/AKT) pathway that serves to stimulate 
glucose transporter 4 (GLUT4) translocation to the plasma membrane in order to 
increase glucose uptake (75-77). Inflammatory signals interfere with these signaling 
events downstream of the insulin receptor leading to decreased insulin sensitivity. In 
contrast to the PI3K pathway, MAPK activation inhibits glucose uptake via the 
phosphorylation of IRS-1 on serine-307 (S307), decreases RNA and protein synthesis of 
IRS-1, and decreases RNA and protein synthesis of GLUT4. S307 phosphorylation 
further inhibits tyrosine phosphorylation leading to the dissociation of IRS proteins from 
the insulin receptor, and thus, impairs GLUT4 translocation and cellular glucose uptake 
(72-74).  
MAPKs, inflammation, and IR. MAPKs are comprised of multiple protein 
isoforms where activation of specific MAPKs is regulated by a cascade of 
phosphorylation events mediated by sequential and concerted activation of upstream 
kinases (Fig.1.3A). For instance, JNK is phosphorylated by upstream MAPK kinases 
(MAP2Ks), which are phosphorylated by MAPK kinase kinases (MAP3Ks) in response to 
diverse external stimuli. Phosphorylation of both the threonine and tyrosine residues of 
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the (T-X-Y) motif within the activation loop by upstream MAP2Ks is essential and 
sufficient for MAPK activation, and ultimately leads to the phosphorylation of target 
proteins and transcription factors within the cytosolic and nuclear compartments (78-80). 
While it is generally accepted that ERK is activated by growth factors and mitogens and 
is associated with cell survival and that JNK and p38 are stress activated (e.g., pro-
inflammatory cytokines, UV irradiation, and reactive oxygen species) and associated 
with cellular stress and apoptosis (81), biological processes regulated by MAPKs are 
cell-type dependent. 
ERK was the first MAPK identified, as it was shown that partially purified 
microtubule-associated protein-2 (MAP-2) protein kinase obtained from insulin-
stimulated 3T3-L1 ADs could phosphorylate and reactivate phosphatase treated 
ribosomal protein S6 kinase (RSK) from Xenopus eggs (82-84). Subsequent 
confirmation of this observation implicated MAP-2 kinase as an S6 kinase kinase (85-
87). Since that time, the original name has changed to MAPK and later, when cloned 
and recognized as an insulin-stimulated kinase similar to yeast kinases involved in cell 
cycle, designated as ERK (88,89). The ERK family contains a TEY (Thr-Glu-Tyr) 
activation motif and can be divided into two groups: classic MAPKs consisting of ERK1 
and 2, and large MAPKs consisting of ERKs 3, 5, 7, and 8 that contain a kinase domain 
and c-terminal domain and range in size from 60 to over 100 kDa (90-92). While it is 
generally concluded that ERK signaling is associated with cell survival and proliferation, 
depending on the cell line and stimulation this pathway may also regulate non-canonical 
and even opposing function. Thus, ERK may respond to stress and apoptosis (93,94). 
Regarding ERK signaling, it has been reported that mice deficient in ERK1 were 
protected against diet-induced obesity and IR by mechanisms involving decreased 
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adipogenesis and increased energy expenditure (81). In contrast, mice deficient in 
signaling adapter p62, an ERK inhibitor, developed mature-onset obesity and IR 
concomitant with increased ERK activity (95), thus implicating ERK in obesity-induced IR 
and disease.    
JNK was initially identified as a protein kinase activated in the liver of rodents 
exposed to cycloheximide (96). Since that time, ten isoforms of JNK have been identified 
that arise from alternative splicing of three genes: JNK1, JNK2, and JNK3, all of which 
belong to the MAPK family of signaling proteins (97,98). Moreover, studies have 
identified JNK as a stress-activated protein kinase that phosphorylates c-Jun on two 
sites in the NH2-terminal domain (99,100), with subsequent studies demonstrating that 
JNK is essential for inflammatory signaling and phosphorylation of transcription factors 
c-Jun/AP-1, required for inflammatory gene expression (101,102). JNK has recently 
emerged as a major contributor in the inflammatory development of IR in obesity 
(103,104), where JNK activation is elevated in liver, muscle, and AT during obesity while 
loss of JNK activity protects animals from IR. For example, deletion of JNK in dietary and 
genetic (ob/ob) mouse models of obesity led to decreased adiposity, improved insulin 
sensitivity, and enhanced insulin receptor signaling. Moreover, JNK activity is elevated in 
ADs during inflammatory stress, triggering IRS-1 inhibition via S307 phosphorylation and 
decreased glucose uptake (71,74,105,106). While JNK activation can quickly suppress 
insulin signaling in the cytosol, it can also translocate into the nucleus to regulate gene 
expression of other pro-inflammatory molecules, further promoting insulin resistance 
(107,108). 
p38α was the first member of the p38 MAPK family identified as a 38 kDa protein 
(p38) that was rapidly phosphorylated on tyrosine in response to LPS, as a target of 
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pyridinylimidazole drugs that inhibited pro-inflammatory cytokine production, and as an 
activator of MAPKAPK2 in cells stimulated with heat shock, arsenite, or interleukin-1 
(109-113). Additional p38 family members, which share 60% sequence homology, were 
subsequently cloned and named p38β, p38δ, p38γ and ERK6. While p38α is 
ubiquitously expressed in most cell types, other p38 MAPKs are encoded by different 
genes and have different tissue expression patterns, where p38β is found primarily in the 
brain, p38γ in skeletal muscle, and p38δ in endocrine glands (114-120). Similar to JNK, 
p38 has emerged as a key player in IR, where p38 activity is increased in response to 
hyperglycemia and in diabetes (121). It has also been reported that p38 activity is higher 
in ADs isolated from type 2 diabetes patients and participates in the downregulation of 
GLUT4 expression (122). Consistent with this, studies report that p38 inhibition improves 
glucose uptake in L6 myocytes and 3T3-L1 ADs, suggesting a role for this signaling 
pathway in obesity-induced IR (123). While p38 can inhibit insulin signaling, it can also 
translocate to the nucleus and activate pro-inflammatory genes involved in AT 
inflammation (124).   
While MAPK pathways are viewed as relatively simple and linear, it is now 
apparent that MAPKs have antagonistic effects (e.g., cell growth vs. cell-cycle arrest) 
that are cell-type dependent. Mounting evidence also indicates that MAPK magnitude, 
duration, and compartmentalization contribute to the diverse and opposing outcomes 
observed in response to external stimuli (125-127) (Fig.1.3B). Consistent with the idea of 
how signal duration elicits different biological outcomes, it has been observed that 
transient ERK activation results in AD differentiation while sustained ERK activation 
inhibits AD differentiation (81,128,129). Similarly, transient activation of JNK provides a 
critical negative feedback for the insulin response while increases in JNK signaling 
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magnitude and duration leads to IR (76). Kinase localization also plays a major role in 
specifying cell fate. For example, uncoupling of nuclear JNK activation from its cytosolic 
effects on IRS-1 suppression led to improved insulin sensitivity in mice (130). Until 
recently, the differences in MAPK magnitude, duration, and localization were traditionally 
attributed to protein scaffolding and upstream kinase activation. However, recent 
evidence demonstrates a critical role for phosphatases in the modulation and even 
control of MAPK signaling (125-127). 
MAPK Phosphatases. While a large proportion of intracellular proteins (30%) 
are subject to dephosphorylation, all 14 known ERK, JNK, and p38 kinases are 
completely inactivated by phosphate removal (125-127,131). Evidence now suggests 
that MAPK deactivation (i.e., dephosphorylation) via phosphatases play a central role in 
mediating signal transduction and cellular outcome (125-127). This is readily apparent in 
the complex changes observed in multiple MAPK signaling pathways, where immune 
function, stress response, and metabolic regulation are altered in animals lacking a 
specific MAPK phosphatase (132). As phosphorylation of the threonine and tyrosine 
residues within the activation loop are needed for MAPK activation, dephosphorylation of 
one or both residues results in inactivation of these molecules (78,108,127).     
Protein phosphatases are classified into three structurally distinct gene families: 
the phosphoprotein phosphatase (PPP) and protein phosphatase M (PPM) families 
encode protein serine/threonine (S/T) phosphatases, whereas the protein tyrosine (Y) 
phosphatase (PTP) family includes both tyrosine-specific and dual-specificity (S/T and 
Y) phosphatases (DUSPs). While protein tyrosine-specific phosphatases (e.g., PTP-SL), 
and serine/threonine phosphatases (e.g., PP2A) can regulate MAPKs in vivo, the largest 
group of phosphatases specific for MAPK deactivation are DUSPs (126,131,133,134). 
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Of the more than 30 DUSPs identified, at least 16 have been shown to dephosphorylate 
MAPKs (133-136). These DUSPs belong to one of two subfamilies that share a highly 
conserved C-terminal catalytic DSP domain, homologous to the VH1-like phosphatase 
isolated from the vaccinia virus (Fig.1.4A). The MAPK-specific DUSPs constitute a 
structurally distinct group of ten proteins identified by an N-terminal domain 
characterized by a non-catalytic MAP Kinase Binding (MKB) domain that functions in the 
docking of MAPKs to the phosphatase (79,126,127) (Fig.1.4B). The MKB domain 
consists of two CH2 domains flanking a kinase interactive motif (KIM) that confers 
specificity for select MAPKs. Consequently, this group of DUSPs displays minimal 
catalytic activity in the absence of substrate. This group of DUSPs can be divided into 
five classes based on gene structure and localization (Fig.1.4A). Group I DUSPs localize 
to the nuclear compartment via a nuclear localization sequence (NLS) proximal to the N-
terminus. Group II DUSPs encode for a nuclear export sequence (NES) that directs 
cytoplasmic localization. Group III DUSPs contain a longer C-terminal domain that 
houses an NLS and NES allowing access to the cytoplasmic and nuclear compartments. 
Group III DUSPs also contain a PEST sequence, important in the modulation of protein 
stability. Dusp10 is classified as group IV and is unique as it contains an extended N-
terminus with potential regulatory motifs. In contrast to the above DUSPs that specifically 
target MAPKs, group V consists of the ‘atypical’ DUSPs, a class of poorly characterized 
enzymes that tend to be smaller and lack the MAPK targeting motifs as they do not 
contain the MKB domain (79,126,127,134).  
DUSPs also display distinct patterns of tissue distribution, expression, 
compartmentalization, and MAPK specificity. For instance, dusp8 is predominantly 
expressed in the eye, brain, heart, and lung and is most specific for JNK deactivation, 
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while dusp4 is abundant in the placenta and highly specific for ERK deactivation. In 
addition, select DUSPs (e.g., dusp1) are classified as immediate early genes rapidly 
induced in response to serum, while others respond to different stimuli. While many 
DUSPs are regulated at the level of gene expression, others are also regulated by 
protein stability and degradation (137-144). For instance, ERK phosphorylation of dusp1 
on S359 and S364 stabilized the phosphatase from ubiquitin-directed degradation in 
CCL39 fibroblasts (138). As dusp1 localizes to the nuclear compartment (Fig.1.4A), ERK 
activated protein stability appears to be an important component in dictating localized 
MAPK activity. Similarly, recent reports demonstrate that p38 phosphorylation of S446 
on dusp16 or ERK phosphorylation of dusp4 on S386 and S391 stabilized the proteins 
from degradation, but did not affect functional phosphatase activity (143,144). Related 
reports are now emerging demonstrating a complex regulation of DUSPs involving 
transcription, translation, mRNA stability, and protein stability, mediated in part by post-
transcriptional and/or post-translational modifications (144-147). These dynamic 
complexities suggest that DUSPs play a pivotal role in modulating localized MAPK 
signaling, potentially affording protection against obesity-induced IR.  
DUSPs, Cancer, and Inflammation. While the physiological role for many 
DUSPs are still largely unknown, emerging reports indicate phosphatase function in 
cancer and the control of immunity (135,148,149). Regarding cancer outcome, mounting 
reports reveal dusp1 overexpression in early stages of prostate, colon, and bladder 
cancer, followed by a loss of expression as tumors become more aggressive or invasive. 
Moreover, empirical evidence demonstrates that dusp1 overexpression negatively 
correlates with JNK activity and apoptosis in prostate cancer (150-153). While 
controversy for JNK and p38 signaling regarding cancer exists in the literature, gene 
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ablation studies suggest that the stress-activated kinases act as tumor suppressors in 
vivo (149,154-156). Additionally, others have shown that p38 and JNK activity are 
essential for cell apoptosis, while activity does not appear to affect tumor metastasis 
(157). Collectively, temporal regulation of dusp1 appears to play an essential role in 
cancer cell development and invasion, while indirectly making tumor cells chemo-
resistant. Dusp2, dusp4, dusp6, and dusp16 have also been shown to play a role in 
various cancer types. High dusp2 levels in patients with serous ovarian carcinomas 
correlated with poor overall survival compared to patients with low expression levels of 
the phosphatase (158). Concerning dusp4, reports indicate this phosphatase is co-
expressed with dusp1 in breast cancer and overexpressed in serous borderline ovarian 
tumors, and pancreatic and liver cancer (159-162). In pancreatic cancer, it was 
recognized that MEK-mediated dusp4 expression led to suppressed ERK activity in cells 
harboring a K-ras mutation (160). Similar to dusp4, dusp6 activity is associated with Ras 
mutation in pancreatic tumors, although this involves loss of dusp6 with disease 
progression (163,164). In this case, loss of dusp6 may synergize with K-ras to increase 
ERK activity, thus contributing to pancreatic tumor development and invasiveness. 
Finally, overexpression of dusp16 was shown to down-regulate JNK activity and thus 
suppress BCR-ABL induced Rat-1 fibroblast transformation (165). In addition, down-
regulation of dusp16, which has been linked to acute myeloid leukemia, led to increased 
JNK and p38 activity that stimulated myeloid cell growth and inhibited differentiation 
(166). Thus, dusp6 and dusp16 may act as potent tumor suppressors via actions on 
ERK and JNK signaling. Taken together, these reports indicate a critical role for DUSPs 
in the regulation of cellular growth and differentiation. As hyperplastic obesity involves 
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PA replication and differentiation, DUSPs may represent key targets that are essential in 
the development of obesity.                   
Parallel to studies involving cancer, reports have emerged addressing a role for 
DUSPs regarding inflammation (135,148). Knockout of dusp1 from macrophages, 
splenocytes, and dendritic cells (DCs) resulted in increased cytokine production that was 
largely dependent on amplified p38 and JNK activity, ultimately making mice hyper-
responsive to endotoxic shock in vivo (167-170). However, the negative relationship 
attributed to dusp1 loss on increased cytokine production was not ubiquitous, as IL-12 
production was specifically reduced in response to LPS insult (167,168). Adding to this 
complexity, activation of pro-inflammatory or anti-inflammatory cytokines in dusp1 
deficient macrophages occurred in a temporal manner, whereby TNFα induction 
occurred early (<2hr) and IL-10 occurred late (>2hr) suggesting dual roles for this 
phosphatase in the regulation of immunity (169). Similar to dusp1, dusp10 deficient mice 
exhibited increased cytokine production in toll-like receptor (TLR) stimulated 
macrophages, but decreased T helper cell proliferation and protection from autoimmune 
encephalomyelitis, revealing a positive and negative role in cellular outcome (171). As 
with the complexities seen for other DUSPs, ERK and p38 activity actually decreased in 
dusp2 deficient mice while JNK activity increased in activated macrophages and mast 
cells. Interestingly, this resulted in reduced inflammation and protected mice from 
inflammatory arthritis (172). While it has been reported that dusp4 negatively regulates 
the inflammatory response in sepsis, others demonstrate that dusp4 plays an essential 
role in protection from infection against Leishmania Mexicana (173,174). Dusp4 deficient 
mice had improved survival in response to LPS and CLP models of sepsis that was 
attributed to increased ERK activation and decreased p38 and JNK signaling. As dusp4 
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knockout led to increased dusp1 expression, the authors concluded that activation of 
ERK in dusp4 deficient mice stimulated dusp1 induction subsequently deactivating p38 
and JNK signaling and ultimately contributing to decreased inflammation (173). 
Conversely, following infection with the parasite Leishmania mexicana, dusp4 deficient 
mice had increased lesion size and parasite burden due in part to increased signaling 
magnitude and duration of p38 and JNK. In addition, deletion of dusp4 potentiated LPS 
induction of pro-inflammatory cytokines IL-6, TNFα, and IL-12, collectively contributing to 
macrophage susceptibility to infection with the parasite (174). Based on the observed 
complexities for the various DUSPs, it is plausible that modulatory actions of DUSPs on 
MAPK signaling contribute to feedback inhibition and intracellular signaling cross-talk, 
ultimately dictating biological outcome. Collectively, these data demonstrate a potential 
role for DUSPs regarding inflammatory response, and highlight the complexities 
involving phosphatase modulation of MAPK signaling.   
While phosphatases have been classically regarded as switches that regulate 
‘over-signaling,’ evidence now demonstrates a more complex role for these molecules in 
MAPK regulation and physiological outcome (148,149). It has been estimated that 
enzymatic activity of phosphatases is markedly greater (>100 x) than that of kinases, as 
MAPKs require both ATP and MAP2Ks for phosphorylation, while dephosphorylation is 
direct (175). Thus, signaling magnitude and duration may be more easily regulated by 
phosphatases than kinases, providing potential targets for obesity and obesity-induced 
IR.        
DUSPs, Obesity, and Insulin Resistance. The function of DUSPs in adipocytes 
is largely unknown and a role for MAPK phosphatases in obesity and IR is just beginning 
to emerge. Dusp6 was identified as a gene that antagonized insulin suppression of the 
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gluconeogenic gene, PEPCK. Additionally, dusp6 was expressed in insulin responsive 
tissues of liver, AT, skeletal muscle, and heart (176). In vivo studies of diet-induced 
obesity demonstrate that dusp6 expression is markedly increased in liver, while 
adenoviral-mediated overexpression of dusp6 in lean mice promote gluconeogenesis 
and increased fasting blood glucose levels (177). Conversely, knockdown of dusp6 in 
lean and obese mice decreased fasting blood glucose levels, attributed to down-
regulation of gluconeogenic genes, PEPCK and G6Pase (177). Others have shown that 
down-regulation of dusp1 in diabetic Sprague-Dawley rats may contribute to decreased 
cardiac function leading to diabetic cardiomyopathy (178) as well as play a role in the 
pathogenesis of diabetic dementia (179). Furthermore, dusp1 appears to play a critical 
role in insulin expression from pancreatic β-cells, where dusp1 inhibition decreased 
insulin expression. Conversely, adenoviral-mediated dusp1 overexpression decreased 
JNK phosphorylation and increased insulin expression (180).  
Our understanding of the DUSPs in ADs is limited to five published works. Dusp9 
was identified as a candidate gene involved in insulin signaling via a functional 
expression screen examining PEPCK promoter activity as a measure of insulin action. 
Dusp9 was expressed in insulin-responsive tissues with markedly increased dusp9 
expression levels observed in obese insulin-resistant rodent models (181). Similarly, 
dusp9 ectopic expression in ADs reversed insulin-stimulated glucose uptake (182). 
Others have demonstrated that dexamethasone-induced IR in ADs inhibits GLUT4 
activity via dusp1 and dusp9 attenuation of p38 MAPK (183). An inverse relationship 
was observed between ERK dephosphorylation and dusp1 expression during adipocyte 
differentiation. Moreover, dusp1 antisense expression led to sustained ERK activation 
and suppressed adipocyte development (184). In a dusp1 knockout study, JNK activity 
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was enhanced in white AT, liver, and skeletal muscle of mice on a high fat diet. 
Furthermore, dusp1 knockout mice were resistant to diet-induced obesity via enhanced 
energy expenditure, yet still developed glucose intolerance on a high fat diet. However, it 
was further observed that dusp1 knockout did not inhibit adipocyte differentiation. 
Interestingly, dusp1 deficient mice exhibit no insulin resistance in the presence of 
enhanced JNK signaling. As dusp1 is restricted to the nuclear compartment, the authors 
concluded that elevated JNK activation, present only in the nucleus, is spatially 
uncoupled from JNK’s cytosolic ability to suppress IR (130). Others have shown that 
dusp1 is down-regulated during adipocyte hypertrophy, concomitant with increased ERK 
activity and MCP-1 expression and secretion. In addition, dusp1 adenoviral-mediated 
overexpression markedly decreased MCP-1 expression, suggesting that down-
regulation of dusp1 plays a critical role in macrophage recruitment within AT (185).   
Review Summary. Obesity and diabetes mellitus are major risk factors that lead 
to cardiovascular disease, stroke, and hypertension. Studies now demonstrate that 
dysregulation of adipokines play a pivotal role in the development of obesity-induced IR 
(1,17), placing AT at the nexus of disease pathology. Moreover, evidence clearly 
demonstrates that obesity is characterized by a state of chronic, low-grade inflammation 
that has been attributed to nutrient overload and a hyper-responsive activation of AT 
immunity (186). Early evidence demonstrated a role for inflammation, where it was 
discovered that TNFα was overexpressed in AT of obese and insulin resistant mice, in 
the coupling of obesity with IR (42). Since then, evidence has established the MAPK 
signaling pathway as critical in linking inflammatory signals to obesity-induced IR 
(71,81). While numerous studies have examined the upstream pathways that regulate 
MAPK signaling, few have examined the downstream deactivation of this pathway and 
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its effects on biological outcome. MAPK-specific DUSPs have emerged as potential 
therapeutic targets in obesity-related diseases (148,149). While in vitro assessment of 
DUSPs demonstrates these phosphatases have high specificity for MAPK signaling, 
limited work in vivo has examined their functional role on MAPKs and biological fate 
(126). Moreover, observations of DUSPs with respect to obesity and IR are limited and 
conflicting. Therefore, we have proposed the following study objectives below to 
elucidate our central hypothesis that DUSPs play a regulatory role on the extent of 
MAPK signaling in ADs under conditions of differentiation and inflammatory stress, 
subsequently affecting MAPK-dependent biological processes.      
 
Study Objectives 
 
Chapter II. Little is known about the regulation of DUSPs with regards to obesity 
in insulin responsive tissues. Therefore, the objective of the study summarized in 
chapter II is to examine DUSP regulation in insulin responsive tissues of genetic and 
diet-induced obese mouse models. We will 1) establish relative DUSP expression across 
tissue types, 2) determine which DUSPs are induced in genetic ob/ob models of obesity 
in these insulin responsive tissues, and 3) determine regulation of DUSPs during the 
development of ob/ob and diet-induced obesity as these animals transition to an 
inflamed, insulin resistant state. 
Chapter III. A role for DUSPs in the development of hyperplastic obesity (i.e. PA 
replication and differentiation) remains unknown. As preadipocyte proliferation and 
differentiation are highly dependent on the timely modulation of MAPK signaling (81), the 
objective of the study summarized in chapter III will examine the regulation and role for 
DUSPs during adipogenesis. While recent evidence suggests a protective role for dusp1 
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on diet-induced obesity, studies examining the mechanisms of dusp1 actions on 
adipocyte differentiation are conflicting (130,184,187). Therefore, chapter III will further 
address a role for dusp1 on MAPK signaling and preadipocyte proliferation and 
differentiation. 
Chapter IV. While a role for select DUSPs on MAPK signaling has been 
established in classical immune cells, no one has examined a role for all MAPK-specific 
DUSPs on MAPK signaling in the macrophage-like preadipocyte and insulin responsive 
adipocyte in response to inflammation. Therefore, the objective of the study summarized 
in Chapter IV is to: 1) establish which DUSPs are induced, 2) determine which DUSPs 
regulate MAPK signaling, 3) evaluate their role on pro-inflammatory gene expression, 
and 4) determine which DUSPs are downstream targets of MAPK signaling in response 
to TNFα as proposed by our working model (Fig.1.5).  
Chapter V. It is well-known that the MAPK-regulated MCP-1 plays a critical role 
in obesity-induced inflammation that contributes to IR (57,58). As recent evidence 
suggests that other chemokines also contribute to macrophage infiltration and obesity-
induced IR (56), the objective of the study summarized in chapter V is to: 1) establish 
CC chemokine expression in response to TNFα, 2) elucidate which chemokines are 
downstream targets of MAPK signaling, and 3) examine the regulatory role of DUSPs on 
nuclear events involving MAPK-dependent chemokine gene expression as proposed in 
part of our working model (Fig.1.5). 
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Figure 1.1. Endocrine actions of AT. 
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Figure 1.2. Adipocyte-Macrophage cross-talk 
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Figure 1.3. MAPK Signaling Cascade 
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Figure 1.4. DUSP Domain Structure 
27 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Working model of DUSPs on MAPK signaling 
regulation and function in adipocytes in response to TNFα 
28 
 
Reference List 
 
 1.  Haslam DW, James WP. Obesity. Lancet. 2005 Oct 1;366:1197-209. 
 2.  Wickelgren I. Obesity: how big a problem? Science. 1998 May 29;280:1364-7. 
 3.  Ogden CL, Carroll MD, McDowell MA, Flegal KM. Obesity among adults in the 
United States--no statistically significant chance since 2003-2004. NCHS Data 
Brief. 2007 Nov;1-8. 
 4.  Ogden CL, Lamb MM, Carroll MD, Flegal KM. Obesity and socioeconomic status 
in adults: United States, 2005-2008. NCHS Data Brief. 2010 Dec;1-8. 
 5.  Flegal KM, Ogden CL, Yanovski JA, Freedman DS, Shepherd JA, Graubard BI, 
Borrud LG. High adiposity and high body mass index-for-age in US children and 
adolescents overall and by race-ethnic group. Am J Clin Nutr. 2010 Apr;91:1020-
6. 
 6.  Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity 
among US adults, 1999-2008. JAMA. 2010 Jan 20;303:235-41. 
 7.  Albright A. What is public health practice telling us about diabetes? J Am Diet 
Assoc. 2008 Apr;108:S12-S18. 
 8.  Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and 
diabetes-related complications. Phys Ther. 2008 Nov;88:1254-64. 
 9.  Mayer-Davis EJ. Type 2 diabetes in youth: epidemiology and current research 
toward prevention and treatment. J Am Diet Assoc. 2008 Apr;108:S45-S51. 
 10.  Miranda JJ, Kinra S, Casas JP, Davey SG, Ebrahim S. Non-communicable 
diseases in low- and middle-income countries: context, determinants and health 
policy. Trop Med Int Health. 2008 Oct;13:1225-34. 
 11.  Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. 
Diabetes Care. 2003 Mar;26:917-32. 
 12.  Sims EA, Danforth E Jr, Horton ES, Bray GA, Glennon JA, Salans LB. Endocrine 
and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 
1973;29:457-96. 
 13.  Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective 
adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes 
mellitus. Effect of weight loss. J Clin Invest. 1988 Oct;82:1398-406. 
29 
 
   14.  Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of 
visceral adiposity. Diabetes. 2000 Jun;49:883-8. 
 15.  Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiology: the 
role of adipose tissue. Nutr Metab Cardiovasc Dis. 2007 Feb;17:125-39. 
 16.  Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, 
et al. Chronic inflammation in fat plays a crucial role in the development of 
obesity-related insulin resistance. J Clin Invest. 2003 Dec;112:1821-30. 
 17.  Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking 
obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008 
May;9:367-77. 
 18.  Wooley SC, Garner DM. Obesity treatment: the high cost of false hope. J Am 
Diet Assoc. 1991 Oct;91:1248-51. 
 19.  Goodrick GK, Foreyt JP. Why treatments for obesity don't last. J Am Diet Assoc. 
1991 Oct;91:1243-7. 
 20.  Barzilai N. Obesity: age-associated weight gain and the development of disease. 
An interview with Nir Barzilai. Interview by Marc E. Weksler. Geriatrics. 1999 
Nov;54:57-4. 
 21.  Villareal DT, Banks MR, Patterson BW, Polonsky KS, Klein S. Weight loss 
therapy improves pancreatic endocrine function in obese older adults. Obesity 
(Silver Spring). 2008 Jun;16:1349-54. 
 22.  Villareal DT, Shah K, Banks MR, Sinacore DR, Klein S. Effect of weight loss and 
exercise therapy on bone metabolism and mass in obese older adults: a one-
year randomized controlled trial. J Clin Endocrinol Metab. 2008 Jun;93:2181-7. 
 23.  Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ. The biology 
of white adipocyte proliferation. Obes Rev. 2001 Nov;2:239-54. 
 24.  Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka 
P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, et al. Prevention of type 
2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose 
tolerance. N Engl J Med. 2001 May 3;344:1343-50. 
 25.  Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, 
Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle 
intervention or metformin. N Engl J Med. 2002 Feb 7;346:393-403. 
 26.  Libman IM, Arslanian SA. Prevention and treatment of type 2 diabetes in youth. 
Horm Res. 2007;67:22-34. 
 
30 
 
 27.  Kennedy GC. The role of depot fat in the hypothalamic control of food intake in 
the rat. Proc R Soc Lond B Biol Sci. 1953 Jan 15;140:578-96. 
 28.  Coleman DL, Hummel KP. The influence of genetic background on the 
expression of the obese (Ob) gene in the mouse. Diabetologia. 1973 Aug;9:287-
93. 
 29.  Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional 
cloning of the mouse obese gene and its human homologue. Nature. 1994 Dec 
1;372:425-32. 
 30.  Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB 
protein: evidence for a peripheral signal linking adiposity and central neural 
networks. Science. 1995 Jul 28;269:546-9. 
 31.  Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone 
RL, Burley SK, Friedman JM. Weight-reducing effects of the plasma protein 
encoded by the obese gene. Science. 1995 Jul 28;269:543-6. 
 32.  Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006 Dec 
14;444:860-7. 
 33.  Maury E, Noel L, Detry R, Brichard SM. In vitro hyperresponsiveness to tumor 
necrosis factor-alpha contributes to adipokine dysregulation in omental 
adipocytes of obese subjects. J Clin Endocrinol Metab. 2009 Apr;94:1393-400. 
 34.  Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr Pharm 
Des. 2010 Jun;16:1896-901. 
 35.  Clowes GH, Jr., Martin H, Walji S, Hirsch E, Gazitua R, Goodfellow R. Blood 
insulin responses to blood glucose levels in high output sepsis and spetic shock. 
Am J Surg. 1978 Apr;135:577-83. 
 36.  Wichterman KA, Chaudry IH, Baue AE. Studies of peripheral glucose uptake 
during sepsis. Arch Surg. 1979 Jun;114:740-5. 
 37.  Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of 
diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic 
insights. Curr Diab Rep. 2004 Jun;4:194-8. 
 38.  Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and 
cardiovascular risk. Curr Atheroscler Rep. 2008 Feb;10:61-70. 
 39.  Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic 
diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res 
Ther. 2008;10:207. 
 40.  Williamson RT. On the Treatment of Glycosuria and Diabetes Mellitus with 
Sodium Salicylate. Br Med J. 1901 Mar 30;1:760-2. 
31 
 
 41.  Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin 
Invest. 2006 Jul;116:1793-801. 
 42.  Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor 
necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 
1993 Jan 1;259:87-91. 
 43.  Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin 
resistance, obesity and diabetes. Trends Immunol. 2004 Jan;25:4-7. 
 44.  Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 
2005 May;115:1111-9. 
 45.  Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. 
Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin 
Endocrinol Metab. 1998 Aug;83:2907-10. 
 46.  Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor 
alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A. 1994 
May 24;91:4854-8. 
 47.  Guo D, Donner DB. Tumor necrosis factor promotes phosphorylation and binding 
of insulin receptor substrate 1 to phosphatidylinositol 3-kinase in 3T3-L1 
adipocytes. J Biol Chem. 1996 Jan 12;271:615-8. 
 48.  Steinberg GR, Michell BJ, van Denderen BJ, Watt MJ, Carey AL, Fam BC, 
Andrikopoulos S, Proietto J, Gorgun CZ, et al. Tumor necrosis factor alpha-
induced skeletal muscle insulin resistance involves suppression of AMP-kinase 
signaling. Cell Metab. 2006 Dec;4:465-74. 
 49.  Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic 
diseases. Nat Rev Immunol. 2008 Dec;8:923-34. 
 50.  Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine 
kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor 
necrosis factor-alpha. J Clin Invest. 1994 Oct;94:1543-9. 
 51.  Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-
induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997 Oct 
9;389:610-4. 
 52.  Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH, Bryer-Ash M. An in vivo model 
for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-
induced insulin resistance: evidence for differential regulation of insulin signaling 
by TNF-alpha. Endocrinology. 1998 Dec;139:4928-35. 
 53.  Romanatto T, Roman EA, Arruda AP, Denis RG, Solon C, Milanski M, Moraes 
JC, Bonfleur ML, Degasperi GR, et al. Deletion of tumor necrosis factor-alpha 
32 
 
receptor 1 (TNFR1) protects against diet-induced obesity by means of increased 
thermogenesis. J Biol Chem. 2009 Dec 25;284:36213-22. 
 54.  Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, Sicard A, 
Rome S, Benis A, et al. Weight loss regulates inflammation-related genes in 
white adipose tissue of obese subjects. FASEB J. 2004 Nov;18:1657-69. 
 55.  Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, 
Pelloux V, Hugol D, et al. Reduction of macrophage infiltration and 
chemoattractant gene expression changes in white adipose tissue of morbidly 
obese subjects after surgery-induced weight loss. Diabetes. 2005 Aug;54:2277-
86. 
 56.  Jiao P, Chen Q, Shah S, Du J, Tao B, Tzameli I, Yan W, Xu H. Obesity-related 
upregulation of monocyte chemotactic factors in adipocytes: involvement of 
nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways. Diabetes. 2009 
Jan;58:104-15. 
 57.  Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, 
Miyachi H, Maeda S, et al. MCP-1 contributes to macrophage infiltration into 
adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 
2006 Jun;116:1494-505. 
 58.  Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, 
Leibel RL, Ferrante AW, Jr. CCR2 modulates inflammatory and metabolic effects 
of high-fat feeding. J Clin Invest. 2006 Jan;116:115-24. 
 59.  Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and 
insulin resistance. Proc Natl Acad Sci U S A. 2003 Jun 10;100:7265-70. 
 60.  Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. 
Obesity is associated with macrophage accumulation in adipose tissue. J Clin 
Invest. 2003 Dec;112:1796-808. 
 61.  Demas GE, Chefer V, Talan MI, Nelson RJ. Metabolic costs of mounting an 
antigen-stimulated immune response in adult and aged C57BL/6J mice. Am J 
Physiol. 1997 Nov;273:R1631-R1637. 
 62.  Maier SF, Watkins LR, Fleshner M. Psychoneuroimmunology. The interface 
between behavior, brain, and immunity. Am Psychol. 1994 Dec;49:1004-17. 
 63.  Browning RC, Kram R. Energetic cost and preferred speed of walking in obese 
vs. normal weight women. Obes Res. 2005 May;13:891-9. 
 64.  Romanyukha AA, Rudnev SG, Sidorov IA. Energy cost of infection burden: an 
approach to understanding the dynamics of host-pathogen interactions. J Theor 
Biol. 2006 Jul 7;241:1-13. 
33 
 
 65.  Leclerc V, Reichhart JM. The immune response of Drosophila melanogaster. 
Immunol Rev. 2004 Apr;198:59-71. 
 66.  Chung S, Lapoint K, Martinez K, Kennedy A, Boysen SM, McIntosh MK. 
Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin 
resistance in primary cultures of newly differentiated human adipocytes. 
Endocrinology. 2006 Nov;147:5340-51. 
 67.  Charriere G, Cousin B, Arnaud E, Andre M, Bacou F, Penicaud L, Casteilla L. 
Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem. 
2003 Mar 14;278:9850-5. 
 68.  Khazen W, M'bika JP, Tomkiewicz C, Benelli C, Chany C, Achour A, Forest C. 
Expression of macrophage-selective markers in human and rodent adipocytes. 
FEBS Lett. 2005 Oct 24;579:5631-4. 
 69.  Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, Busse R, Bouloumie A. 
From blood monocytes to adipose tissue-resident macrophages: induction of 
diapedesis by human mature adipocytes. Diabetes. 2004 May;53:1285-92. 
 70.  Fain JN, Bahouth SW, Madan AK. TNFalpha release by the nonfat cells of 
human adipose tissue. Int J Obes Relat Metab Disord. 2004 Apr;28:616-22. 
 71.  Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, 
Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature. 
2002 Nov 21;420:333-6. 
 72.  Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y. A molecular 
basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 
and IRS-2 inhibits their binding to the juxtamembrane region of the insulin 
receptor and impairs their ability to undergo insulin-induced tyrosine 
phosphorylation. J Biol Chem. 1997 Nov 21;272:29911-8. 
 73.  Lee YH, Giraud J, Davis RJ, White MF. c-Jun N-terminal kinase (JNK) mediates 
feedback inhibition of the insulin signaling cascade. J Biol Chem. 2003 Jan 
31;278:2896-902. 
 74.  Fujishiro M, Gotoh Y, Katagiri H, Sakoda H, Ogihara T, Anai M, Onishi Y, Ono H, 
Abe M, et al. Three mitogen-activated protein kinases inhibit insulin signaling by 
different mechanisms in 3T3-L1 adipocytes. Mol Endocrinol. 2003 Mar;17:487-
97. 
 75.  Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-
Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-
alpha. Arch Physiol Biochem. 2008 Jul;114:183-94. 
 76.  Zick Y. Insulin resistance: a phosphorylation-based uncoupling of insulin 
signaling. Trends Cell Biol. 2001 Nov;11:437-41. 
34 
 
 77.  Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. 
Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with 
the insulin receptor and inhibits insulin action. J Biol Chem. 2002 Jan 
11;277:1531-7. 
 78.  Pearson G, Robinson F, Beers GT, Xu BE, Karandikar M, Berman K, Cobb MH. 
Mitogen-activated protein (MAP) kinase pathways: regulation and physiological 
functions. Endocr Rev. 2001 Apr;22:153-83. 
 79.  Zhang Y, Dong C. Regulatory mechanisms of mitogen-activated kinase signaling. 
Cell Mol Life Sci. 2007 Nov;64:2771-89. 
 80.  Tanoue T, Nishida E. Molecular recognitions in the MAP kinase cascades. Cell 
Signal. 2003 May;15:455-62. 
 81.  Bost F, Aouadi M, Caron L, Binetruy B. The role of MAPKs in adipocyte 
differentiation and obesity. Biochimie. 2005 Jan;87:51-6. 
 82.  Ray LB, Sturgill TW. Rapid stimulation by insulin of a serine/threonine kinase in 
3T3-L1 adipocytes that phosphorylates microtubule-associated protein 2 in vitro. 
Proc Natl Acad Sci U S A. 1987 Mar;84:1502-6. 
 83.  Ray LB, Sturgill TW. Characterization of insulin-stimulated microtubule-
associated protein kinase. Rapid isolation and stabilization of a novel 
serine/threonine kinase from 3T3-L1 cells. J Biol Chem. 1988 Sep 5;263:12721-
7. 
 84.  Sturgill TW, Ray LB, Erikson E, Maller JL. Insulin-stimulated MAP-2 kinase 
phosphorylates and activates ribosomal protein S6 kinase II. Nature. 1988 Aug 
25;334:715-8. 
 85.  Gregory JS, Boulton TG, Sang BC, Cobb MH. An insulin-stimulated ribosomal 
protein S6 kinase from rabbit liver. J Biol Chem. 1989 Nov 5;264:18397-401. 
 86.  Ahn NG, Weiel JE, Chan CP, Krebs EG. Identification of multiple epidermal 
growth factor-stimulated protein serine/threonine kinases from Swiss 3T3 cells. J 
Biol Chem. 1990 Jul 15;265:11487-94. 
 87.  Ahn NG, Krebs EG. Evidence for an epidermal growth factor-stimulated protein 
kinase cascade in Swiss 3T3 cells. Activation of serine peptide kinase activity by 
myelin basic protein kinases in vitro. J Biol Chem. 1990 Jul 15;265:11495-501. 
 88.  Boulton TG, Gregory JS, Jong SM, Wang LH, Ellis L, Cobb MH. Evidence for 
insulin-dependent activation of S6 and microtubule-associated protein-2 kinases 
via a human insulin receptor/v-ros hybrid. J Biol Chem. 1990 Feb 15;265:2713-9. 
35 
 
 89.  Boulton TG, Yancopoulos GD, Gregory JS, Slaughter C, Moomaw C, Hsu J, 
Cobb MH. An insulin-stimulated protein kinase similar to yeast kinases involved 
in cell cycle control. Science. 1990 Jul 6;249:64-7. 
 90.  Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem. 1995 
Jun 23;270:14843-6. 
 91.  Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995 Jun;9:726-35. 
 92.  Kuo WL, Duke CJ, Abe MK, Kaplan EL, Gomes S, Rosner MR. ERK7 expression 
and kinase activity is regulated by the ubiquitin-proteosome pathway. J Biol 
Chem. 2004 May 28;279:23073-81. 
 93.  Jain RG, Phelps KD, Pekala PH. Tumor necrosis factor-alpha initiated signal 
transduction in 3T3-L1 adipocytes. J Cell Physiol. 1999 Apr;179:58-66. 
 94.  Keshet Y, Seger R. The MAP kinase signaling cascades: a system of hundreds 
of components regulates a diverse array of physiological functions. Methods Mol 
Biol. 2010;661:3-38. 
 95.  Rodriguez A, Duran A, Selloum M, Champy MF, Diez-Guerra FJ, Flores JM, 
Serrano M, Auwerx J, Diaz-Meco MT, Moscat J. Mature-onset obesity and insulin 
resistance in mice deficient in the signaling adapter p62. Cell Metab. 2006 
Mar;3:211-22. 
 96.  Kyriakis JM, Avruch J. pp54 microtubule-associated protein 2 kinase. A novel 
serine/threonine protein kinase regulated by phosphorylation and stimulated by 
poly-L-lysine. J Biol Chem. 1990 Oct 5;265:17355-63. 
 97.  Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, Davis RJ. 
Selective interaction of JNK protein kinase isoforms with transcription factors. 
EMBO J. 1996 Jun 3;15:2760-70. 
 98.  Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000 Oct 
13;103:239-52. 
 99.  Adler V, Polotskaya A, Wagner F, Kraft AS. Affinity-purified c-Jun amino-terminal 
protein kinase requires serine/threonine phosphorylation for activity. J Biol Chem. 
1992 Aug 25;267:17001-5. 
 100.  Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and 
UV-responsive protein kinase that binds and potentiates the c-Jun activation 
domain. Genes Dev. 1993 Nov;7:2135-48. 
 101.  Manning AM, Mercurio F. Transcription inhibitors in inflammation. Expert Opin 
Investig Drugs. 1997 May;6:555-67. 
36 
 
 102.  Ventura JJ, Kennedy NJ, Lamb JA, Flavell RA, Davis RJ. c-Jun NH(2)-terminal 
kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol Cell 
Biol. 2003 Apr;23:2871-82. 
 103.  Karin M, Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, 
physiology and clinical importance. IUBMB Life. 2005 Apr;57:283-95. 
 104.  Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? 
Nat Rev Drug Discov. 2003 Jul;2:554-65. 
 105.  Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal 
kinase promotes insulin resistance during association with insulin receptor 
substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000 Mar 
24;275:9047-54. 
 106.  Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W, 
Grivennikov S, Wynshaw-Boris A, Scadeng M, et al. JNK1 in hematopoietically 
derived cells contributes to diet-induced inflammation and insulin resistance 
without affecting obesity. Cell Metab. 2007 Nov;6:386-97. 
 107.  Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. 
2001 Aug;60:349-56. 
 108.  Turjanski AG, Vaque JP, Gutkind JS. MAP kinases and the control of nuclear 
events. Oncogene. 2007 May 14;26:3240-53. 
 109.  Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and 
hyperosmolarity in mammalian cells. Science. 1994 Aug 5;265:808-11. 
 110.  Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, 
Blumenthal MJ, Heys JR, et al. A protein kinase involved in the regulation of 
inflammatory cytokine biosynthesis. Nature. 1994 Dec 22;372:739-46. 
 111.  Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, 
Hunt T, Nebreda AR. A novel kinase cascade triggered by stress and heat shock 
that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock 
proteins. Cell. 1994 Sep 23;78:1027-37. 
 112.  Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowley S, Hsuan J, Saklatvala 
J. Interleukin-1 activates a novel protein kinase cascade that results in the 
phosphorylation of Hsp27. Cell. 1994 Sep 23;78:1039-49. 
 113.  Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee 
JC. SB 203580 is a specific inhibitor of a MAP kinase homologue which is 
stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995 May 
8;364:229-33. 
37 
 
 114.  Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J. Characterization of the 
structure and function of a new mitogen-activated protein kinase (p38beta). J Biol 
Chem. 1996 Jul 26;271:17920-6. 
 115.  Li Z, Jiang Y, Ulevitch RJ, Han J. The primary structure of p38 gamma: a new 
member of p38 group of MAP kinases. Biochem Biophys Res Commun. 1996 
Nov 12;228:334-40. 
 116.  Lechner C, Zahalka MA, Giot JF, Moller NP, Ullrich A. ERK6, a mitogen-activated 
protein kinase involved in C2C12 myoblast differentiation. Proc Natl Acad Sci U 
S A. 1996 Apr 30;93:4355-9. 
 117.  Goedert M, Cuenda A, Craxton M, Jakes R, Cohen P. Activation of the novel 
stress-activated protein kinase SAPK4 by cytokines and cellular stresses is 
mediated by SKK3 (MKK6); comparison of its substrate specificity with that of 
other SAP kinases. EMBO J. 1997 Jun 16;16:3563-71. 
 118.  Jiang Y, Gram H, Zhao M, New L, Gu J, Feng L, Di PF, Ulevitch RJ, Han J. 
Characterization of the structure and function of the fourth member of p38 group 
mitogen-activated protein kinases, p38delta. J Biol Chem. 1997 Nov 
28;272:30122-8. 
 119.  Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated 
protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J 
Biol Chem. 1998 Jan 16;273:1741-8. 
 120.  Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role 
in human diseases. Biochim Biophys Acta. 2007 Aug;1773:1358-75. 
 121.  Begum N, Ragolia L. High glucose and insulin inhibit VSMC MKP-1 expression 
by blocking iNOS via p38 MAPK activation. Am J Physiol Cell Physiol. 2000 
Jan;278:C81-C91. 
 122.  Carlson CJ, Koterski S, Sciotti RJ, Poccard GB, Rondinone CM. Enhanced basal 
activation of mitogen-activated protein kinases in adipocytes from type 2 
diabetes: potential role of p38 in the downregulation of GLUT4 expression. 
Diabetes. 2003 Mar;52:634-41. 
 123.  Furtado LM, Somwar R, Sweeney G, Niu W, Klip A. Activation of the glucose 
transporter GLUT4 by insulin. Biochem Cell Biol. 2002;80:569-78. 
 124.  Hoareau L, Bencharif K, Rondeau P, Murumalla R, Ravanan P, Tallet F, Delarue 
P, Cesari M, Roche R, Festy F. Signaling pathways involved in LPS induced 
TNFalpha production in human adipocytes. J Inflamm (Lond). 2010;7:1. 
 125.  Ebisuya M, Kondoh K, Nishida E. The duration, magnitude and 
compartmentalization of ERK MAP kinase activity: mechanisms for providing 
signaling specificity. J Cell Sci. 2005 Jul 15;118:2997-3002. 
38 
 
 126.  Dickinson RJ, Keyse SM. Diverse physiological functions for dual-specificity MAP 
kinase phosphatases. J Cell Sci. 2006 Nov 15;119:4607-15. 
 127.  Kondoh K, Nishida E. Regulation of MAP kinases by MAP kinase phosphatases. 
Biochim Biophys Acta. 2007 Aug;1773:1227-37. 
 128.  Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP 
kinase-mediated phosphorylation of PPARgamma. Science. 1996 Dec 
20;274:2100-3. 
 129.  Bost F, Aouadi M, Caron L, Even P, Belmonte N, Prot M, Dani C, Hofman P, 
Pages G, et al. The extracellular signal-regulated kinase isoform ERK1 is 
specifically required for in vitro and in vivo adipogenesis. Diabetes. 2005 
Feb;54:402-11. 
 130.  Wu JJ, Roth RJ, Anderson EJ, Hong EG, Lee MK, Choi CS, Neufer PD, Shulman 
GI, Kim JK, Bennett AM. Mice lacking MAP kinase phosphatase-1 have 
enhanced MAP kinase activity and resistance to diet-induced obesity. Cell 
Metab. 2006 Jul;4:61-73. 
 131.  Barford D, Das AK, Egloff MP. The structure and mechanism of protein 
phosphatases: insights into catalysis and regulation. Annu Rev Biophys Biomol 
Struct. 1998;27:133-64. 
 132.  Salojin K, Oravecz T. Regulation of innate immunity by MAPK dual-specificity 
phosphatases: knockout models reveal new tricks of old genes. J Leukoc Biol. 
2007 Apr;81:860-9. 
 133.  Farooq A, Zhou MM. Structure and regulation of MAPK phosphatases. Cell 
Signal. 2004 Jul;16:769-79. 
 134.  Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, 
Hunter T, Dixon J, Mustelin T. Protein tyrosine phosphatases in the human 
genome. Cell. 2004 Jun 11;117:699-711. 
 135.  Lang R, Hammer M, Mages J. DUSP meet immunology: dual specificity MAPK 
phosphatases in control of the inflammatory response. J Immunol. 2006 Dec 
1;177:7497-504. 
 136.  Keyse SM. Protein phosphatases and the regulation of MAP kinase activity. 
Semin Cell Dev Biol. 1998 Apr;9:143-52. 
 137.  Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. 
Glucocorticoids inhibit MAP kinase via increased expression and decreased 
degradation of MKP-1. EMBO J. 2001 Dec 17;20:7108-16. 
39 
 
 138.  Brondello JM, Pouyssegur J, McKenzie FR. Reduced MAP kinase phosphatase-
1 degradation after p42/p44MAPK-dependent phosphorylation. Science. 1999 
Dec 24;286:2514-7. 
 139.  Lin YW, Yang JL. Cooperation of ERK and SCFSkp2 for MKP-1 destruction 
provides a positive feedback regulation of proliferating signaling. J Biol Chem. 
2006 Jan 13;281:915-26. 
 140.  Keyse SM, Emslie EA. Oxidative stress and heat shock induce a human gene 
encoding a protein-tyrosine phosphatase. Nature. 1992 Oct 15;359:644-7. 
 141.  Marchetti S, Gimond C, Chambard JC, Touboul T, Roux D, Pouyssegur J, Pages 
G. Extracellular signal-regulated kinases phosphorylate mitogen-activated protein 
kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its 
proteasomal degradation. Mol Cell Biol. 2005 Jan;25:854-64. 
 142.  Matsuguchi T, Musikacharoen T, Johnson TR, Kraft AS, Yoshikai Y. A novel 
mitogen-activated protein kinase phosphatase is an important negative regulator 
of lipopolysaccharide-mediated c-Jun N-terminal kinase activation in mouse 
macrophage cell lines. Mol Cell Biol. 2001 Oct;21:6999-7009. 
 143.  Katagiri C, Masuda K, Urano T, Yamashita K, Araki Y, Kikuchi K, Shima H. 
Phosphorylation of Ser-446 determines stability of MKP-7. J Biol Chem. 2005 Apr 
15;280:14716-22. 
 144.  Peng DJ, Zhou JY, Wu GS. Post-translational regulation of mitogen-activated 
protein kinase phosphatase-2 (MKP-2) by ERK. Cell Cycle. 2010 Dec 1;9:4650-
5. 
 145.  Xu S, Furukawa T, Kanai N, Sunamura M, Horii A. Abrogation of DUSP6 by 
hypermethylation in human pancreatic cancer. J Hum Genet. 2005;50:159-67. 
 146.  Chi H, Flavell RA. Acetylation of MKP-1 and the control of inflammation. Sci 
Signal. 2008;1:e44. 
 147.  Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase 
phosphatases: critical roles in development and cancer. Am J Physiol Cell 
Physiol. 2010 Aug;299:C189-C202. 
 148.  Jeffrey KL, Camps M, Rommel C, Mackay CR. Targeting dual-specificity 
phosphatases: manipulating MAP kinase signalling and immune responses. Nat 
Rev Drug Discov. 2007 May;6:391-403. 
 149.  Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. 
Cancer Metastasis Rev. 2008 Jun;27:253-61. 
 150.  Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi-
Galluzzi C, Stork PJ. Expression of mitogen-activated protein kinase 
40 
 
phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J 
Pathol. 1996 Nov;149:1553-64. 
 151.  Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, 
Wishnow K, Kaplan I, Stork PJ, Loda M. Mitogen-activated protein kinase 
phosphatase 1 is overexpressed in prostate cancers and is inversely related to 
apoptosis. Lab Invest. 1997 Jan;76:37-51. 
 152.  Magi-Galluzzi C, Murphy M, Cangi MG, Loda M. Proliferation, apoptosis and cell 
cycle regulation in prostatic carcinogenesis. Anal Quant Cytol Histol. 1998 
Oct;20:343-50. 
 153.  Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein 
B, Kinzler KW. Gene expression profiles in normal and cancer cells. Science. 
1997 May 23;276:1268-72. 
 154.  Kennedy NJ, Sluss HK, Jones SN, Bar-Sagi D, Flavell RA, Davis RJ. 
Suppression of Ras-stimulated transformation by the JNK signal transduction 
pathway. Genes Dev. 2003 Mar 1;17:629-37. 
 155.  Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle. 2003 
May;2:199-201. 
 156.  Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, 
Pasparakis M, Nebreda AR. p38alpha MAP kinase is essential in lung stem and 
progenitor cell proliferation and differentiation. Nat Genet. 2007 Jun;39:750-8. 
 157.  Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP 
kinase phosphatase regulation: roles in cell growth, death, and cancer. 
Pharmacol Rev. 2008 Sep;60:261-310. 
 158.  Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Trope CG, Reich R. 
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian 
carcinoma. Gynecol Oncol. 2004 May;93:517-23. 
 159.  Yokoyama A, Karasaki H, Urushibara N, Nomoto K, Imai Y, Nakamura K, Mizuno 
Y, Ogawa K, Kikuchi K. The characteristic gene expressions of MAPK 
phosphatases 1 and 2 in hepatocarcinogenesis, rat ascites hepatoma cells, and 
regenerating rat liver. Biochem Biophys Res Commun. 1997 Oct 29;239:746-51. 
 160.  Yip-Schneider MT, Lin A, Marshall MS. Pancreatic tumor cells with mutant K-ras 
suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-
2. Biochem Biophys Res Commun. 2001 Feb 2;280:992-7. 
 161.  Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein 
kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 2003 
Mar 10;191:229-37. 
41 
 
 162.  Sieben NL, Oosting J, Flanagan AM, Prat J, Roemen GM, Kolkman-Uljee SM, 
van ER, Cornelisse CJ, Fleuren GJ, van EM. Differential gene expression in 
ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign 
behavior of serous borderline tumors. J Clin Oncol. 2005 Oct 10;23:7257-64. 
 163.  Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor 
suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol. 
2003 Jun;162:1807-15. 
 164.  Furukawa T, Fujisaki R, Yoshida Y, Kanai N, Sunamura M, Abe T, Takeda K, 
Matsuno S, Horii A. Distinct progression pathways involving the dysfunction of 
DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-
mucinous neoplasms of the pancreas. Mod Pathol. 2005 Aug;18:1034-42. 
 165.  Hoornaert I, Marynen P, Goris J, Sciot R, Baens M. MAPK phosphatase 
DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-
13, reduces BCR-ABL-induced transformation. Oncogene. 2003 Oct 30;22:7728-
36. 
 166.  Zaidi SK, Dowdy CR, van Wijnen AJ, Lian JB, Raza A, Stein JL, Croce CM, Stein 
GS. Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and 
blocks differentiation by activating a miR-24/MKP-7/MAPK network. Cancer Res. 
2009 Nov 1;69:8249-55. 
 167.  Zhao Q, Wang X, Nelin LD, Yao Y, Matta R, Manson ME, Baliga RS, Meng X, 
Smith CV, et al. MAP kinase phosphatase 1 controls innate immune responses 
and suppresses endotoxic shock. J Exp Med. 2006 Jan 23;203:131-40. 
 168.  Hammer M, Mages J, Dietrich H, Servatius A, Howells N, Cato AC, Lang R. Dual 
specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and 
protects mice from lethal endotoxin shock. J Exp Med. 2006 Jan 23;203:15-20. 
 169.  Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, Flavell RA. Dynamic 
regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 
(MKP-1) in innate immune responses. Proc Natl Acad Sci U S A. 2006 Feb 
14;103:2274-9. 
 170.  Salojin KV, Owusu IB, Millerchip KA, Potter M, Platt KA, Oravecz T. Essential 
role of MAPK phosphatase-1 in the negative control of innate immune responses. 
J Immunol. 2006 Feb 1;176:1899-907. 
 171.  Zhang Y, Blattman JN, Kennedy NJ, Duong J, Nguyen T, Wang Y, Davis RJ, 
Greenberg PD, Flavell RA, Dong C. Regulation of innate and adaptive immune 
responses by MAP kinase phosphatase 5. Nature. 2004 Aug 12;430:793-7. 
 172.  Jeffrey KL, Brummer T, Rolph MS, Liu SM, Callejas NA, Grumont RJ, Gillieron C, 
Mackay F, Grey S, et al. Positive regulation of immune cell function and 
42 
 
inflammatory responses by phosphatase PAC-1. Nat Immunol. 2006 Mar;7:274-
83. 
 173.  Cornell TT, Rodenhouse P, Cai Q, Sun L, Shanley TP. Mitogen-activated protein 
kinase phosphatase 2 regulates the inflammatory response in sepsis. Infect 
Immun. 2010 Jun;78:2868-76. 
 174.  Al-Mutairi MS, Cadalbert LC, McGachy HA, Shweash M, Schroeder J, Kurnik M, 
Sloss CM, Bryant CE, Alexander J, Plevin R. MAP kinase phosphatase-2 plays a 
critical role in response to infection by Leishmania mexicana. PLoS Pathog. 
2010;6:e1001192. 
 175.  Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat 
Immunol. 2002 Dec;3:1129-34. 
 176.  Xu H, Yang Q, Shen M, Huang X, Dembski M, Gimeno R, Tartaglia LA, Kapeller 
R, Wu Z. Dual specificity MAPK phosphatase 3 activates PEPCK gene 
transcription and increases gluconeogenesis in rat hepatoma cells. J Biol Chem. 
2005 Oct 28;280:36013-8. 
 177.  Wu Z, Jiao P, Huang X, Feng B, Feng Y, Yang S, Hwang P, Du J, Nie Y, et al. 
MAPK phosphatase-3 promotes hepatic gluconeogenesis through 
dephosphorylation of forkhead box O1 in mice. J Clin Invest. 2010 Nov 
1;120:3901-11. 
 178.  Weng Y, Shen F, Li J, Shen Y, Zhang X. Expression changes of mitogen-
activated protein kinase phosphatase-1 (MKP-1) in myocardium of 
streptozotocin-induced diabetic rats. Exp Clin Endocrinol Diabetes. 2007 
Jul;115:455-60. 
 179.  Zhou J, Wang L, Ling S, Zhang X. Expression changes of growth-associated 
protein-43 (GAP-43) and mitogen-activated protein kinase phosphatase-1 (MKP-
1) and in hippocampus of streptozotocin-induced diabetic cognitive impairment 
rats. Exp Neurol. 2007 Aug;206:201-8. 
 180.  Zhang B, Hosaka M, Sawada Y, Torii S, Mizutani S, Ogata M, Izumi T, Takeuchi 
T. Parathyroid hormone-related protein induces insulin expression through 
activation of MAP kinase-specific phosphatase-1 that dephosphorylates c-Jun 
NH2-terminal kinase in pancreatic beta-cells. Diabetes. 2003 Nov;52:2720-30. 
 181.  Xu H, Dembski M, Yang Q, Yang D, Moriarty A, Tayber O, Chen H, Kapeller R, 
Tartaglia LA. Dual specificity mitogen-activated protein (MAP) kinase 
phosphatase-4 plays a potential role in insulin resistance. J Biol Chem. 2003 Aug 
8;278:30187-92. 
 182.  Emanuelli B, Eberle D, Suzuki R, Kahn CR. Overexpression of the dual-
specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin 
resistance. Proc Natl Acad Sci U S A. 2008 Mar 4;105:3545-50. 
43 
 
 183.  Bazuine M, Carlotti F, Tafrechi RS, Hoeben RC, Maassen JA. Mitogen-activated 
protein kinase (MAPK) phosphatase-1 and -4 attenuate p38 MAPK during 
dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol. 
2004 Jul;18:1697-707. 
 184.  Sakaue H, Ogawa W, Nakamura T, Mori T, Nakamura K, Kasuga M. Role of 
MAPK phosphatase-1 (MKP-1) in adipocyte differentiation. J Biol Chem. 2004 
Sep 17;279:39951-7. 
 185.  Ito A, Suganami T, Miyamoto Y, Yoshimasa Y, Takeya M, Kamei Y, Ogawa Y. 
Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant 
protein-1 during the course of adipocyte hypertrophy. J Biol Chem. 2007 Aug 
31;282:25445-52. 
 186.  Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic 
diseases. Nat Rev Immunol. 2008 Dec;8:923-34. 
 187.  Engelman JA, Berg AH, Lewis RY, Lin A, Lisanti MP, Scherer PE. Constitutively 
active mitogen-activated protein kinase kinase 6 (MKK6) or salicylate induces 
spontaneous 3T3-L1 adipogenesis. J Biol Chem. 1999 Dec 10;274:35630-8. 
 
 
 
44 
 
CHAPTER II 
REGULATION OF DUAL-SPECIFICITY PHOSPHATASES IN INSULIN-RESPONSIVE 
TISSUE OF GENETIC AND DIET-INDUCED MODELS OF OBESITY 
 
Abstract 
 Obesity is characterized by chronic, low-grade inflammation in metabolic tissues 
that leads to insulin resistance (IR) and type 2 diabetes. Mounting evidence 
demonstrates that signaling cascades, such as mitogen-activated protein kinases 
(MAPKs), link inflammation to obesity-induced IR. Moreover, recent reports demonstrate 
a key role for MAPK-specific dual-specificity phosphatases (DUSPs) in the regulation of 
MAPK signaling and control of inflammation. This study investigates DUSP mRNA 
regulation under conditions of genetic and diet-induced obesity (DIO) in insulin-
responsive adipose tissue (AT), liver, skeletal muscle, and heart, as dysfunction of these 
tissues in obesity triggers IR and consequently premature death. Data presented here 
demonstrate that DUSP expression in lean C57BL/6J mice is tissue specific, where a 
majority of these phosphatases (dusp2, dusp4, dusp5, dusp9) are most abundantly 
expressed in AT. These data further demonstrate divergent regulation of DUSPs in 
insulin-responsive tissues of genetic obesity. Finally, we show that DUSPs were 
divergently regulated in AT based on the developmental stage (i.e., early vs. mid-stage) 
and model of obesity (i.e., genetic vs. DIO) as well as the inflammatory environment 
resulting from obesity. Collectively, these results suggest that tissue-specific regulation 
of DUSPs contributes to obesity-associated inflammation and IR. Moreover, these data 
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collectively establish a platform for future studies investigating a role for DUSPs in 
metabolically critical tissues linking obesity with metabolic inflammatory diseases.   
   
Introduction 
Obesity is a modern pandemic that plays a causal role in the development of IR 
and type 2 diabetes (1). Mounting evidence over the last several years demonstrates 
that inflammation is a central mediator that links obesity with IR (2-4). Based on the 
hallmarks of obesity-induced inflammation, obesity is increasingly being associated with 
the phenomenon termed ‘metaflammation’, which is described as a state of chronic, low-
grade inflammation coordinated by metabolic cells such as adipocytes in response to 
nutrient overload that consequently leads to metabolic dysfunction (5). While AT is the 
predominant site of cytokine expression during obesity (2), it is now recognized that 
other metabolically active, insulin-responsive tissues such as liver experience increased 
inflammation in the obese state (4,6-9). Unlike liver and AT, obesity-derived 
inflammation from muscle and heart remains a point of debate (7,10,11). However, 
inflammatory mediators from liver and adipose can alter skeletal muscle and heart 
metabolism (7,10,11), ultimately impacting systemic glucose homeostasis (4) as well as 
cardiac contractility and vascular function (9).  
Investigations upstream of inflammatory mediators have identified MAPKs, 
consisting of extracellular signal-regulated kinase (ERK), p38, and c-Jun N terminal 
kinase (JNK), as major signaling pathways that contribute to metabolic tissue 
dysfunction (4,12). MAPKs have been shown to be activated in these metabolic tissues 
in response to obesity-associated inflammation and serve as mediators of IR through 
transcriptional mechanisms involving adipocyte gene expression as well as the 
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expression and secretion of other proinflammatory molecules (4,13-16). In addition to 
nuclear events involving AP-1 mediated gene expression, MAPK activity has also been 
linked to cytosolic suppression of proximal insulin signaling through JNK phosphorylation 
of specific serine residues of IRS-1 demonstrating that compartmentalized signaling 
events can impact different properties of tissue dysfunction (16-18).   
While upstream kinases were traditionally viewed as major controllers of MAPK 
activity, recent evidence demonstrates that downstream phosphatases play a central 
role in mediating MAPK signaling and biological consequences involving inflammation 
(19-21). As phosphorylation of threonine and tyrosine residues within the activation loop 
are needed for MAPK activation, dephosphorylation of one or both residues results in 
inactivation of these molecules (14,21,22). MAPK-specific dual-specificity phosphatases 
(DUSPs) have recently emerged as central modulators of MAPK signaling critical for 
biological processes involving inflammation and IR (23,24), where DUSP loss of function 
results in increased MAPK signaling that corresponds to increased inflammation along 
with diabetic cardiomyopathy and diabetic dementia (25-29). This subclass of protein 
tyrosine phosphatases constitutes a structurally distinct group of ten proteins identified 
by a non-catalytic MAP Kinase Binding (MKB) domain that functions in the specific 
docking of DUSPs to MAPKs, subsequently dephosphorylating threonine and tyrosine 
residues within the activation loop (20,21,30).  
In this report, we investigated DUSP regulation in key metabolically active, 
insulin-responsive tissues of AT, liver, skeletal muscle, and heart under conditions 
obesity. These tissues were selected as evidence demonstrates that they act as major 
regulators of blood glucose homeostasis and vascular function (6,9). Moreover, we 
examined the developmental role of obesity on DUSP regulation in AT using both 
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genetic and diet-induced models of obesity. This report demonstrates that DUSPs are 
regulated in a tissue specific manner based on the degree of obesity, the stage of 
obesity, the model of obesity as well as the inflammatory environment resulting from 
obesity. Collectively, these data suggest that divergent regulation of DUSPs may 
contribute to tissue-specific metaflammation and obesity, providing prospective 
therapeutic targets for obesity-associated metabolic inflammatory diseases.  
 
Materials and Methods 
 Mice and experimental diets. Animals used for this study include genetically 
obese male B6.V-Lepob/J (B6-ob/ob) mice and their lean littermates as well as 
C57BL/6J mice rendered obese by diet and their lean controls. All mice were housed 
and treated by the supplier (Jackson Laboratories, Bar Harbor, Maine) until shipment 1 
wk prior to tissue harvest. B6-ob/ob mice and lean littermates were purchased for 
experimentation at 6 wks and 10 wks of age and given free access to standard 
laboratory chow diet. C57BL/6J mice subjected to diet-induced obesity (DIO) were fed a 
high fat diet (HFD) consisting of 60% kcal from fat (Research Diets Inc. D12492) from 6 
wks of age until shipment. Lean C57BL/6J control mice were fed a control diet (CD) 
consisting of 10% kcal from fat (Research Diet Inc. D12450B) from 6 wks of age until 
shipment. Both diets contained 10% kcal from protein with the balance in caloric value 
provided by differences in carbohydrate content. Mice receiving both diets had free 
access to food and shipped for experimentation at 18 wks and 24 wks of age. All 
animals were euthanized by CO2 gas asphyxiation and epididymal AT, liver, skeletal 
muscle, and heart collected and processed for preparation of total RNA. Animal care and 
use was in compliance with the Institute of Laboratory Animal Research Guide for the 
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Care and Use of Laboratory Animals and approved by the institutional Animal Use and 
Care Committee of the Louisiana State University. Animals were weighed and tissues 
flash frozen in the laboratory of Jacqueline Stephens (Biological Sciences, Louisiana 
State University) and shipped to UNCG for further processing. 
Real-Time RT-PCR: Total RNA was isolated from epididymal AT, liver, skeletal 
muscle, and heart by utilizing Trizol reagent according to manufacturer’s protocol, and 
processed as described by Qiagen RNA clean-up protocol. Total RNA quality was 
assessed via RNA integrity gels and total RNA was quantified with a Nanodrop ND-1000 
spectrophotometer. Total RNA was reverse-transcribed to cDNA in a 10 µl reaction 
volume using a high capacity cDNA reverse transcription kit (Applied Biosystems). The 
reverse transcription (RT) master mix containing RT buffer, deoxyribonucleotide 
triphosphate (dNTP) mix, RT random primers, RNase inhibitor (1.0 U/µl), and MultiScribe 
RT was added to 1 µg RNA and RNase-free water. Reverse transcription reaction 
conditions followed the protocol (25°C for 10 min, 37°C for 120 min, 85°C for 5 sec, 
followed by 4°C indefinitely/ RT complete) and utilized the Gene Amp PCR System 9700 
thermal cycler (Applied Biosystems) for cDNA synthesis. 
PCR amplification was run utilizing the 7500 fast system (Applied Biosystems) 
that consisted of enzyme activation at 95°C for 20 sec, followed by 40 cycles of 
denaturation at 95°C for 3 sec combined with annealing/extension at 60°C for 30 sec. All 
data were analyzed with the ABI 7500 real time PCR system (Applied Biosystems). 
TaqMan primer probes used in this study (Table 2.1) were purchased from Applied 
Biosystems. Data were recorded and analyzed with Sequence Detector Software 
(Applied Biosystems) and graphs visualized with SigmaPlot software. All data were 
presented as mean  standard error of the mean (SEM) and representative of at least 
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two experiments performed in duplicate. Data were normalized to 18S and measured as 
relative differences using the 2-ΔΔCT method as previously described (31,32).  
Statistical analyses were conducted using SPSS v18. Differences in gene 
expression between lean and obese animals were determined via student’s t-test where 
a p-value of <0.05 was considered significant. mRNA tissue distribution data were 
analyzed using analysis of variance, with Tukey's post-hoc analysis used when 
the p value for the respective parameter was statistically significant (p < 0.05).  
 
Results 
 DUSP expression in insulin-responsive tissues of C57BL/6J mice. A role for 
select DUSPs (e.g., dusp1 and dusp6) has recently been demonstrated under conditions 
of genetic and diet-induced models of obesity (33-35). As activation of MAPKs increase 
in multiple tissues during the state of metaflammation contributing to obesity-induced IR 
and premature death (16,18,36,37), we initially compared relative mRNA expression of 
all known MAPK-specific DUSPs in insulin-responsive tissues from 10 wk old C57BL/6J 
wildtype mice using qRT-PCR. All ten DUSPs were measurable in lean AT within the 
detectable limits of 36 threshold cycles (CT) with dusp5, dusp7, dusp8, and dusp9 least 
abundantly expressed (27 cycles) and dusp1, dusp6, and dusp10 most abundantly 
expressed (24 cycles) (Table 2.1). Only dusp2 fell outside this narrow range of 
expression at 30 cycles. Using DUSP structural differences involving the presence of 
nuclear localization sequences (NLS) or nuclear export sequences (NES), we and others 
have grouped DUSPs based on the probability of localization to the nucleus (group I) or 
cytosol (group II), respectively (Table 2.1). DUSPs containing both NLS and NES were 
designated as group III phosphatases that may localize to either compartment (20,21). 
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To assess differences in tissue distribution, DUSPs were normalized to 18S ribosomal 
RNA and expressed as fold-differences relative to AT. DUSPs were differentially 
expressed in insulin-responsive tissues with dusp2, dusp4, and dusp5 most abundantly 
expressed in white AT (WAT) regarding group I phosphatases (Fig.2.1A). Further 
examination of group I DUSPs, demonstrated that dusp4 expression was markedly more 
abundant (~14-fold) in WAT than in all other tissue types. Similarly, dusp5 was 20-fold 
greater in WAT than in liver or skeletal muscle, but not different in heart (Fig.2.1A). While 
dusp2 was significantly more abundant in WAT, its expression relative to the other tissue 
types was less marked with 4-fold, 1.5-fold, and 2-fold greater than liver, skeletal 
muscle, and heart, respectively. In contrast to other group I phosphatases, expression of 
dusp1 was more abundant in heart and skeletal muscle than in WAT or liver.  
Regarding group II phosphatases, expression of dusp6 and dusp9 were also 
markedly more abundant in WAT, with expression of dusp9 ~50-fold greater in WAT 
compared to liver, skeletal muscle, and heart (Fig.2.1B). While expression of dusp6 was 
significantly greater in WAT (~2.5 fold) relative to skeletal muscle and heart, it was 
expressed equivalent to that of liver. Conversely, dusp7 was significantly more elevated 
in heart tissue relative to liver (~20 fold), AT (~3 fold), and skeletal muscle (~3 fold). In 
contrast to group I and group II DUSPs, expression of group III phosphatases was most 
abundant in skeletal muscle or heart where dusp8 was approximately 4-fold greater than 
WAT and 86-fold higher than liver (Fig.2.1C). Skeletal muscle had the highest 
expression of dusp10 compared to WAT (~4-fold), liver (~30-fold), and heart (~6-fold). 
Interestingly, dusp16 was the only phosphatase examined of any group that displayed 
similar levels of mRNA abundance across all four tissue types. Collectively, these data 
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demonstrated divergent tissue distribution of MAPK-specific DUSPs suggesting the 
probability of tissue-specific regulation and function.  
 DUSP regulation in insulin-responsive tissues under conditions of genetic 
obesity. The impact of genetic obesity on the expression of DUSPs in insulin-responsive 
tissues was further examined in 10 wk old B6-ob/ob mice, where leptin-deficient mice 
were given free access to standard chow for 10 wks presented with 83% greater body 
weight compared to wildtype littermates (Table 2.2). Using this genetic model of obesity, 
we compared the expression of each DUSP between lean and obese animals in all four 
insulin responsive tissues. Regarding the effect of genetic obesity on group I 
phosphatases, dusp1 was induced in WAT and liver, while dusp5 was elevated in liver 
and skeletal muscle. Obesity also increased dusp2 and dusp4, but only in WAT and 
skeletal muscle, respectively.  Conversely, obesity suppressed dusp1, dusp2, and dusp5 
in heart tissue as well as dusp4 in the liver. Of group II phosphatases, dusp6 was 
elevated only in liver tissue and suppressed in the heart. Dusp7 was the only 
phosphatase examined whose expression was completely unaffected by obesity in all 
four tissues. In contrast, dusp9 was markedly elevated ~5-fold in WAT, ~4-fold in liver 
and more than 30-fold in skeletal muscle, while remaining constant in heart tissue. As for 
group III phosphatases, dusp8 and dusp10 were only elevated in the liver while being 
suppressed by obesity in skeletal muscle. Dusp8 and dusp16 were also suppressed in 
skeletal muscle and WAT, respectively.   
 Collectively, these data demonstrated that inducible MAPK-specific DUSPs were 
divergently regulated by genetic obesity at the level of gene expression in a tissue-
specific manner. Several generalizations were noted. As a group, group I phosphatases 
were the most affected by obesity with all four members being induced modestly, but 
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significantly, by obesity in one or more insulin responsive tissues. In contrast, dusp9 
(group II) was markedly elevated by obesity in three of the four tissues examined, where 
gene expression exceeded a 30-fold induction in skeletal muscle. Dusp8 (group III) was 
also increased markedly with obesity, but only in the liver. While some phosphatases 
(i.e., dusp7 and dusp16) were mostly unaffected by obesity, select DUSPs increased in 
one tissue while decreasing in another. Of the four insulin responsive tissues tested, the 
heart was the only tissue, in which obesity did not lead to an increase in any DUSP, 
rather it actually led to a suppression of 5 of the 10 phosphatases examined.   
 Developmental regulation of DUSPs in AT of genetic and diet-induced 
obesity. Other reports have suggested that AT is the predominant site for the 
development of obesity-associated inflammation leading to systemic metabolic 
disruption. As data presented here demonstrated that DUSPs were most abundantly 
expressed in AT relative to other insulin responsive tissues, we next examined the 
developmental role of obesity on AT gene expression using both genetic and diet-
induced models of obesity. For genetic obesity development, B6-ob/ob mice and 
wildtype littermates were purchased (Jackson Laboratory) for studies conducted at 6 
wks and 10 wks of age. According to the supplier, mice homozygous for the obese 
mutation exhibit hyperplasia with ensuing obesity notable at 1 month of age and 
transient glucose intolerance that begins at ~6 wks of age and subsides between 12-16 
wks of age. Thus, ages of mice chosen for this study represented models of early stage 
(6 wks) and mid-stage (10 wks) obesity with developing obesity-related metabolic 
disorders. As illustrated in Table 2.2, 6 wk and 10 wk old B6-ob/ob mice used in this 
study presented with 67% and 83% increases in body weight, respectively, relative to 
lean littermates. For development of diet-induced obesity (DIO), C57BL/6J males were 
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fed by the supplier a high fat diet (HFD; 60% kcal) starting at six weeks of age. Control 
B6 males were fed a control diet (CD) containing 10% kcal from fat and the same protein 
content as the HFD. The source of increased fat in the HFD was from lard, which 
contains abundant proinflammatory saturated fatty acids. Studies were conducted at 18 
wks and 24 wks of age, representing 12 wks and 18 wks of specialized diet, 
respectively.  As shown in Table 2.2, 18 wk and 24 wk old mice fed a HFD in this study 
presented with 13% and 26% increases in body weight, respectively, relative to lean 
mice fed the control diet. 
 RNA was isolated from AT harvested at two stages of obesity development from 
epididymal fat pads from male B6-ob/ob and DIO mice and assessed by qRT-PCR, 
normalized to 18S rRNA, and presented relative to lean controls. Initially, relative 
differences in adipsin were assessed to confirm that both stages of development in each 
animal model represented cellular changes indicative of the onset of obesity. It is well 
established that this adipocyte-specific gene is markedly suppressed in adipose tissue 
isolated from obese animals relative to lean controls (38). As illustrated in Fig.2.3, both 
models of obesity presented with marked suppression of adipsin at both stages of 
development. Moreover, the suppression was progressively more pronounced with time, 
with 40-fold and 80-fold suppression determined for early and late stage obesity in B6-
ob/ob animals and 7-fold and 25-fold suppression for early and late stage obesity in DIO 
animals.  To further characterize the stage of development, relative mRNA abundance 
was determined for MCP-1, IL-6 and TNFα as inflammatory markers critical to the 
development of chronic AT inflammation during obesity (6,39,40). The chemokine MCP-
1, which has been shown to play an early role in macrophage recruitment to AT during 
the onset of obesity (39,40), increased greater than 8-fold at both stages of development 
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and in both models of obesity (Fig.2.3). Conversely, IL-6 and TNFα were elevated only 
during late stages in B6-ob/ob mice fed standard chow. Both cytokines were elevated in 
DIO mice fed HFD at both stages of development with progressive increases in TNFα 
correlating to either time on HFD or the stage of obesity development. Along with 
changes in body weight, relative changes in mRNA abundance of these four genes 
characterized both animal models as early to mid-stage development of obesity.  
Relative DUSP gene expression was further examined in AT during the 
development of obesity as assessed above. Several generalizations could be made. 
First, dusp9 (group II) was the only phosphatase examined where mRNA abundance 
increased in both models of obesity and at both stages of development, including early 
stage B6-ob/ob where the onset of obesity preceded the increase in inflammatory 
cytokines. Moreover, dusp9 gene expression progressively increased with the stage of 
development in both animal models. These data were consistent with other observations 
from our laboratory where dusp9 was shown to increase during adipocyte differentiation, 
but displayed no changes in gene expression in undifferentiated preadipocytes or 
mature adipocytes over time following TNFα stimulation (data not shown; Ch.3&4). 
Second, dusp4 (group I) increased only in early stage B6-ob/ob mice that were shown 
here to have no changes in TNFα expression and was suppressed in late stage DIO 
mice that presented with the greatest increase in TNFα expression. These data were 
also consistent with other observations from our laboratory where dusp4 was observed 
to increase with adipocyte differentiation, but was markedly suppressed with TNFα 
stimulation (data not shown; Ch.3&4). Third, dusp1 and dusp2 (group I) were elevated in 
obese relative to lean AT only during conditions that also displayed an increase in TNFα; 
an observation that was again consistent with unpublished data demonstrating that 
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dusp1 increased at the level of gene expression with TNFα stimulation (Ch.4). Fourth, 
dusp5 and dusp6 increased during both stages of development in DIO mice, but not B6-
ob/ob mice. Neither phosphatase was markedly affected by TNFα stimulation in 
adipocytes (data not shown, Ch.4), suggesting a role for other inflammatory mediators 
associated with HFD unrelated to obesity development. Fifth, dusp7, dusp8 and dusp16 
displayed no increases in gene expression in either model at either stage of 
development. Finally, except for a modest decrease in dusp16 only in late stage B6-
ob/ob, the development of obesity did not result in suppression of DUSP gene 
expression in AT. Collectively, these data demonstrated DUSP gene expression was 
divergently regulated based on the degree of obesity, the stage of obesity, the model of 
obesity as well as the inflammatory environment resulting from obesity.    
 
Discussion 
 This investigation presents the first empirical evidence that MAPK-specific 
DUSPs are divergently regulated in metabolically active, insulin responsive tissues 
under conditions of genetic obesity, and differentially regulated in AT based on the 
degree, stage, and model of obesity as well as the inflammatory environment resulting 
from obesity. First, we show that DUSPs are divergently regulated in all four tissue types 
analyzed and that DUSPs were most abundantly expressed in AT. Second, we present 
evidence that DUSPs were differentially regulated in genetic obesity in a tissue-specific 
manner. Finally, these data show that DUSP regulation in AT was dependent on the 
developmental stage of obesity (i.e., early vs. mid), the model system that characterized 
obesity (i.e., genetic or diet-induced), and the development of obesity-associated 
inflammation. Collectively, these data provide novel insight into DUSP regulation in 
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insulin responsive tissues involved in blood glucose homeostasis and vascular function, 
potentially establishing therapeutic targets for obesity-associated metabolic inflammatory 
diseases. 
 Mounting evidence demonstrates that DUSPs show different patterns of tissue 
expression, allowing individual DUSPs to regulate tissue-specific MAPK-dependent 
biological processes (23). This investigation presents the first empirical evidence 
demonstrating that all ten MAPK-specific DUSPs were differentially regulated in 
metabolically active, insulin-responsive tissues, supporting a tissue-specific functional 
role for individual DUSPs on the modulation of MAPK signaling. Tissue-specific 
regulation of DUSPs, therefore, may also contribute to MAPK-dependent processes that 
link obesity with metabolic inflammatory diseases. Data presented here demonstrate that 
DUSPs were divergently regulated by genetic obesity at the level of gene expression in 
a tissue-specific manner. Recent studies have identified dusp6 as a candidate gene 
involved in insulin signaling in the liver, where loss-of-function in lean and obese mice 
decreased fasting blood glucose levels that was attributed to down-regulation of 
gluconeogenic genes, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase 
(33,35). While we report that dusp6 was expressed most abundantly in AT and liver 
compared to skeletal muscle and heart, we further show that dusp6 was only induced in 
the liver under conditions of genetic obesity, suggesting that tissue-specific regulation of 
dusp6 is essential for liver gluconeogenesis. Of the four tissues examined, the heart was 
the only tissue in which obesity did not lead to an increase in any DUSP, but actually led 
to a suppression of 5 of the 10 phosphatases examined. While loss-of-functions studies 
demonstrate that induction of individual DUSPs protects against vascular endothelial 
inflammation and atherosclerosis (41-43), these data suggest that suppression of 
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DUSPs with genetic obesity potentially contributes to obesity-mediated heart disease. 
Collectively, these data highlight the therapeutic potential for individual DUSPs in the 
tissue-specific regulation of MAPK-dependent processes that link obesity to metabolic 
inflammatory diseases.    
While metaflammation leads to metabolic instability, AT remains the predominant 
site of proinflammatory cytokine expression during obesity. Moreover, evidence 
demonstrates that AT inflammation happens gradually over time, where cytokine and 
chemokine expression as well as macrophage infiltration increase with the development 
of obesity (2,12,12,39,40). Recent reports, for instance, demonstrate that macrophage-
related genes MIP-1α and MCP-1 increased within 3 weeks of a high fat diet (HFD) and 
continued to rise at 16 and 26 weeks on a HFD concomitant with macrophage infiltration 
and the development of systemic IR (39). Data presented above demonstrate that 
proinflammatory chemokine and cytokine mRNA was increased in AT of C57BL/6J mice 
at 10 wks, while TNFα continued to rise at 18 wks on a HFD. We also show that only 
MCP-1 was increased in 6 wk old B6-ob/ob mice, while MCP-1, IL-6, and TNFα were 
increased in 10 wk old B6-ob/ob mice. Similar to the gradual development of AT 
inflammation, we observed a progressive decline in the adipocyte-specific gene adipsin, 
which has previously been reported to decrease with the degree of obesity (38). 
Collectively these data support the hypothesis that AT inflammation progressively occurs 
with the development of obesity. 
Increased reports demonstrate a functional role for DUSPs in the regulation of 
inflammation, where DUSP loss-of-function studies demonstrate that MAPK-dependent 
inflammation of immuno-modulating cells is markedly activated (25-27,44). Data 
presented here demonstrate that DUSPs were divergently regulated in AT based on the 
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degree, stage, and model of obesity as well as the inflammatory environment resulting 
from obesity. We show that dusp1 and dusp2 were only induced under conditions of 
obesity where inflammatory genes IL-6 and TNFα were elevated. Furthermore, we report 
that dusp4 was only induced under conditions of obesity with no inducible inflammatory 
gene expression of TNFα, while dusp4 was suppressed with DIO where TNFα was 
markedly elevated. Consistent with these observations, reports have shown that dusp1 
and dusp4 regulate MAPK-dependent inflammation in response to endotoxic shock and 
parasitic infection (25-27,44), where loss-of-function promoted inflammation and 
worsened animal response to shock or infection. We further report that dusp5 and dusp6 
were upregulated under conditions of diet-induced obesity and not genetic obesity. As 
others have reported a role for fatty acids in the regulation of individual DUSPs (45,46), 
these data suggest that high fat feeding, and not obesity per se, promotes inducible 
dusp5 and dusp6 expression. Moreover, reports show that saturated fatty acids bind to 
toll-like receptors leading to increased AT inflammation (47,48). As obesity occurs in the 
presence of chronic, positive energy intake, these data suggest that select DUSP 
regulation in vivo reflects diet-induced models of obesity. Collectively these data suggest 
that inflammatory progression in AT resulting from obesity and/or high fat feeding 
divergently regulate DUSPs potentially linking obesity with metabolic dysfunction. 
Of the phosphatases examined, dusp9 was the only DUSP induced under all 
conditions of genetic and diet-induced obesity in AT. Moreover, dusp9 was upregulated 
in AT, liver, and muscle with genetic obesity. Others have also shown that dusp9 is 
upregulated in AT under conditions of obesity (24,49), while gain-of-function studies 
demonstrate that dusp9 blocks adipogenesis (24,34,49). While no study has examined 
dusp9 loss of function on adipogenesis, these data collectively suggest that obesity 
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regulates dusp9 mRNA expression. Furthermore, reports have identified Dusp9 as a 
candidate gene involved in insulin signaling, while others show that dusp9 
overexpression improved stress-induced IR (33,35,49). Collectively, these data suggest 
a functional role for dusp9 in the development of obesity and metabolic regulation.   
 In summary, previous reports (20,23) demonstrate the importance of 
phosphorylation and dephosphorylation by upstream kinases and downstream 
phosphatases in the regulation of MAPK signaling and metabolic function. Data are 
presented demonstrating that DUSPs are divergently regulated in a tissue-specific 
manner, and that obesity-associated induction of DUSPs is highly dependent on the 
tissue examined. Furthermore, we show that progression of obesity and inflammation 
resulting from obesity as well as diet divergently regulate DUSPs in AT. Collectively, 
these data suggest that differential regulation of DUSPs potentially contribute to MAPK-
dependent tissue-specific biological processes linking obesity with metabolic 
inflammatory diseases.    
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Table 2.1.  DUSP, adipocyte, and inflammatory genes analyzed in this study. 
 
 symbol name/alias     accession ABI number CT 
dual specificity phosphatases 
(DUSPs) 
GP MKB NLS NES    
 Dusp1 MKP-1, hVH1 I ● ●  NM_013642 Mm00457274_g1 24 
 Dusp2 PAC1 I ● ●  NM_010090 Mm00839675_g1 30 
 Dusp4 MKP-2, hVH2 I ● ●  NM_176933 Mm00723761_m1 25 
 Dusp5 hVH3 I ● ●  
NM_0010853
90 
Mm01266104_m1 27 
 Dusp6 MKP-3, rVH6 II ●  ● NM_026268 Mm00650255_g1 24 
 Dusp7 MKP-X II ●  ● NM_153459 Mm00463228_m1 27 
 Dusp9 MKP-4 II ●  ● NM_029352 Mm00512646_m1 27 
 Dusp8 M3/6, hVH5 III ● ● ● NM_008748 Mm00456230_m1 27 
 Dusp10 MKP-5 III ● ● ● NM_022019 Mm00517678_m1 24 
 Dusp16 MKP-7, MKP-M III ● ● ● NM_130447 Mm00459935_m1 25 
adipocyte and inflammatory genes    
 Cfd complement factor D, adipsin NM_013456 Mm00442664_m1 17 
 Ccl2 monocyte chemoattractant protein-1 (MCP-1) NM_011333 Mm00441242_m1 26 
 IL-6 interleukin-6 NM_031168 Mm99999064_m1 32 
 TNFα tumor necrosis factor-alpha  NM_013693 Mm99999068_m1 28 
reference gene    
 18S 18 ribosomal RNA X03205 4342930E 9 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1. DUSP, adipocyte, and inflammatory genes analyzed in this study. DUSPs 
that contained the MAPK binding domain (MKB) were assigned to groups (GP) based on 
structural differences involving the presence or absence of a nuclear localization sequence 
(NLS), nuclear export sequence (NES), or both that may dictate subcellular localization to 
the nucleus (group I), cytosol (group II), or either compartment (group III).  
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Table 2.2. Final body weight of C57BL/6J and B6.V-Lep
Ob
/J mice used in this study. 
 
 Final body weight 
(g) 
Difference in  
body weight (g) 
% Change in  
final body weight 
 
Age 
 
Lean 
 
Ob/ob 
 
Ob/ob-Lean 
 
Ob/ob 
 
6 wk 
 
21.8 
 
36.4 
 
14.6 
 
67% 
10 wk 28.6 52.4 23.8 83% 
 
Age 
 
CD 
 
HFD 
 
HFD-CD 
 
HFD 
 
18 wk 
 
30.8 
 
34.7 
 
3.9 
 
13% 
24 wk 32.2 40.6 8.4 26% 
 CD=Control Diet 
HFD=High Fat Diet 
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Figure 2.1. Tissue-specific expression of DUSPs. 
Epidydimal white AT (WAT), liver, skeletal muscle (SK 
Muscle), and heart were harvested and total RNA 
prepared from C57BL/6J male mice. Gene expression of 
all ten DUSPs was analyzed via qRT-PCR. All data were 
normalized to 18S rRNA and tissues set relative to WAT. 
Statistical ANOVA was used to determine significant 
differences, p<0.05. Tukey's post-hoc analysis was performed when the p value for the 
respective parameter was statistically significant (p < 0.05). Additionally, DUSPs were 
grouped based on localization sequences: group I (NLS), group II (NES), and group III 
(NLS/NES). 
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Figure 2.2. Tissue-specific expression of DUSPs under conditions of leptin-
deficient obesity. White AT (WAT), liver, skeletal muscle (Sk Muscle), and heart 
were harvested and prepared for total RNA from 10-wk-old male B6.V-Lep
Ob
/J (ob/ob) 
mice and their lean litter mates. Relative DUSP mRNA abundance was measured via 
qRT-PCR and statistical significance determined at p<0.05 via student’s t-test. All data 
were normalized to 18S rRNA and expressed relative to lean littermates. Graphical 
grouping of DUSPs is based on localization sequence, where group I (nuclear) 
contains and NLS, group II (cytosolic) contains and NES, and group III 
(cytosolic/nuclear) contains NLS and NES sequences.  
64 
 
 
 
 
 
Figure 2.3. AT specific regulation of DUSPs and inflammatory mediators during the 
development of obesity under conditions of genetic and diet-induced obesity. AT was 
harvested and RNA prepared from A) 6-wk-old and B) 10-wk-old male B6.V-Lep
Ob
/J (ob/ob) 
mice and their lean litter mates, along with male C57B116J C) 18-wk-old and D) 24-wk-old 
DIO mice and their lean controls. Relative DUSP mRNA abundance was measured via 
qRT-PCR and statistical significance determined student’s t-test (p<0.05). All data were 
normalized to 18S rRNA and expressed relative to lean littermates.  
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CHAPTER III 
ROLE FOR DUAL-SPECIFICITY PHOSPHATASES ON MITOGEN-ACTIVATED 
PROTEIN KINASE SIGNALING DURING ADIPOCYTE DIFFERENTIATION 
 
Abstract 
Knowledge concerning mechanisms that control proliferation and differentiation of 
preadipocytes is essential to our understanding of adipocyte hyperplasia and the 
development of obesity. Timely regulation of mitogen-activated protein kinase (MAPK) 
phosphorylation and dephosphorylation by upstream kinases and downstream 
phosphatases is critical for coupling extracellular stimuli to cellular growth and 
differentiation. Using differentiating 3T3-L1 preadipocytes as a model of adipocyte 
hyperplasia, we examined a role of dual-specificity phosphatases (DUSPs) on the timely 
modulation of MAPK signaling during states of growth arrest, proliferation, and 
differentiation. Using real-time reverse transcription PCR (qRT-PCR), we report that 
several DUSPs were induced during early (i.e., dusp1, dusp2, dusp5, and dusp6), mid 
(i.e., dusp4), and late (i.e., dusp9 and dusp16) stage adipocyte differentiation 
concomitant with ERK and p38 dephosphorylation. As timely modulation of ERK and p38 
activation during early differentiation is essential for adipogenesis, we further 
demonstrate that de novo mRNA synthesis was required for ERK and p38 
dephosphorylation, suggesting a modulatory role for ‘inducible’ phosphatases in MAPK 
signaling. Moreover, we show that pharmacological inhibition of early DUSPs markedly 
increased ERK and p38 signaling magnitude and duration during early adipogenesis. As 
conflicting reports have emerged for dusp1 regarding adipocyte differentiation, we 
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further demonstrate that dusp1-specific knockdown plays a modulatory role in MAPK 
signaling during early adipocyte differentiation, but did not block adipocyte differentiation. 
Collectively, these data suggest that cooperative actions of DUSPs is essential for 
modulating  timely dephosphorylation of MAPK signaling during adipocyte differentiation, 
providing prospective therapeutic targets for the treatment of obesity and its co-
morbidities. 
 
Introduction 
Obesity is a global pandemic that contributes to the development of stroke, heart 
disease, and type 2 diabetes (1). Obesity develops from an increase in adipose tissue 
(AT) mass due to enlargement of adipocyte size (hypertrophy) and cell number 
(hyperplasia) (2,3). As mature adipocytes (ADs) are resistant to cell division, hyperplasia 
generally refers to the recruitment of new ADs through proliferation and subsequent 
differentiation of adipocyte precursor cells referred to as ‘preadipocytes’ (PAs). While PA 
replication slows during adulthood to provide a constant balance of PAs to ADs when 
weight remains constant, adipocyte hyperplasia plays a critical role in the onset of 
obesity throughout all stages of life, particularly during childhood obesity and in adults 
under morbid conditions (4-7). Unlike hypertrophic obesity, exercise and caloric 
restriction are less effective in treating obesity derived from adipocyte hyperplasia 
(4,8,9). Despite evidence suggesting that hyperplastic obesity is associated with the 
poorest prognosis of treatment, mechanisms regulating adipocyte hyperplasia remain 
largely unknown. 
Intracellular signaling molecules play a critical role in linking environmental cues 
to increases in AT mass involving proliferation and differentiation of PAs. Major signaling 
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transduction cascades essential for adipocyte hyperplasia include phosphatidylinositol-3 
kinases (PI3Ks) and mitogen-activated protein kinases (MAPKs) (10,11).  MAPK activity 
is regulated by a cascade of phosphorylation events mediated by sequential activation of 
upstream kinases, where MAPK is phosphorylated by upstream MAPK kinases 
(MAP2Ks), which are phosphorylated by MAPK kinase kinases (MAP3Ks) in response to 
diverse external stimuli. Phosphorylation of both threonine and tyrosine residues of the 
(T-X-Y) motif within the activation loop is essential and sufficient for MAPK activity, 
leading to the phosphorylation of target proteins and transcription factors within the 
cytosolic and nuclear compartments (12-14) linking environmental cues to PA 
proliferation and differentiation.  
Of the major MAPK signaling pathways, only extracellular signal-regulated kinase 
(ERK) and p38 MAPK have been shown to regulate AD differentiation (10). Evidence 
suggests that timely activation (i.e., phosphorylation) as well as deactivation (i.e., 
dephosphorylation) of ERK and p38 is necessary for adipogenesis (10,15-19). Loss-of-
function studies have demonstrated a critical role for rapid and transient ERK activity 
regarding the induction of the early adipogenic transcription factor CCAAT/enhancer-
binding protein β (C/EBPβ). Activation of C/EBPβ is necessary for PA replication as well 
as the induction of C/EBPα and peroxisome proliferator-activated receptor (PPAR) γ; two 
master regulators of adipocyte-specific gene expression (18,20,21). Conversely, 
prolonged ERK activity has been shown to phosphorylate and inactivate PPARγ blocking 
AD differentiation (22). Similar evidence suggests that transient p38 activity is also 
critical for AD differentiation, whereas prolonged p38 activity results in cell death 
(16,23,24). Collectively, these observations suggest that timely activation of MAPKs, 
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involving a precise balance in phosphorylation/dephosphorylation mechanisms, is 
essential for PA proliferation and differentiation.  
While differences in MAPK signaling have traditionally been attributed to 
upstream kinases, recent evidence suggests that MAPK deactivation via phosphatases 
plays a central role in mediating signal transduction and cellular outcome (25-27). As 
phosphorylation of threonine and tyrosine residues within the activation loop is needed 
for MAPK activation, dephosphorylation of one or both residues results in inactivation of 
these molecules (12,27,28). MAPK-specific DUSPs constitute a structurally distinct 
group of ten proteins identified by a non-catalytic MAP Kinase Binding (MKB) domain 
that functions in the docking of MAPKs to the phosphatase (13,26,27). Moreover, the 
MKB domain consists of two CH2 domains flanking a kinase interactive motif (KIM) that 
confers specificity for select MAPKs. Recent attention has been given to these MAPK-
specific DUSPs regarding both proliferation and differentiation (29). While some reports 
demonstrate that overexpression of select DUSPs correlate to JNK and p38 deactivation 
and resistance to cell death (30-32), others show that loss of DUSP expression 
contributes to increased MAPK signaling and cellular growth (33-36). Reports also 
demonstrate an essential role for DUSPs in myocyte, neuronal, and osteoblast 
differentiation (37-39), where the precise balance of MAPK phosphorylation and 
dephosphorylation was necessary for differentiation of each cell type. Taken together, 
these data suggest that DUSP-MAPK interaction is essential for cellular growth and 
differentiation.  
Dusp1 has recently emerged in reports examining mouse models of diet-induced 
obesity where dusp1 knockout mice had enhanced nuclear JNK, p38, and ERK activity 
in white adipose tissue, liver, and skeletal muscle (40). Furthermore, these mice were 
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resistant to diet-induced obesity on a high fat diet and presented with increased energy 
expenditure. However, mouse embryonic fibroblasts from wildtype and dusp1 knockout 
mice differentiated in a similar manner demonstrating that dusp1 is not essential for 
adipocyte differentiation (40). Conversely, others have shown that dusp1 antisense 
expression in 3T3-L1 PAs led to sustained ERK activation and inhibition of adipogenesis 
(41). Considering the role DUSPs play in proliferation and differentiation, we explored 
the regulation and role of DUSPs during adipocyte differentiation using the murine 3T3-
L1 cell line. When grown to a state of density-arrest, quiescent PAs stimulated with a 
cocktail containing MDI synchronously re-enter the cell cycle for 1-2 rounds of 
proliferation prior to terminal growth arrest and AD differentiation (18,42). In this report, 
we demonstrate that MAPK-specific DUSPs are differentially expressed in PAs and ADs. 
Moreover, we show that several DUSPs are induced during early (i.e., dusp1, dusp2, 
dusp5, and dusp6), mid (i.e., dusp4), and late (i.e., dusp9 and dusp16) stages of AD 
differentiation concomitant with MAPK dephosphorylation. Additionally, pharmacological 
inhibition of early DUSPs increased MAPK signaling duration suggesting a cooperative 
role for DUSPs on MAPK dephosphorylation. Collectively, these data represent the first 
study in any cell type that examined all ten MAPK-specific DUSPs during differentiation 
and highlight an essential role for DUSPs in the timely modulation of MAPK 
dephosphorylation that is critical for adipogenesis.  
 
Materials and Methods 
Materials: Dulbecco’s Modified Eagle’s Medium (DMEM), calf bovine serum (CS), 
and trypsin-EDTA were purchased from Invitrogen. Fetal bovine serum (FBS) was 
obtained from HyClone. Antibodies used for immunoblotting include phospho-ERK, 
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phosho-p38, total p38, aP2, GAPDH, and α-tubulin purchased from Cell Signaling and 
dusp1, PPARγ, and C/EBPα purchased from Santa Cruz Biotechnology. Enhanced 
chemiluminescence (ECL) reagents were obtained from Perkin-Elmer Life Sciences. 
Actinomycin D was purchased from Sigma Aldrich triptolide was obtained from 
Calbiochem. All Taqman primer probes (Table 3.1) used in this study were purchased 
from Applied Biosystems. The murine 3T3-L1 cell line was purchased from Howard 
Green, Harvard Medical School (43). 
Cell Culture: 3T3-L1 preadipocytes were propagated in DMEM supplemented 
with 10% CS until density-induced growth arrest, as previously described (42). At 2 days 
post-confluence, growth medium was replaced with DMEM supplemented with 10% 
FBS, 0.5mM 1-methyl-3-isobutylxanthine, 1 µM dexamethasone, and 1.7 µM insulin 
(MDI). Throughout the study, ‘time 0’ refers to density arrested cells immediately before 
the addition of MDI to the culture medium. Experiments described herein were 
conducted within the period of differentiation spanning from density arrest (d0) through 8 
days (d8) post-MDI. All experiments were repeated at least 3 times to validate results 
and ensure reliability. 
Immunoblotting: Cell monolayers were washed with phosphate-buffered saline 
(PBS) and scraped into ice-cold lysis buffer containing 1.0 M Tris, pH 7.4, 150 mM NaCl, 
1% Triton X, 0.5% Nonidet P-40 (NP40), 1 mM EDTA, 1 mM EGTA, and 10 mM N-
ethylmaleimide. Phosphatase (20 mM ß-glycerophosphate, 10 mM NaFl, and 2 µM 
sodium vanadate), as well as protease (0.3 µM aprotonin, 21 µM leupeptin, 1 µM 
pepstatin, 50 µM phenanthroline, and 0.5 µM phenylmethylsulfonyl fluoride) inhibitors 
were added to lysis buffer prior to cell harvest. Cell lysates were sonicated, centrifuged 
(13,000 x g, 10 min, 4°C), and the supernatant transferred to a fresh tube. Bicinchoninic 
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acid assay (Pierce, Rockford, IL) was used to determine protein concentration. Cell 
lysates were resuspended in loading buffer containing 0.25 M Tris, pH 6.8, 4% sodium 
dodecyl sulfate (SDS), 10% glycerol, 10% dithiothreitol, and 0.01% bromophenol blue 
and heated for 5 min at 80°C. Proteins were resolved on SDS-polyacrylamide gel 
electrophoresis gels (PAGE) and transferred to polyvinylidene fluoride membranes 
(Millipore Corp., Billerica, MA). After transfer, membranes were blocked with 4% milk and 
probed with indicated primary antibodies overnight at 4°C. Membranes were 
subsequently probed with horseradish peroxidase-conjugated secondary antibodies for 1 
hr at room temperature. Immunoblots were immersed in ECL and visualized by 
autoradiography using CL-XPosure film (Pierce). 
Real-Time qRT-PCR: Total RNA was extracted and genomic DNA contamination 
was removed using the RNeasy Plus Mini Kit (Qiagen) following the manufacturer’s 
protocol. Total RNA was quantified with a Nanodrop ND-1000 spectrophotometer and 
reverse-transcribed to cDNA in a 10 µl reaction volume using a high capacity cDNA 
reverse transcription kit (Applied Biosystems). The reverse transcription (RT) master mix 
containing RT buffer, deoxyribonucleotide triphosphate (dNTP) mix, RT random primers, 
RNase inhibitor (1.0 U/µl), and MultiScribe RT was added to 1 µg RNA and RNase-free 
water. Reverse transcription reaction conditions followed the protocol (25°C for 10 min, 
37°C for 120 min, 85°C for 5 sec, followed by 4°C indefinitely/RT complete) and utilized 
the Gene Amp PCR System 9700 thermal cycler (Applied Biosystems) for cDNA 
synthesis. 
PCR amplification was run utilizing the 7500 fast system (Applied Biosystems) 
that consisted of enzyme activation at 95°C for 20 sec, followed by 40 cycles of 
denaturation at 95°C for 3 sec combined with annealing/extension at 60°C for 30 sec. All 
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data were analyzed with the ABI 7500 real time PCR system (Applied Biosystems). Data 
were recorded and analyzed with Sequence Detector Software (Applied Biosystems) 
and graphs visualized with SigmaPlot software. All data were presented as mean  
standard error of the mean (SEM) and representative of at least two experiments 
performed in duplicate. Data were normalized to 18S previously validated by this lab as 
a suitable reference gene under these experimental conditions (44). Relative differences 
between treated and untreated control samples were analyzed by the 2-ΔΔCT method as 
previously described (44,45). 
Statistical analyses were conducted using SPSS v18. Phenotypic differences 
were determined via student’s t-test where a p-value of <0.05 was considered 
significant. Knockdown and Inhibitor data were analyzed using analysis of variance, with 
Tukey's post-hoc analysis used when the p value for the respective parameter was 
statistically significant (p < 0.05).  
Flow Cytometry: Cell monolayers were washed with PBS and trypsinized. 
Detached cells were diluted in ice-cold PBS, and gently pelleted by centrifugation (300 x 
g, 5 minutes, 4°C). PBS was decanted, and cells were fixed and permeabilized by drop-
wise addition of 70% ethanol at –20°C while vortexing. Cells were washed in PBS and 
incubated in the dark for 30 min with a propidium iodide staining solution (50 µg/mL 
propidium iodide and 100 µg/mL RNase A in PBS). DNA fluorescence was measured 
with using the Guava easyCyte HT flow cytometer (Millipore) equipped with a 488-nm 
argon laser. Width (FL2W) and area (FL2A) of propidium iodide fluorescence were 
recorded for at least 5,000 counts, and DNA histograms were extracted from FL2W-
FL2A dot plots. Histograms were analyzed with Modfit software. 
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RNA Interference. SMARTpools containing four different short interfering RNAs 
(siRNAs) for dusp1 specific sequences as well as non-targeting sequences were 
transfected using DharmaFect 3 transfection reagent according to manufacturer’s 
(Dharmacon) protocol. Briefly, 3T3-L1 preadipocytes were propagated in 6-well culture 
dishes until reaching density-induced growth arrest. Growth medium was then replaced 
with DMEM supplemented with 10% CS, 3 µl DharmaFect 3 reagent and either 100 nM 
dusp1 specific siRNA or non-targeting siRNA for 72 hr. Growth medium was 
subsequently switched to differentiation medium containing MDI as described above. 
 
RESULTS 
Regulation of MAPK dephosphorylation by mechanisms involving de novo 
mRNA synthesis during 3T3-L1 adipocyte differentiation. While it is well established 
that ERK and p38 play functional roles during AD differentiation, the extent (i.e., 
magnitude and duration) of MAPK activity during distinct stages of differentiation 
remains uncertain (10,18,24). As others have reported that MAPK activity is required for 
early stages of differentiation and inhibits late stages of differentiation, the ‘timing’ of 
activity is critical for proper differentiation. To elucidate a role for phosphorylation and 
dephosphorylation mechanisms regarding MAPK activity during adipocyte hyperplasia, 
we utilized the well-established 3T3-L1 murine cell line for this study. This cell line 
synchronously progresses through distinct stages of the cell cycle before entering a 
state of terminal growth arrest concomitant with activation of a cascade of transcription 
factors that mediate late stage adipocyte gene expression and acquisition of the 
functional AD phenotype. To determine the extent of MAPK activity during these distinct 
stages of adipocyte differentiation, density-arrested PAs were stimulated with MDI and 
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cell lysates harvested over early (0hr-24hr) and late (d0-d8) stages of differentiation and 
immunoblotted with phosphospecific antibodies that recognize MAPKs only when 
phosphorylated on both amino acid residues that are sufficient and essential for MAPK 
activity. As illustrated in Fig.3.1A, ERK and p38 were rapidly phosphorylated (15 min) 
and then completely dephosphorylated (<4hr) during early adipocyte differentiation. Also 
shown is the phosphorylation state of MEK, the upstream MAPK kinase responsible for 
ERK phosphorylation, demonstrating that ERK was completely dephosphorylated 6-10 
hrs before MEK phosphorylation (i.e., activity) returned to baseline. The disconnect 
between the phosphorylation state of ERK and its upstream kinase is further illustrated 
in Fig.3.1.B, where phospho-ERK dropped below baseline following the initial activation 
throughout later stages of differentiation even though MEK retained some degree of 
activity at or exceeding baseline throughout 8 days of differentiation. It should also be 
noted (Fig.3.1.B) that the decrease in ERK activity below baseline levels occurred 
kinetically with the induction of PPARγ which is a known target of ERK whose 
transcriptional activity is suppressed when phosphorylated by ERK (22). Lastly, while the 
duration of p38 phosphorylation was nearly identical to ERK during the first 4 hrs of 
differentiation (Fig.3.1.A), the phosphorylation state of p38 displayed a biphasic pattern 
that was not similar to ERK during later stages of differentiation (Fig.3.1.B). Immunoblot 
analysis of total p38 remained unchanged during all stages of adipocyte differentiation 
which served as a loading control (Fig.3.1A-B).  
Data presented above suggest a role for phosphatases in the deactivation of 
MAPK signaling. As others have shown several DUSPs act as immediate early genes to 
regulate MAPKs (26), we developed the working hypothesis that ‘inducible’ DUSPs 
mediate the dephosphorylation of ERK and p38 during adipocyte differentiation. To 
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initially test our working hypothesis, we examined if ERK and p38 signaling involved de 
novo mRNA synthesis. Preadipocytes were pretreated with and without 1 ng/ml 
actinomycin D for 30 mins to inhibit mRNA synthesis prior to stimulation with MDI. Cell 
lysates were harvested over time during early adipocyte differentiation (<24h) and 
immunoblotted for bisphosphorylated ERK and p38 as discussed above. As illustrated in 
Fig.3.1C, blocking RNA synthesis resulted in a marked increase in the duration of ERK 
extending from less than 4 h in the absence of actinomycin D to more than 24 h when 
RNA synthesis was inhibited. No discernable effects were noted regarding the 
magnitude of peak ERK phosphorylation. Conversely, inhibition of RNA synthesis had a 
marked effect of p38 magnitude and minimal impact of p38 duration. The increase in p38 
phosphorylation at 24 hrs post-MDI was likely due to prolonged exposure of actinomycin 
D. While MAPK dephosphorylation (i.e., ERK duration and p38 magnitude) was 
dependent on de novo mRNA synthesis, initial MAPK phosphorylation was completely 
unaffected by actinomycin D. Collectively, these data suggest that the extent of MAPK 
signaling is regulated by a balance of upstream kinases and downstream inducible 
phosphatases. 
Inducible DUSP gene expression during early and late adipocyte 
differentiation. As the magnitude and duration of MAPK signaling duration were 
dependent on de novo mRNA synthesis, we tested the hypothesis that inducible DUSPs 
modulate the extent of MAPK phosphorylation during adipocyte differentiation. For this, 
we initially compared relative mRNA expression of all known MAPK-specific DUSPs in 
PAs (d0) versus ADs (d8) using qRT-PCR. As illustrated in Table 3.1, all ten DUSPs 
were measurable in PAs within the detectable limits of 36 threshold cycles (CT), with 
dusp2, dusp8, and dusp9 least abundantly expressed at 32 cycles and dusp1, dusp6 
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and dusp7 most abundantly expressed at 24 cycles. This 8 cycle difference was 
equivalent to a 256-fold difference (i.e., 28) in base-line mRNA abundance in PAs.  
DUSPs were grouped based on structural differences involving the presence of a 
nuclear localization sequence (NLS) or nuclear export sequence (NES) that may 
facilitate localization to the nucleus (group I) or cytosol (group II), respectively. DUSPs 
containing both sequences were grouped as phosphatases that may be localized to 
either compartment (group III) (26,27). Fig.3.2-3.4 illustrates comparative data from 
DUSPs for each group where DUSP mRNA was normalized to 18S ribosomal RNA and 
expressed as fold-differences relative to untreated controls. Panel A for Fig.3.2-3.4 
illustrates relative difference between PAs (d0) and ADs (d8). Panels B and C depict 
relative changes in DUSP mRNA abundance during early and late stages of 
differentiation, respectively. Relative mRNA levels of dusp4 and dusp9 were significantly 
elevated in ADs compared to PAs, while dusp1, dusp2, dusp6, and dusp7 were 
significantly elevated in PAs compared to ADs. Dusp5, dusp8, dusp10, and dusp16 
showed no marked differences between cell phenotypes (Fig.3.2A-3.4A). To determine 
which DUSPs were induced at the level of gene expression during differentiation, PAs 
were stimulated with MDI and relative mRNA abundance assessed by qRT-PCR over 
time representing early (Panel B) and late stage (Panel C) differentiation. Prior to these 
studies, we set an arbitrary threshold of 2.5-fold change as a conservative measure of 
biological differences versus technical variation as measured by qRT-PCR (46). Thus, 
DUSP gene expression was only considered ‘inducible’ when relative mRNA levels 
exceeded this threshold. Determinations were examined over time to establish when 
select DUSPs were induced as well as whether the induction was transient versus 
sustained as insight to functional roles. For characterization purposes, DUSPs were also 
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considered ‘suppressed’ when relative values fell below 0.5-fold differences in mRNA 
abundance. 
As illustrated in Fig.3.2, all four DUSPs representing Group I phosphatases were 
rapidly and transiently induced following induction of differentiation with dusp1, dusp2, 
and dusp5 reaching greater than 10-fold changes in mRNA by 2 hrs post-MDI. Dusp2 
and dusp5 mRNA rapidly declined with values remaining at or below baseline from 12 
hrs through d10 of differentiation. While dusp1 also declined following a 45-fold peak in 
mRNA abundance at 2 hrs, the decline was more gradual with values remaining above 
baseline through d6 of differentiation. Dusp4 was unique among these phosphatases 
with biphasic expression with a transient, small peak (3-fold) occurring at 4 hrs and a 
more sustained, larger peak (7-fold) occurring at 4d and remaining above baseline 
through d10. While the kinetic profile of all four Group I DUSPs was consistent with the 
timing of MAPK dephosphorylation during early stages of differentiation, the mid-stage 
biphasic induction of dusp4 occurred concomitantly with the time period when ERK 
phosphorylation falls below baseline levels and PPARγ is expressed. 
Dusp6 was the only group II phosphatase determined to be rapidly and 
transiently induced during early adipocyte differentiation where a 3.5-fold induction 
peaked at 1 hr and returned to baseline within 12 hrs post-MDI (Fig.3.3). Interestingly, 
dusp6 and dusp7 mRNA abundance fell markedly below baseline values from d1 
through d10 of differentiation. In contrast, dusp9 displayed a reciprocal pattern of 
expression where mRNA fell below baseline during early stages of differentiation 
followed by a gradual induction during late stages remaining markedly elevated (8-fold) 
through d10 of differentiation. While all three Group III phosphatases were suppressed 
during early differentiation (Fig.3.4), dusp8 and dusp10 returned to baseline by d4 of 
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differentiation. Dusp16 was the only group III phosphatase transiently induced during 
late stages with peak mRNA abundance observed at d4 of differentiation.    
Inhibition of DUSPs during early adipocyte differentiation correlates with 
prolonged MAPK signaling. Data presented above demonstrate that select DUSPs 
were induced in a manner consistent with functional roles in MAPK dephosphorylation 
during early stages and maintained suppression during late stages of adipocyte 
differentiation. To determine a role for early ‘inducible’ phosphatases on the extent (i.e., 
magnitude and duration) of MAPK phosphorylation during early stages of differentiation, 
PAs were pretreated with or without 1 µM triptolide (TRP) for 30 min prior to MDI 
stimulation. TRP is a bioactive compound purified from the Chinese herb Tripterygium 
wilfordii and shown to be effective as an immunosuppressant and anti-inflammatory 
agent and a potent inhibitor of dusp1 gene expression (47). RNA was isolated at 0 hr 
and 1 hr post-MDI in the absence or presence of TRP and expression of all DUSPs 
induced within 2 hrs post-MDI examined by qRT-PCR. MDI-induced gene expression of 
dusp1, dusp2, dusp5, and dusp6 was completely ablated in the presence of TRP 
(Fig.3.5A). To determine if TRP influenced the extent of MAPK phosphorylation, cell 
lysates were harvested over time and immunoblotted for phosphorylated ERK and p38. 
MDI stimulation markedly increased ERK and p38 phosphorylation. In the absence of 
TRP, MDI stimulation also resulted in the accumulation of dusp1 protein in a manner 
kinetically consistent with the dephosphorylation phase of both MAPKs, which returned 
to baseline by 6 hrs post-MDI (Fig.3.5B). In contrast, TRP pretreatment abolished the 
accumulation of dusp1 and prolonged the duration of phosphorylated ERK and p38 
through 24 hrs post-MDI stimulation. While TRP also resulted in a modest increase in 
phospho-ERK magnitude, pretreatment of this inhibitor did not block the phosphorylation 
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of either MAPK by upstream MAPK kinases following MDI stimulation. Collectively, these 
data suggest that one or more inducible DUSP plays a functional role in modulating the 
extent of MAPK phosphorylation during adipocyte differentiation. 
Dusp1 is induced during early adipocyte differentiation. While data 
presented above suggest a cooperative role for DUSPs on MAPK deactivation, 
discrepancies on dusp1 expression reported here and elsewhere (23,41,48) led us to 
further examine the regulation of this phosphatase during adipocyte differentiation. While 
some, including this report, show an immediate induction of dusp1 that decreases over 
the course of differentiation (23,48,49), others report a progressive increase in dusp1 
mRNA and protein expression over the course of adipogenesis (41). Therefore, we 
examined dusp1 mRNA and protein expression over the complete course of adipocyte 
differentiation. Total RNA and whole cell lysates were collected over time and dusp1 
mRNA and protein expression as well as MAPK phosphorylation examined via qRT-PCR 
and immunoblot analysis, respectively. Dusp1 gene expression was rapidly (<1 hr) and 
robustly induced post-MDI stimulation that gradually decreased over the course of 
differentiation (Fig.3.6). Correspondingly, dusp1 protein expression mirrored mRNA 
expression, with a rapid increase at 2 hr followed by a gradual decrease in protein by 8h 
post-MDI. Moreover, protein and mRNA abundance returned to or fell below baseline 
expression by d6 of differentiation. Collectively, these data clearly demonstrate an 
expression profile for dusp1 that was consistent with a functional role in limiting the 
extent of MAPK phosphorylation previously shown to be essential for adipocyte 
differentiation.  
Dusp1 knockdown amplifies MAPK signaling during 3T3-L1 preadipocyte 
differentiation. To establish a mechanistic role for dusp1 on MAPK signaling, 3T3-L1 
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PAs were transfected with siRNA targeted to dusp1 or non-targeting control sequences 
for 72 h prior to stimulation with MDI. Total RNA and whole cell lysates were harvested 
over time and analyzed for relative dusp1 mRNA abundance and MAPK 
phosphorylation, respectively. Dusp1 gene expression was markedly induced during 
early differentiation in cells transfected with control siRNA (Fig.3.7A). In contrast, both 
basal (>70%) and MDI-stimulated (>60%) induction of dusp1 mRNA was significantly 
suppressed in cells treated with dusp1 specific siRNA. Specific knockdown of dusp1 
mRNA nearly ablated the accumulation of dusp1 protein resulting from MDI stimulation 
(Fig.3.7B). Moreover, specific knockdown of dusp1 mRNA and protein markedly 
increased magnitude and duration of ERK phosphorylation as well as the magnitude of 
p38 phosphorylation following MDI stimulation.   
DUSP1-mediated regulation of MAPK signaling is not sufficient for 
inhibition of adipocyte hyperplasia. Data presented above demonstrate that dusp1 
regulates MAPK dephosphorylation during early adipocyte differentiation. As recent 
reports differ on the role of dusp1 during adipogenesis (40,41), we further examined the 
biological role of dusp1 on PA proliferation and differentiation as essential components 
of adipocyte hyperplasia. A continuum of sequential events culminates in the activation 
of PPARγ and C/EBPα in order to regulate adipocyte gene expression and acquisition of 
the mature adipocyte phenotype during adipogenesis (50-52). Among the early events 
leading to PPARγ and C/EBPα, is an ‘obligatory’ prerequisite period of mitotic clonal 
expansion, in which density-arrested PAs synchronously re-enter the cell cycle prior to 
activation of adipocyte-specific genes and terminal growth arrest (18). To determine if 
dusp1 plays a regulatory role during clonal expansion, density-arrested PAs were 
transfected with dusp1 specific or non-targeting siRNA for 72 hrs prior to stimulation with 
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MDI. Cells were harvested at 0 hr and 20 hr post-MDI, fixed, and stained with propidium 
iodide for flow cytometric analysis of cell cycle progression. As shown in Fig.3.8A, two 
DNA peaks in the 2n and 4n range, representing G0/G1 and G2/M cell populations, were 
present in all histograms. Stimulation with MDI resulted in similar shifts from G0/G1 to S 
and G2/M phase populations demonstrating synchronous cell cycle progression in cells 
transfected with dusp1 or control siRNA. To confirm these results, cell lysates were 
harvested under identical conditions and analyzed for cyclin A protein expression, which 
we have previously shown to accumulate during S phase in this cell model (53).  Cyclin 
A protein accumulated with both dusp1-specific and control siRNA, with modestly 
elevated cyclin A protein accumulation with dusp1 knockdown (Fig.3.8B). Collectively, 
these data demonstrate that dusp1 does not block cell cycle progression, which is a 
known prerequisite for adipocyte differentiation. To the contrary, the modest increase in 
cyclin A following dusp1 knockdown would be indicative of more efficient S-phase entry, 
possibly resulting from elevated MAPK phosphorylation.  
To elucidate a role for dusp1 on adipocyte differentiation, density-arrested PAs 
were transfected with control siRNA or dusp1 siRNA 72 hrs prior to stimulation with MDI. 
Phase contrast microscopy was used to assess changes in cell morphology and lipid 
accumulation between undifferentiated PAs (d0) and fully mature ADs (d8). As shown in 
Fig.3.8C, PAs (d0) transfected with siRNA for dusp1 or non-targeting sequences 
displayed nearly identical fibroblast-like morphology. Similarly, transfection with dusp1-
specific or non-targeting sequences prior to differentiation resulted in no discernable 
differences in the lipid-filled morphology of fully mature ADs (d8). To determine if dusp1 
expression was essential for accumulation of proteins that mediate adipocyte 
differentiation, cell lysates were harvested from cells transfected with dusp1 and control 
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sequences and immunoblotted for PPARγ, C/EBPα, and aP2 as illustrated in Fig.3.8D. 
PPARγ and C/EBPα represent major transcription factors that mediate the expression of 
functional proteins such as the fatty acid binding protein aP2 during adipogenesis. As 
shown in Fig.3.8D, PPARγ, C/EBPα, and aP2 increased similarly with differentiation in 
cells transfected with dusp1-specific or non-targeting control siRNA. Similarly, PPARγ, 
C/EBPα, and aP2 increased with differentiation (d8) in cells transfected with dusp1 
siRNA. As dusp1 protein accumulation was markedly attenuated at 2 hr post-MDI with 
dusp1 siRNA, these data clearly demonstrate that knockdown of dusp1 alone was not 
sufficient to block adipogenesis suggesting the possibility of redundant or collective roles 
between multiple phosphatases in limiting the extent of MAPK phosphorylation that is 
essential for adipocyte differentiation. 
       
Discussion 
This report presents evidence demonstrating that the MAPK-specific DUSPs are 
regulated in a manner consistent with MAPK dephosphorylation during adipocyte 
differentiation. First, we demonstrate that the extent of MAPK signaling was dependent 
on de novo mRNA synthesis suggesting a role for ‘inducible’ phosphatases. Second, we 
show that several DUSPs were induced during adipocyte differentiation concomitant with 
dephosphorylation of ERK and p38 signaling. Third, we demonstrate that 
pharmacological inhibition of early inducible DUSPs markedly prolonged ERK and p38 
signaling during early adipocyte differentiation. Finally, we show that while dusp1 played 
a regulatory role in ERK and p38 signaling magnitude and duration, dusp1 specific 
knockdown was not sufficient to inhibit adipocyte hyperplasia. Collectively, these data 
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demonstrate that cooperative actions of several DUSPs play modulatory roles in timely 
MAPK dephosphorylation during adipocyte hyperplasia.  
Mounting evidence demonstrates that the timely phosphorylation as well as 
dephosphorylation of ERK and p38 is critical for adipogenesis (10,15-19), where the 
rapid and transient activation (i.e., phosphorylation) of ERK and p38 is essential for 
preadipocyte proliferation as well as the induction and activation of C/EBPβ, both of 
which are required for adipogenesis (18-21). Conversely, prolonged ERK activity has 
been shown to phosphorylate and inactivate PPARγ blocking AD differentiation (22), 
while prolonged p38 activity results in cell death (16,23,24). However, the extent of 
MAPK phosphorylation during distinct stages of adipocyte differentiation remains 
uncertain. Data presented here demonstrate a rapid and transient activation of ERK 
signaling during early adipocyte differentiation. Consistent with previous reports (10,17), 
these data further demonstrate that ERK phosphorylation is suppressed during mid and 
late stages of adipocyte differentiation falling below basal expression, concomitant with 
the induction of PPARγ. As prolonged phosphorylation of ERK inhibits PPARγ activity 
and subsequently adipogenesis (54), these data suggest that transient activation during 
early differentiation and suppression of ERK phosphorylation during late differentiation 
are necessary for the mature adipocyte phenotype. While phosphorylation of p38 during 
early adipocyte differentiation was similar to ERK, it displayed a biphasic pattern of 
induction during late stage differentiation. While some have reported suppression of p38 
phosphorylation during late adipocyte differentiation (15,16), others have noted similar 
biphasic activity (55). As reports demonstrate that ectopic expression of p38 drives 
adipocyte differentiation in 3T3-L1 preadipocytes and NIH 3T3 fibroblasts (16,23,24), it 
remains uncertain if biphasic p38 activity or loss of activity during late differentiation is 
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required for adipocyte differentiation. Collectively, these observations suggest that timely 
phosphorylation and dephosphorylation of MAPKs is essential for adipogenesis.  
Until recently, upstream kinases rather than phosphatases were viewed as major 
regulators of MAPK signaling. However, many phosphatases are now recognized as key 
modulators and even controllers of cellular signaling and biological processes involving 
proliferation and differentiation (56,57). This is evident in reports that demonstrate that 
kinases can be dephosphorylated in the continued presence of stimulation, where 
protein tyrosine phosphatases have been shown to control protein tyrosine kinase 
signaling in response to oxidative stress (56). Data presented in our report demonstrate 
disconnect between the phosphorylation state of ERK and its upstream kinase MEK, 
where ERK was completely dephosphorylated in the presence of MEK phosphorylation 
(i.e., activity) during early differentiation. Moreover, phospho-ERK dropped below 
baseline following the initial activation throughout later stages of differentiation even 
though MEK retained some degree of activity, suggesting a role of phosphatases in the 
timely modulation of MAPK signaling. Recently, DUSPs have been shown to play a 
critical role in MAPK dephosphorylation of myocyte, osteocyte, and neuronal cells (37-
39), where the timely balance of MAPK phosphorylation and dephosphorylation dictates 
cellular growth and differentiation within these cell types (37,39,58). For instance, timely 
modulation of ERK activation is essential for myogenesis, where decreased ERK 
activity, concomitant with increased dusp1, is necessary for muscle-specific gene 
expression. While ectopic expression of dusp1 was sufficient to block inhibitory actions 
of ERK on muscle-specific genes, prolonged induction also blocked myogenesis, 
suggesting that timely modulation of phosphorylation and dephosphorylation is critical for 
myocyte growth and differentiation (37). As we further report that inhibition of de novo 
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mRNA synthesis markedly prolonged ERK and p38 phosphorylation, these data 
collectively suggest that ‘inducible’ DUSPs may account for the timely balance of MAPK 
phosphorylation and dephosphorylation that is critical for adipocyte differentiation.   
 Data presented here demonstrate that several DUSPs were induced during 
early, mid, and late stages of adipocyte differentiation, consistent with the 
dephosphorylation of ERK and p38 during early differentiation and continued 
suppression of ERK phosphorylation during mid and late stages of differentiation. As the 
kinetic patterns of the ‘inducible’ DUSPs were markedly different, it is conceivable that 
phosphatases play a cooperative role in the modulation of MAPK dephosphorylation. 
Reports now demonstrate that increased expression of immediate early DUSPs plays a 
key role in the dephosphorylation of MAPKs in other cell types (26,59,60). Consistent 
with this, we demonstrate that inhibition of the immediate early (<2hr) DUSPs led to 
marked increases in ERK and p38 signaling duration. Unpublished observations from 
our lab further demonstrate that DUSP inhibition with the bioactive compound TRP also 
blocked preadipocyte proliferation and differentiation in the presence of sustained MAPK 
phosphorylation. While TRP has been shown to be effective as an immunosuppressant 
and anti-inflammatory agent, these data provide convincing evidence that DUSPs 
cooperatively work to modulate timely MAPK signaling that is critical for adipocyte 
differentiation (18,47,54). As DUSPs may contribute to the transient phosphorylation of 
MAPKs during early differentiation, induction of DUSPs during late stage adipocyte 
differentiation may also play a crucial role in the continued suppression of ERK 
phosphorylation that is pivotal for PPARγ activity and adipogenesis (22). Evidence for 
this can be seen in nude mice treated with parathyroid hormone and PTH-related protein 
(PTHrP), in which dusp1 is upregulated followed by increases in bone formation. Loss of 
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dusp1 markedly increased ERK phosphorylation during late osteoblast differentiation, in 
which ERK dephosphorylation is required for terminal growth arrest and bone formation 
(58). Data presented here demonstrate that dusp4, dusp9, and dusp16 were induced 
during mid- and late-stage adipocyte differentiation, where ERK phosphorylation fell 
below basal expression of untreated PAs (d0). While some evidence suggests that 
ectopic expression of dusp9 blocks adipocyte differentiation (61), a role for these late 
stage phosphatases regarding MAPK signaling and adipogenesis remains unknown.  
Dusp1 is an immediate early gene whose expression is induced rapidly and 
transiently by various extracellular stimuli including agents used to differentiate 3T3-L1 
PAs such as insulin, glucocorticoids, and cAMP analogs (62-64). As conflicting reports 
regarding dusp1 during adipocyte differentiation have recently emerged 
(23,40,41,48,49), we report that dusp1 was induced rapidly and transiently during early 
stages of adipocyte differentiation where mRNA decayed slowly over the course of 
differentiation eventually returning to baseline by d6. While this expression profile of 
dusp1 is consistent with some reports in 3T3-L1 PAs (23,48,49), it is inconsistent with 
others (41) where it was reported to increase during late stage adipocyte differentiation. 
We further show that loss of dusp1 via siRNA knockdown markedly increased the 
magnitude and duration of ERK and p38 phosphorylation during early adipocyte 
differentiation, but did not block preadipocyte proliferation or differentiation. Moreover, 
examination of cyclin A suggests that S-phase transition was more efficient in the 
presence of increased MAPK signaling, consistent with the role of MAPKs on cellular 
proliferation (18). Consistently, ERK, JNK, and p38 phosphorylation was increased in AT 
of dusp1 deficient mice compared to wild-type counterparts (40), while MEFs from wild-
type and dusp1 knockout mice differentiated in a similar manner demonstrating that 
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dusp1 is not essential for adipocyte differentiation (40). While our data demonstrate a 
role for dusp1 on MAPK dephosphorylation during early adipocyte differentiation, others 
have shown that dusp1 antisense expression in 3T3-L1 PAs led to sustained ERK 
activation during late differentiation and inhibition of adipogenesis (41). Collectively, 
these data demonstrate an essential role for dusp1 regarding MAPK dephosphorylation, 
although its role with differentiation remains unresolved.  
In summary, data outlined here and elsewhere (10,26,57) demonstrate that the 
timely modulation of MAPK phosphorylation and dephosphorylation, essential for 
proliferation and differentiation, is regulated in part by downstream DUSPs. Data are 
presented demonstrating that several ‘inducible’ DUSPs are associated with the 
dephosphorylation of ERK and p38 during adipocyte differentiation. While loss of dusp1 
via siRNA, alone, increased the duration and magnitude of ERK and p38 
phosphorylation, it did not block adipogenesis, suggesting that DUSPs cooperatively 
modulate MAPK dephosphorylation and adipocyte differentiation. While further studies 
are needed regarding the cooperative actions of DUSPs during adipocyte differentiation, 
this report establishes a platform for future investigations regarding timely MAPK 
signaling during adipogenesis. As work on DUSP regulation and function continues, 
elucidation into the molecular actions of these phosphatases may provide therapeutic 
targets for the treatment and prevention of obesity and obesity-induced insulin 
resistance. 
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Table 3.1.  DUSP genes analyzed in this study. 
 
 symbol name/alias     accession ABI number CT 
dual specificity phosphatases  GP MKB NLS NES    
 Dusp1 MKP-1, hVH1 I ● ●  NM_013642 Mm00457274_g1 24 
 Dusp2 PAC1 I ● ●  NM_010090 Mm00839675_g1 32 
 Dusp4 MKP-2, hVH2 I ● ●  NM_176933 Mm00723761_m1 27 
 Dusp5 hVH3 I ● ●  NM_001085390 Mm01266104_m1 27 
 Dusp6 MKP-3, rVH6 II ●  ● NM_026268 Mm00650255_g1 24 
 Dusp7 MKP-X II ●  ● NM_153459 Mm00463228_m1 24 
 Dusp9 MKP-4 II ●  ● NM_029352 Mm00512646_m1 31 
 Dusp8 M3/6, hVH5 III ● ● ● NM_008748 Mm00456230_m1 32 
 Dusp10 MKP-5 III ● ● ● NM_022019 Mm00517678_m1 26 
 Dusp16 MKP-7, MKP-M III ● ● ● NM_130447 Mm00459935_m1 26 
reference gene    
 18S 18 ribosomal RNA X03205 4342930E 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. DUSP genes analyzed in this study. DUSPs that contained the MAPK binding 
domain (MKB) were assigned to groups (GP) based on structural differences involving the 
presence or absence of a nuclear localization sequence (NLS), nuclear export sequence 
(NES), or both that facilitate subcellular localization to the nucleus (group I), cytosol (group 
II), or both compartments (group III).  
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Figure 3.1. MAPK dephosphorylation is regulated by de novo mRNA synthesis. 
Preadipocytes were stimulated to differentiate with the hormonal cocktail MDI as outlined 
above and cell lysates harvested during A) early (0h-24h) and B) late differentiation (d0-
d8) prior to immunoblot analysis of bisphosphorylated MEK, ERK, and p38 as well as 
total p38 and PPARγ. C) Preadipocytes were stimulated with MDI in the absence or 
presence of 1 ng/ml Actinomycin D (AD). Cell lysates were collected at indicated times 
and protein expression of bisphosphorylated ERK and p38 along with GAPDH analyzed 
via immunoblotting. 
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Figure 3.2. Induction of group I DUSP mRNA during adipocyte differentiation. A) 
Total RNA was harvested from preadipocytes (d0) and adipocytes (d8) and mRNA 
expression of group I DUSPs measured using qRT-PCR. Data were normalized to 18S 
rRNA and expressed relative to untreated preadipocytes (d0). Statistical significance 
was determined by Student’s t-test (* p<0.05). Preadipocytes were stimulated to 
differentiate and total RNA was harvested during B) early and C) late differentiation prior 
to mRNA analysis of nuclear DUSPs with qRT-PCR. All data were normalized to 18S 
rRNA and expressed relative to untreated cells (d0/0h). Genes selected as ‘inducible’ 
were upregulated above a 2.5-fold criterion indicated by a dashed line on the graph.   
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Figure 3.3. Induction of group II DUSP mRNA during adipocyte differentiation. A) mRNA 
expression group II DUSPs was measured in untreated preadipocytes (d0) and mature 
adipocytes (d8) using qRT-PCR. Data were normalized to 18S rRNA and expression measured 
as relative differences compared to untreated preadipocytes (d0). Statistical significance was 
determined by Student’s t-test (* p<0.05). Preadipocytes were stimulated to differentiate and 
total RNA was harvested during B) early and C) late differentiation prior to mRNA analysis of 
cytosolic DUSPs with qRT-PCR. All data were normalized to 18S rRNA and expressed relative 
to untreated cells (d0/0h). Genes selected as ‘inducible’ were upregulated above a 2.5-fold 
criterion indicated by a dashed line on the graph. 
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Figure 3.4. Regulation of group III DUSP mRNA during adipocyte differentiation. A) Total 
RNA was harvested from preadipocytes (d0) and mature adipocytes (d8) and mRNA 
expression of group III DUSPs measured using qRT-PCR. Data were normalized to 18S rRNA 
and expression measured as relative differences compared to untreated preadipocytes (d0). 
Significance was determined by Student’s t-test (* p<0.05). In addition, preadipocytes were 
stimulated to differentiate and total RNA harvested during B) early and C) late differentiation 
prior to mRNA analysis of cytosolic/nuclear DUSPs with qRT-PCR. All data were normalized to 
18S rRNA and expressed relative to untreated cells (d0/0h). Genes selected as ‘inducible’ were 
upregulated above a 2.5-fold criterion indicated by a dashed line on the graph. 
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Figure 3.5. Inhibition of DUSPs enhances ERK and p38 phosphorylation during early 
adipocyte differentiation. Preadipocytes were stimulated to differentiate with MDI in the 
presence or absence of 1 µM triptolide (TRP) pretreatment (30 min). A), RNA was isolated at 
0h and 1h post-MDI stimulation and mRNA expression of dusp1, dusp2, dusp5, and dusp6 
analyzed via qRT-PCR. Data were normalized to 18S rRNA and changes in gene expression 
measured as fold differences relative to untreated preadipocytes (0h). Statistical differences 
were determined by ANOVA. Tukey's post-hoc analysis was performed when the p value for 
the respective parameter was statistically significant (p < 0.05). B) Cell lysates were collected 
over time post-MDI stimulation and protein expression of bisphosphorylated ERK and p38 
along with dusp1 and α-Tubulin examined via immunoblotting.  
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Figure 3.6. Dusp1 kinetically follows MAPK dephosphorylation during early adipocyte 
differentiation. Preadipocytes were stimulated to differentiate with MDI and RNA isolated 
during A) early and C) late adipocyte differentiation prior to mRNA analysis of dusp1 via qRT-
PCR. Data were normalized to 18S rRNA and expressed as relative differences compared to 
untreated preadipocytes (d0). Dusp1 gene expression was considered inducible when 
upregulated above a 2.5 fold criterion indicated by a dashed line. Cell lysates were harvested 
during B) early and D) late adipocyte differentiation prior to immunoblot analysis of 
bisphosphorylated MEK, ERK, and p38 as well as dusp1, and total p38 expression.  
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Figure 3.7. Dusp1 knockdown markedly increases ERK and p38 signaling magnitude and 
duration during early adipocyte differentiation. Preadipocytes were transfected with 
DharmaFect 3 transfection reagent in the presence of non-targeting control siRNA or siRNA 
specific for dusp1 for 72 hours prior to stimulation with MDI. A) Cell lysates were harvested for 
RNA at 0h and 1h post-MDI stimulation and mRNA expression of dusp1 analyzed via qRT-PCR. 
Data were normalized to 18S rRNA and changes in gene expression measured as fold 
differences relative to untreated control siRNA (0h). Statistical differences were determined by 
ANOVA. Tukey's post-hoc analysis was performed when the p value for the respective 
parameter was statistically significant (p < 0.05). B) Cell lysates were collected over time post-
MDI stimulation for control siRNA and dusp1 siRNA and protein expression of 
bisphosphorylated ERK and p38 along with dusp1, total p38, and α-Tubulin examined via 
immunoblotting. 
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Figure 3.8. Dusp1 knockdown does not inhibit 3T3-L1 adipogenesis. Preadipocytes 
were transfected with non-targeting control siRNA or siRNA specific for dusp1 for 72 hrs 
prior to stimulation with MDI. A) Cells were fixed at d0 and 20h post-MDI and DNA stained 
with propidium iodide. DNA histograms were assessed via flow cytometry. B) Cell lysates 
were collected over time and protein expression of dusp1, cyclin A, cyclin D1, and α-
Tubulin examined via immunoblotting. C) Examination of cell morphology of untreated 
preadipocytes and mature adipocytes treated with control siRNA or dusp1 siRNA was 
assessed for lipid accumulation using phase contrast microscopy at 10X and 20X 
magnitude. D) Cell lysates were collected from preadipocytes (d0) and mature adipocytes 
(d8) treated with control siRNA (C) or dusp1 siRNA (D1) and protein expression of 
adipocyte genes PPARγ, C/EBPα, and aP2 examined via immunoblot analysis.  
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CHAPTER IV 
ROLE FOR DUAL-SPECIFICITY PHOSPHATASES ON MITOGEN-ACTIVATED 
PROTEIN KINASE SIGNALING IN ADIPOCYTES IN RESPONSE TO 
INFLAMMATORY STRESS 
 
Abstract 
Obesity is a major risk factor for heart disease, stroke, insulin resistance, and type 2 
diabetes. Early evidence demonstrated an essential role for the proinflammatory 
cytokine tumor necrosis factor α (TNFα) during obesity and obesity-induced insulin 
resistance (IR). Since then, reports have established mitogen-activated protein kinases 
(MAPKs) as major signaling pathways linking inflammation to obesity-induced IR. While 
upstream kinases were traditionally viewed as major regulators of MAPK signaling, 
many phosphatases are now recognized as key modulators and even controllers of 
cellular signaling and biological processes involving inflammation. Using 3T3-L1 
adipocytes, we examined a role for dual-specificity phosphatases (DUSPs) on TNFα-
induced activation of three major MAPKs, ERK, JNK, and p38. We report that all three 
MAPKs examined were phosphorylated in preadipocytes (PAs) and adipocytes (ADs) in 
response to TNFα, where signaling magnitude and duration were phenotype-specific. 
We observed that MAPK dephosphorylation included mechanisms involving de novo 
mRNA synthesis, suggesting a role for ‘inducible’ phosphatases. We further report that 
mRNA abundance of several DUSPs was induced in PAs and ADs in response to TNFα, 
concomitant with dephosphorylation of all three MAPKs. Moreover, we demonstrate that 
RNA interference (RNAi)-mediated DUSP knockdown of dusp1, dusp8, 
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and dusp16 led to a marked increase in signaling magnitude and duration of ERK, JNK, 
and p38 that subsequently resulted in significant increases in MAPK-dependent mRNA 
expression of MCP-1, IL-6, and Cox-2 in response to TNFα. Collectively, this study 
demonstrates cooperative actions of DUSPs on MAPK dephosphorylation and regulation 
of MAPK-dependent inflammation, highlighting the therapeutic potential of DUSPs on 
MAPK-dependent processes involved in adipose tissue (AT) inflammation and IR. 
 
Introduction 
Obesity is an irrefutable risk factor for the development of type 2 diabetes 
mellitus which develops following prolonged IR predominantly in liver, muscle, and AT 
(1). While the mechanistic link between obesity and systemic IR is a matter of ongoing 
investigation, there is mounting evidence demonstrating that AT dysfunction plays a 
central role in the sequelae of whole-body metabolic changes that result in the loss of 
insulin sensitivity (1,2). Central to this argument is the development of obesity-induced 
chronic, low grade inflammation within AT that leads to localized IR with ensuing 
elevated plasma levels of proinflammatory cytokines and free fatty acids that impart 
peripheral IR and altered glucose homeostasis in liver and muscle (1-3). Molecular 
mechanisms that underlie the initiation of AT inflammation during the onset of obesity 
include the expression and release of various chemokines, such as monocyte 
chemoattractant protein-1 (MCP-1), that promote infiltration of macrophages that are 
considered to be the primary source of inflammatory mediators of IR (1,4). 
Tumor necrosis factor α (TNFα) is well established in a causal role responsible 
for adipocyte IR within targeted AT (3,5). This proinflammatory cytokine is expressed in 
macrophages as well as in cells of adipocyte lineage as a 26 kDa transmembrane 
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monomer that is enzymatically cleaved to a 17 kDa soluble form of TNFα. Both forms of 
TNFα have been shown to exert biological activity suggesting that this cytokine may 
impinge upon insulin sensitivity through autocrine, paracrine, or endocrine modalities 
(5,6). TNFα has been shown to suppress insulin signaling, alter glucose homeostasis, 
promote lipolysis, and inhibit lipogenesis in cultured adipocytes (1,3,6,7). Regarding a 
role in metabolic disease, others have reported that TNF is elevated in AT of obese 
subjects and that genetic ablation of TNF action can restore insulin sensitivity in vitro 
and in vivo (1,6,8). While the contribution of AT to circulating levels of TNF has been 
debated, there is consensus that AT-derived TNF can impact whole-body insulin 
sensitivity by impairing AT function through localized IR as well as through TNF-
mediated effects on proinflammatory gene expression (1,2). 
Metabolic effects of TNF are predominantly mediated through nuclear factor-
kappa B (NF-B) and mitogen-activated protein kinase (MAPK) signaling pathways 
involving extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase 
(JNK), and p38. All four pathways have been shown to be activated in AT in response to 
TNF stimulation and serve as mediators of localized IR through transcriptional 
mechanisms involving adipocyte gene expression as well as the expression and 
secretion of other proinflammatory molecules (2,9-12). In addition to nuclear events 
involving AP-1 mediated gene expression, MAPK activity has also been linked to 
cytosolic suppression of proximal insulin signaling through JNK phosphorylation of 
specific serine residues of IRS-1 demonstrating that compartmentalized signaling events 
can impact different properties of AT dysfunction (12-14). 
It is well recognized that all MAPK family members are activated when both 
threonine and tyrosine residues of the (T-X-Y) motif within the activation loop are 
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phosphorylated (10,15). While upstream MAPK kinases have historically been 
considered the principal regulators of MAPK activity, recent literature has pointed to 
phosphatases as powerful and even dominant controllers of many MAPK-dependent 
biological processes (16,17). Dual specificity phosphatases (DUSPs) are a subclass of 
protein tyrosine phosphatases that specifically inhibit MAPK activity through 
dephosphorylation of both threonine and tyrosine residues. Within this subclass, there 
are ten known DUSPs that are MAPK-specific as they contain a MAP kinase-binding 
(MKB) domain that selectively imparts catalytic activity toward ERK, JNK, or p38 (17,18). 
These MAPK-specific DUSPs are further classified based on nuclear localization 
sequences (NLS) as well as nuclear export sequences (NES) that may direct DUSP 
localization and activity to the nucleus, cytosol, or both. DUSPs are highly inducible at 
the level of gene expression in a cell type and stimulus-dependent manner (17,18).  For 
immune cells, these stimuli commonly include cytokines, reactive oxygen species, and 
pathogen-associated molecules that engage toll-like receptors (17). 
In this report, we examined the impact of DUSPs on experimental outcome 
during TNF-mediated inflammatory stress using 3T3-L1 murine adipocytes. This cell 
line provided the opportunity to examine nearly pure populations of undifferentiated 
preadipocytes as well as mature adipocytes representing cellular effectors of AT 
dysfunction without macrophage contamination. This study identifies individual DUSPs 
as key regulators of inflammatory stress in adipocytes and highlights the potential for 
therapeutic control of MAPK-dependent biological processes associated with AT 
inflammation.   
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Materials and Methods 
Materials: Dulbecco’s Modified Eagle’s Medium (DMEM), calf bovine serum, and 
trypsin-EDTA were purchased from Invitrogen. Fetal bovine serum (FBS) was obtained 
from HyClone. The following antibodies were used for western blot analysis: phospho-
ERK, phosho-p38, phosphor-JNK, total JNK, total p38, α-Tubulin, and GAPDH (Cell 
Signaling). Pharmacological inhibitors of ERK (U0126), JNK (SP600125), p38 
(SB203580), and JNK-VIII were purchased from CalBiochem. Enhanced 
chemiluminescence (ECL) reagents were obtained from Perkin-Elmer Life Sciences. All 
Taqman primer probes (Table 4.1) used in this study were purchased from Applied 
Biosystems. The murine 3T3-L1 cell line was purchased from Howard Green, Harvard 
Medical School (19).   
Cell Culture: 3T3-L1 preadipocytes were propagated in DMEM supplemented 
with 10% CS until density-induced growth arrest, as previously described (20). At 2 days 
post-confluence, growth medium was replaced with DMEM supplemented with 10% 
FBS, 0.5mM 1-methyl-3-isobutylxanthine, 1 µM dexamethasone, and 1.7 µM insulin 
(MDI). Throughout the study, ‘time 0’ refers to density arrested cells immediately before 
the addition of MDI to the culture medium. Experiments described herein were 
conducted in density-arrested preadipocytes (d0) and mature adipocytes (d8) stimulated 
in parallel with 100 pM TNFα. All experiments were repeated at least 3 times to validate 
results and ensure reliability. 
Immunoblotting: Cell monolayers were washed with phosphate-buffered saline 
(PBS) and scraped into ice-cold lysis buffer containing 1.0 M Tris, pH 7.4, 150 mM NaCl, 
1% Triton X, 0.5% Nonidet P-40 (NP40), 1 mM EDTA, 1 mM EGTA, and 10 mM N-
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ethylmaleimide. Phosphatase (20 mM ß-glycerophosphate, 10 mM NaFl, and 2 µM 
sodium vanadate), as well as protease (0.3 µM aprotonin, 21 µM leupeptin, 1 µM 
pepstatin, 50 µM phenanthroline, and 0.5 µM phenylmethylsulfonyl fluoride) inhibitors 
were added to lysis buffer prior to cell harvest. Cell lysates were sonicated, centrifuged 
(13,000 x g, 10 min, 4°C), and the supernatant transferred to a fresh tube. Bicinchoninic 
acid assay (Pierce, Rockford, IL) was used to determine protein concentration. Cell 
lysates were resuspended in loading buffer containing 0.25 M Tris, pH 6.8, 4% sodium 
dodecyl sulfate (SDS), 10% glycerol, 10% dithiothreitol, and 0.01% bromophenol blue 
and heated for 5 min at 80°C. Proteins were resolved on SDS-polyacrylamide gel 
electrophoresis gels (PAGE) and transferred to polyvinylidene fluoride membranes 
(Millipore Corp., Billerica, MA). After transfer, membranes were blocked with 4% milk and 
probed with indicated primary antibodies overnight at 4°C. Membranes were 
subsequently probed with horseradish peroxidase-conjugated secondary antibodies for 1 
hr at room temperature. Immunoblots were immersed in ECL and visualized by 
autoradiography using CL-XPosure film (Pierce). 
Real-Time qRT-PCR: Total RNA was extracted and genomic DNA contamination 
was removed using the RNeasy Plus Mini Kit (Qiagen) following the manufacturer’s 
protocol. Total RNA was quantified with a Nanodrop ND-1000 spectrophotometer and 
reverse-transcribed to cDNA in a 10 µl reaction volume using a high capacity cDNA 
reverse transcription kit (Applied Biosystems). The reverse transcription (RT) master mix 
containing RT buffer, deoxyribonucleotide triphosphate (dNTP) mix, RT random primers, 
RNase inhibitor (1.0 U/µl), and MultiScribe RT was added to 1 µg RNA and RNase-free 
water. Reverse transcription reaction conditions followed the protocol (25°C for 10 min, 
37°C for 120 min, 85°C for 5 sec, followed by 4°C indefinitely/RT complete) and utilized 
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the Gene Amp PCR System 9700 thermal cycler (Applied Biosystems) for cDNA 
synthesis. 
PCR amplification was run utilizing the 7500 fast system (Applied Biosystems) 
that consisted of enzyme activation at 95°C for 20 sec, followed by 40 cycles of 
denaturation at 95°C for 3 sec combined with annealing/extension at 60°C for 30 sec. All 
data were analyzed with the ABI 7500 real time PCR system (Applied Biosystems). Data 
were recorded and analyzed with Sequence Detector Software (Applied Biosystems) 
and graphs visualized with SigmaPlot software. All data were presented as mean  
standard error of the mean (SEM) and representative of at least two experiments 
performed in duplicate. Data were normalized to 18S previously validated by this lab as 
a suitable reference gene under these experimental conditions (21). Relative differences 
between treated and untreated control samples were analyzed by the 2-ΔΔCT method as 
previously described (21,22). 
Statistical analyses were conducted using SPSS v18. Phenotypic differences 
were determined via student’s t-test where a p-value of <0.05 was considered 
significant. Knockdown data were analyzed using ANOVA, with Tukey's post-
hoc analysis used when the p value for the respective parameter was statistically 
significant (p < 0.05). Inhibitor data were analyzed using analysis of variance, with 
Dunnett’s post-hoc analysis conducted to assess differences from controls (TNFα) when 
p<0.05.  
RNA Interference. SMARTpools containing four different short interfering RNAs 
(siRNAs) for dusp1, dusp8, and dusp16 specific sequences as well as non-targeting 
sequences were transfected using DharmaFect 3 transfection reagent according to 
manufacturer’s (Dharmacon) protocol. Briefly, 3T3-L1 preadipocytes were propagated in 
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6-well culture dishes until reaching density-induced growth arrest. Growth medium was 
then replaced with DMEM supplemented with 10% CS, 3 µl DharmaFect 3 reagent and 
either 100 nM dusp1, dusp8, and/or dusp16 specific siRNA or non-targeting siRNA for 
72 hr. Growth medium was subsequently switched to differentiation medium containing 
MDI as described above. 
 
Results 
Phenotypic differences between preadipocytes and adipocytes regarding 
TNFα-mediated changes in magnitude and duration of MAPK activity. AT is 
comprised of lipid-laden, insulin-sensitive adipocytes (ADs) and a stromovascular 
fraction containing numerous metabolically relevant cell types including undifferentiated 
adipocyte precursor cells known as preadipocytes (PAs), as well as smooth muscle 
cells, endothelial cells, fibroblasts, leukocytes, and macrophages (1). The onset of 
obesity is associated with marked AT recruitment of macrophages that likely represent 
the major source of elevated TNFα that imparts AT dysfunction by increasing 
proinflammatory cytokine and chemokine gene expression in PAs and insulin resistance 
in ADs (1). As PAs and ADs are both responsive to TNFα action, we examined the effect 
of TNFα stimulation on MAPK activity in these functionally diverse cell types of adipocyte 
lineage. This phenotypic comparison of MAPK activity was accomplished using the 3T3-
L1 murine adipocyte cell line that yielded undifferentiated, quiescent PAs prior to 
differentiation and greater than 90% conversion to mature ADs following differentiation. 
Analyses were cell type-specific as this well-established cell line was devoid of other cell 
types (e.g., macrophages) that comprise AT. Cells were differentiated by established 
protocol for 8 days to yield functionally mature ADs and compared to undifferentiated, 
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density-arrested PAs of similar passage. PAs and ADs were stimulated concurrently with 
increasing concentrations of murine TNFα. Total cell lysates were harvested at 15 mins 
post-TNFα stimulation and assayed for MAPK activity by immunoblotting with 
phosphospecific antibodies that recognize ERK, JNK, and p38 only when 
bisphosphorylated on both residues that are known to be both essential and sufficient for 
catalytic activity (10). As illustrated in Fig.4.1A, the magnitude of phosphospecific protein 
accumulation representing all three MAPKs increased in a concentration-dependent 
fashion in both PAs and ADs, with an estimated ED50 of approximately 100 pM. This 
concentration was selected for further analyses as it closely approximates the 
concentration of TNFα in human and animal models of obesity and has been shown to 
suppress insulin signaling in culture (3,6). By comparison, the ‘magnitude’ of MAPK 
accumulation was markedly more robust in PAs relative to ADs for any given 
concentration. This was especially noted for p38 where ADs were nearly refractory to 
TNF stimulation. To compare phenotypic difference in the ‘duration’ of MAPK signaling, 
PAs and ADs were stimulated with 100 pM TNFα in parallel and lysates harvested over 
time and immunoblotted for ERK, JNK, and p38 phosphorylation. As shown in Fig.4.1B, 
TNFα stimulation resulted in a rapid, but transient activation of all three MAPKs in PAs 
where robust phosphorylation was observed at 15 mins with complete 
dephosphorylation by 60 mins post-TNFα. Conversely, the same concentration of TNFα 
produced markedly lower magnitude, but sustained duration of JNK and ERK with no 
phosphorylation observed for p38 in mature ADs. As the abundance of total p38 protein 
was not affected by TNFα, rapid changes in magnitude and duration regarding MAPK 
phosphorylation likely reflected a balance of kinase and phosphatase mechanisms that 
were regulated in a phenotype-specific manner. 
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Regulation of MAPK de-phosphorylation by mechanisms involving de novo 
mRNA synthesis. Data presented above demonstrated that TNFα stimulation resulted 
in robust and transient phosphorylation of all three MAPKs in a cell type-specific manner. 
As each kinase was rapidly dephosphorylated in the presence of TNFα, these data 
supported the premise that MAPK phosphatases modulate magnitude and/or duration of 
MAPK activity.  As many MAPK phosphatases have been classified as immediate early 
genes capable of rapid changes in gene expression (17), we developed the working 
hypothesis that ‘inducible’ expression of DUSPs mediates MAPK dephosphorylation in 
response to inflammation. To test this hypothesis, we initially determined if magnitude 
and/or duration of MAPK signaling were dependent on de novo mRNA synthesis. These 
determinations were performed in PAs as all three MAPKs were robustly and transiently 
phosphorylated and dephosphorylated in this cell type. With this reasoning, PAs were 
pretreated with and without actinomycin D for 30 mins prior to TNFα stimulation at a 
concentration (1 ng/ml) previously shown to effectively block RNA synthesis (23,24). Cell 
lysates were harvested over time following 100 pM TNFα stimulation and immunoblotted 
for ERK, JNK, and p38 phosphorylation. As illustrated in Fig.4.2, preventing de novo 
RNA synthesis resulted in marked increases in both magnitude and duration of ERK and 
JNK phosphorylation extending from less than 60 mins in the absence of actinomycin D 
to more than 2 hrs when RNA synthesis was inhibited. In contrast, while the magnitude 
of p38 phosphorylation was increased in the presence of actinomycin D, no effect on 
duration was observed. These effects were not attributed to generalized stress as 
actinomycin D treatment for more than 4 hrs in the absence of TNFα produced no 
increase in MAPK phosphorylation (data not shown). It is important to note that while 
rapid MAPK dephosphorylation was dependent on de novo mRNA synthesis, initial 
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MAPK phosphorylation was completely unaffected by actinomycin D. Collectively, these 
data suggested that the magnitude and duration of MAPK phosphorylation was 
modulated by a balance of upstream kinases and downstream ‘inducible’ phosphatases. 
Cell type-specific induction of select DUSP gene expression following 
TNFα stimulation.  As the extent of MAPK phosphorylation was dependent on de novo 
mRNA synthesis, we tested our hypothesis that inducible DUSPs modulate MAPK 
activity following TNFα stimulation in a phenotype-specific manner. For this, we initially 
screened unstimulated PAs for mRNA abundance of all known DUSPs that contain MKB 
domains responsible for selective catalytic activity only toward MAPKs. As illustrated in 
Table 4.1, all ten DUSPs were easily measured by qRT-PCR within the detectable limits 
of 36 threshold cycles (CT) with dusp1, dusp6, and dusp7 most abundantly and dusp8 
and dusp9 least abundantly expressed. This screen was extended to compare 
differences in basal DUSP expression between unstimulated PAs and ADs. DUSPs 
were grouped based on structural differences involving the presence or absence of NLS 
and NES sequences that may dictate subcellular localization to the nucleus (group I) and 
cytosol (group II), respectively (Table 4.1). DUSPs that contain both NLS and NES 
sequences were grouped as phosphatases that could localized to either compartment 
(group III) (17).  DUSP mRNA abundance was normalized to 18S ribosomal RNA and 
expressed relative to the value observed in PAs. As illustrated in Fig.4.3, relative mRNA 
abundance of dusp4 and dusp9 was significantly elevated in ADs compared to PAs. 
Dusp1, dusp2, dusp6, and dusp7 were significantly elevated in PAs compared to ADs. 
Dusp5, dusp8, dusp10, and dusp16 showed no marked differences in basal expression 
between these cell types. 
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To determine which DUSPs were induced at the level of gene expression during 
inflammatory stress, PAs and ADs were stimulated in parallel with 100 pM TNFα and 
relative mRNA abundance assessed by qRT-PCR over time. Prior to these studies, we 
set an arbitrary threshold of 2.5-fold change (dashed line) as a conservative measure of 
biological differences versus technical variation as measure by qRT-PCR (25). Thus, 
DUSP gene expression was only considered ‘inducible’ when relative mRNA levels 
exceeded this threshold. Determinations were examined over time to establish when 
select DUSPs were induced as well as whether the induction was transient versus 
sustained as insight to functional roles. As illustrated in Fig.4.4, Dusp1 was the only 
group I phosphatase induced in PAs with a 20-fold transient increase in relative gene 
expression peaking at 1 hr post-TNF kinetically consistent with a functional role in the 
rapid dephosphorylation of MAPK as shown in Fig.4.1B. In addition, dusp8 and dusp16 
(group III) were rapidly induced in PAs, but in contrast to dusp1, mRNA levels remained 
elevated ≥4h following TNF stimulation suggesting the possibility of divergent roles in 
mediating MAPK magnitude and duration. Parallel determinations in ADs revealed that 
dusp1, dusp5, and dusp8 were also induced within 2 hrs post-TNF stimulation. It 
should be noted, however, that while dusp8 met our criterion for induction in both cell 
types, the magnitude of induction was dramatically greater in PAs versus ADs. No 
member of group II phosphatases was induced following TNF stimulation in either cell 
type.  It is also important to note that while there were similarities between cell types, 
there were marked difference such as the induction of dusp5 in ADs, but not PAs and 
the induction of dusp16 in PAs, but not ADs. While this study was focused on 
understanding the role of inducible DUSPs during inflammatory stress, these data further 
demonstrated that select DUSPs were suppressed following TNF stimulation. Using a 
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criterion of 0.5 fold changes in mRNA abundance as an arbitrary threshold for gene 
suppression (dotted line), mRNA levels for dusp2 and dusp4 of group I phosphatases 
were markedly suppressed in both cell types where the degree of suppression was 
sustained for more than 24 hrs. Dusp9 (group II) was also suppressed, but transiently 
and only in ADs, not PAs. 
Dusp1, dusp8, and dusp16 modulate MAPK phosphorylation following 
TNF stimulation. Data presented above demonstrated that select DUSPs were 
induced in a manner that would be consistent with divergent regulatory roles in 
modulating the extent of MAPK phosphorylation in a cell type-specific manner. As 
dusp1, dusp8, and dusp16 were induced in PAs following transient phosphorylation of all 
three MAPKs, we focused additional effort in this study toward understanding the 
mechanistic role and regulation of these DUSPs in PAs only. To determine a 
mechanistic role for these DUSPs on MAPK signaling, PAs were transfected with short 
interfering RNA (siRNA) targeted to either dusp1, dusp8, or dusp16 as well as non-
targeting control siRNA for 72 hrs prior to stimulation with 100 pM TNF. Total RNA and 
whole cell lysates were harvested over time and analyzed for relative mRNA abundance 
and phosphorylated MAPK protein, respectively. Targeted siRNA dramatically 
suppressed TNF-mediated induction of each DUSP to 70-85% of that observed for 
non-targeting control siRNA (Fig.4.5A, C, E). Moreover, 72 hr exposure to targeted 
siRNA decreased basal dusp1 and dusp16, but not dusp8 mRNA. Fig.4.5(B,D,F) depicts 
the effect of mRNA knockdown for each individual DUSP on the phosphorylation state of 
MAPK from protein harvested from the same experiments. As illustrated, suppression of 
dusp1 mRNA increased basal levels of phosphorylated ERK and JNK as well as 
magnitude of TNFα-mediated JNK phosphorylation through 1 hr post-stimulation. While 
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dusp8 siRNA had no discernable effect on basal phoshorylation, targeted knockdown 
markedly increased the duration of ERK and JNK through 4 hrs post-TNFα stimulation. 
Dusp16 siRNA yielded only a modest increase in magnitude of ERK and JNK (Fig.4.5F). 
No discernable effects were noted regarding p38 phosphorylation for dusp1, dusp8, or 
dusp16. As individual DUSP knockdown demonstrated a functional role regarding MAPK 
signaling, we further investigated the cooperative action of inducible DUSPs on MAPK 
dephosphorylation. For this, PAs were transfected with pools of oligonucleotides 
containing siRNAs for each DUSP 72 hrs prior to TNFα stimulation.  As illustrated in 
Fig.4.6A, pooled siRNA for dusp1, dusp8 and dusp16 attenuated TNFα-mediated mRNA 
induction for each DUSP similar to that shown above for individual DUSP siRNAs. 
Combined targeted knockdown of all three phosphatases resulted in marked increases 
in the magnitude and duration of ERK, JNK, and p38 phosphorylation when compared to 
control (Fig.4.6B). Collectively, these data demonstrated synergistic actions of 
phosphatases in the regulation of MAPK signaling. The rapid and transient induction of 
dusp1 kinetically matched the functional effect on ‘magnitude’ of ERK and JNK 
phosphorylation while the more delayed and prolonged induction of dusp8 was 
consistent the functional role on ‘duration’ of ERK and JNK phosphorylation. Moreover, 
pooled siRNA had an additive effect on both magnitude and duration of all three MAPKs 
including p38 relative to that observed when each DUSP was targeted individually.   
DUSP-modulation of MAPK phosphorylation alters TNFα-mediated 
proinflammatory gene expression. Data presented above demonstrated that induction 
of select DUSPs modulated both magnitude and duration of MAPK phosphorylation. To 
determine if these effects on MAPK activity resulted in MAPK-dependent changes in 
biological function, we examined changes in mRNA abundance over time following 
122 
 
TNFα stimulation of four proinflammatory genes known to be expressed in adipocytes 
under conditions of inflammatory stress. As illustrated in Fig.4.7A, TNFα stimulation 
resulted in rapid and transient changes in MCP-1, IL-6, Cox-2, and TNFα gene 
expression in density-arrested PAs. To determine a role for MAPK activity regarding 
these changes in gene expression, PAs were pretreated with U0126, SP600125, and 
SB203850, representing potent and selective inhibitors of ERK, JNK, and p38, 
respectively, for 1 hr prior to stimulation with TNFα. Total RNA was harvested after 2 hrs 
post-TNFα stimulation corresponding to the time of peak induction for all four 
proinflammatory genes. As shown in Fig.4.7B, TNFα induction of MCP-1, IL-6, and Cox-
2 was significantly suppressed by individual MAPK inhibitors; an effect that was 
magnified when all inhibitors were used in combination. To determine a role for DUSPs 
on these MAPK-dependent changes in gene expression, PAs were transfected with a 
combination of dusp1, dusp8, and dusp16 siRNA 72 hrs prior to stimulation with TNFα. 
As illustrated in Fig.4.8, knockdown of these inducible DUSPs significantly elevated 
TNFα-mediated induction of each proinflammatory gene that was shown above to be 
downstream of MAPK activity. In direct contrast, TNFα-mediated induction in TNFα gene 
expression was significantly suppressed following DUSP knockdown. While TNFα gene 
expression was notably suppressed by MAPK inhibitors, the effects were not significant, 
suggesting that other non-MAPK signaling pathways played more dominant roles in 
regulating the expression of this proinflammatory gene. 
JNK activity is required for Dusp8 mRNA synthesis in response to TNFα. 
Other studies have proposed a canonical role for DUSPs whereby MAPK-mediated 
changes in DUSP gene expression result in the expression of targeted phosphatases 
that specifically modulate MAPK activity (26,27).  To determine if MAPKs play a role in 
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TNFα-mediated changes in DUSP gene expression, PAs were pretreated with 
pharmacological inhibitors as discussed above and total RNA harvested at 1 hr and 2 
hrs post-TNFα stimulation corresponding to peak induction of dusp1 and dusp8/16, 
respectively. Surprisingly, JNK signaling was the only MAPK pathway involved and only 
in regards to dusp8 gene expression (Fig.4.9A). Pharmacological blockade of each 
MAPK pathway, or a combination thereof, did not significantly suppress TNFα induction 
of dusp1 or dusp16. As all pharmacological inhibitors have off-target effects, we 
confirmed these data regarding dusp8 by comparing the effect of two structurally 
independent inhibitors of JNK activity (SP600125 and JNK Inhibitor VII). As illustrated in 
Fig.4.9B, both inhibitors suppressed TNFα-mediated changes in dusp8 gene expression 
in a similar, concentration-dependent manner, collectively demonstrating a regulatory 
feedback loop modulating the extent of MAPK phosphorylation and activity. While TNFα 
stimulation clearly induced dusp1 and dusp16 gene expression, the induction appeared 
to be independent of MAPK signaling.  
Discussion 
Our report presents the first empirical evidence demonstrating that regulating the 
extent of MAPK phosphorylation by inducible MAPK-specific phosphatases has a 
profound influence on biological outcome downstream of MAPK signaling under 
conditions of inflammatory stress in cells of adipocyte lineage. First, we show that TNFα 
stimulation leads to cell type-specific phosphorylation of ERK, JNK, and p38 with robust, 
but transient effects on magnitude in PAs and subtle, but prolonged effects on duration 
in ADs. Second, we illustrate that in contrast to MAPK phosphorylation, mechanisms 
leading to rapid MAPK dephosphorylation are dependent on de novo RNA synthesis 
demonstrating a role for inducible gene expression in regulating the extent of MAPK 
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activity. Third, we show that DUSP gene expression is regulated following TNFα 
stimulation in a cell type and phosphatase-specific manner where kinetics of dusp1, 
dusp8, and dusp16 mRNA accumulation are consistent with determined roles on 
magnitude and duration of MAPK phosphorylation as well as biological function 
stemming from MAPK activity. Fourth, we illustrate MAPK-dependent and -independent 
regulation of these inducible DUSPs following TNFα stimulation establishing a feedback 
modulation of MAPK activity and functional outcome. Collectively, these data establish 
mechanistic roles for select, inducible, MAPK-specific phosphatases in mediating the 
extent of MAPK-dependent changes in gene expression highlighting potential 
therapeutic targets linking obesity with metabolic inflammatory diseases.  
It is now well established that obesity is associated with AT inflammation, where 
cells within AT including PAs, ADs, and macrophages produce and secrete various pro-
inflammatory cytokines in response to pathogens and cellular stress (28-30). Evidence 
further demonstrates that both PAs and ADs play a central role in AT inflammation and 
IR. While PAs are generally considered more inflammatory than ADs (28,31), others 
have shown that PAs share traits with macrophages such as phagocytosis and 
expression of membrane-bound NADPH oxidases (32). Consist with this notion, 
transcriptional profiling suggests that macrophages and PAs are genetically related (33), 
while further reports demonstrate that PAs can trans-differentiate into macrophage-like 
cells (32) and that PAs may, in part, originate from AT macrophages (34). Data 
presented in this investigation demonstrate that the magnitude of MAPK phosphorylation 
was markedly greater in PAs compared to ADs, while ERK and JNK signaling duration 
was prolonged in ADs compared to PAs in response to inflammatory stress. While p38 
phosphorylation was observed in PAs, it was not seen in ADs stimulated under the same 
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conditions, suggesting that PAs are more responsive to external inflammatory cues. As 
reports demonstrate that activation of MAPKs results in increased inflammation, others 
have shown that the extent (i.e., duration) of MAPK phosphorylation is also important in 
controlling biological processes, where prolonged phosphorylation of JNK inhibits insulin 
signaling (12,13). Therefore, timely modulation of JNK and ERK phosphorylation in ADs 
suggests that diverse inflammatory regulation (i.e., magnitude and duration) between 
different cell types may be equally important in AT inflammation and obesity-induced IR. 
Traditionally, upstream kinases rather than phosphatases were viewed as major 
regulators of MAPK signaling. However, phosphatases are now recognized as key 
modulators and even controllers involved in timely modulation of MAPK signaling and 
inflammation (16,17). As recent reports demonstrate that ‘inducible’ DUSPs modulate 
MAPKs dephosphorylation in various cell types (26,35,36), we show that all MAPK-
specific DUSPs examined were expressed in both PAs and ADs. Moreover, we 
demonstrate clear phenotypic differences in basal DUSP expression, as four of the ten 
DUSPs were markedly elevated in PAs compared to ADs while two of the ten DUSPs 
were markedly elevated in ADs compared to PAs. Data presented here further report 
phenotypic differences in TNFα-induced DUSP gene expression, where dusp1, dusp8, 
and dusp16 were induced in PAs and dusp1, dusp5, and dusp8 induced in ADs. As 
TNFα-mediated induction of dusp1 and dusp8 was greater in PAs compared to ADs, 
these data suggest that phenotypic differences in the duration (i.e., transient vs. 
prolonged) of ERK and JNK phosphorylation may reflect DUSP expression. Collectively, 
these data suggest that both upstream kinases and downstream phosphatases may 
influence the observed phenotypic differences in PAs and ADs regarding inflammatory 
signaling and inflammatory status.  
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Molecular mechanisms that underlie AT inflammation during the onset of obesity 
include the expression and release of various chemokines (i.e., MCP-1) and cytokines 
(i.e., TNFα and IL-6) that promote infiltration of macrophages and IR (1,3,4). While it is 
well established that MAPKs serve as central mediators linking inflammation to 
adipocyte IR (2,12,14), they also contribute to the activation of downstream 
transcriptional programs (e.g. AP-1) involved in proinflammatory cytokine production, 
further exacerbating AT inflammation (2,30). Recent reports not only demonstrate a role 
for DUSPs in the modulation of MAPK signaling, but also the downstream regulation of 
MAPK-dependent processes including inflammatory gene expression, where mice 
deficient in select DUSPs have increased JNK and p38 signaling that corresponds to 
increased expression of TNFα and IL-6 (36-39). Upon further examination of 
inflammatory PAs, where MAPK activation was transient, we demonstrate that DUSP 
induction kinetically favored MAPK dephosphorylation in the presence of continued 
TNFα, suggesting a functional role for ‘inducible’ phosphatases on MAPK signaling. 
Moreover, we show that mechanisms leading to MAPK dephosphorylation were 
dependent on de novo mRNA synthesis, further highlighting a role for ‘inducible’ DUSPs 
in the regulation of MAPKs. As RNAi-mediated knockdown of DUSPs in PAs resulted in 
increased magnitude and duration of ERK, JNK, and p38 phosphorylation, these data 
confirm that DUSPs play a pivotal role in the modulatory timing of MAPK signaling under 
conditions of inflammatory stress. While no MAPK-dependent cytosolic change was 
examined in this study, data presented here demonstrate that the modulatory actions of 
DUSPs on MAPK signaling significantly increased nuclear events involving pro-
inflammatory gene expression of MAPK-dependent MCP-1, IL-6, and Cox-2 in PAs 
challenged with TNFα. Collectively, these data demonstrate that DUSPs play a central 
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role in the modulation of MAPK dephosphorylation, ultimately affecting downstream 
regulation of MAPK-dependent nuclear processes involved in AT inflammation.   
Regulation of DUSPs was originally thought to occur in a ‘feedback’ manner 
(26,27,35), in which MAPKs induce DUSP expression that, in turn, dephosphorylates 
MAPKs. We report that only dusp8 was downstream of JNK phosphorylation, while 
dusp1 and dusp16 were not regulated by MAPK signaling. Recent evidence suggests 
that MAPK-independent pathways also regulate DUSPs expression under conditions of 
inflammatory stress, where protein kinase A (PKA) and PKC have been shown to 
regulate dusp1 mRNA expression (40-42). Thus, MAPK-independent regulation of 
DUSPs may play a critical role in cellular signaling cross-talk. This is evident in studies 
that demonstrate MAPK cross-talk between the janus kinase–signal transducer and 
activator of transcription (JAK-STAT) and phosphatidylinositol 3-kinase (PI3K) pathways 
(10,43). Moreover, data presented here suggest that MAPK-dependent regulation of 
dusp8 is essential for feedback and cross-talk modulation of MAPKs, as it was shown 
that dusp8 modulates JNK and ERK dephosphorylation. Consistently, others 
demonstrate that sustained JNK phosphorylation in response to mitogenic stimuli blocks 
ERK activation in COS-7 cells via transcriptional mediated processes (44), with recent 
reports suggesting a positive regulation of ERK from the JNK phosphatases dusp10 and 
dusp16 (45). Interestingly, DUSP knockdown significantly attenuated TNFα-induced 
TNFα gene expression in PAs. While these data demonstrate that TNFα regulation is 
MAPK-independent, it is possible that modulatory actions of DUSPs on MAPK signaling 
altered other signaling pathway(s) involved in TNFα regulation. Taken together, these 
findings suggest that cross-talk within and between signaling modules occur in part 
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through the regulation of inducible DUSPs, potentially contributing to MAPK-dependent 
and -independent regulation of AT inflammation and IR. 
In summary, data outlined here and elsewhere (17,35) highlight the importance 
of timely MAPK phosphorylation and dephosphorylation resulting from upstream kinases 
and downstream phosphatases in the regulation of inflammatory signaling and 
inflammatory status. We demonstrate that DUSPs regulate MAPK dephosphorylation 
and MAPK-dependent inflammatory gene expression in 3T3-L1 adipocytes in response 
to inflammatory stress. Moreover, we report that MAPK-dependent and MAPK-
independent regulation of DUSPs is critical in signaling feedback inhibition and cross-
talk that potentially contributes to AT inflammation. As work on DUSP regulation and 
function continues, elucidation into the molecular actions of these phosphatases may 
provide therapeutic targets for the treatment and prevention of AT inflammation and 
obesity-induced IR. 
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Table 4.1.  DUSPs and inflammatory genes analyzed in this study. 
 
 symbol name/alias     accession ABI number CT 
dual specificity phosphatases GP MKB NLS NES    
 Dusp1 MKP-1, hVH1 I ● ●  NM_013642 Mm00457274_g1 24 
 Dusp2 PAC1 I ● ●  NM_010090 Mm00839675_g1 32 
 Dusp4 MKP-2, hVH2 I ● ●  NM_176933 Mm00723761_m1 27 
 Dusp5 hVH3 I ● ●  NM_001085390 Mm01266104_m1 27 
 Dusp6 MKP-3, rVH6 II ●  ● NM_026268 Mm00650255_g1 24 
 Dusp7 MKP-X II ●  ● NM_153459 Mm00463228_m1 24 
 Dusp9 MKP-4 II ●  ● NM_029352 Mm00512646_m1 31 
 Dusp8 M3/6, hVH5 III ● ● ● NM_008748 Mm00456230_m1 32 
 Dusp10 MKP-5 III ● ● ● NM_022019 Mm00517678_m1 26 
 Dusp16 MKP-7, MKP-M III ● ● ● NM_130447 Mm00459935_m1 26 
inflammatory genes    
 Ccl2 monocyte chemoattractant protein-1 (MCP-1) NM_011333 Mm00441242_m1 21 
 IL-6 interleukin-6 NM_031168 Mm99999064_m1 29 
 Ptgs2 cyclooxygenase-2 (COX-2) NM_011198 Mm00478372_m1 29 
 TNFα tumor necrosis factor-alpha  NM_013693 Mm99999068_m1 35 
reference gene    
 18S 18 ribosomal RNA X03205 4342930E 9 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1. DUSP and inflammatory genes analyzed in this study. DUSPs that contained 
the MAPK binding domain (MKB) were assigned to groups (GP) based on structural 
differences involving the presence or absence of a nuclear localization sequence (NLS), 
nuclear export sequence (NES), or both that may dictate subcellular localization to the 
nucleus (group I), cytosol (group II), or either compartment (group III).  
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Figure 4.1. Phenotypic differences in TNFα-stimulated MAPK signaling between 
PAs and ADs. A) PAs and ADs were stimulated in parallel with increasing doses of 
TNFα and cell lysates harvested at 15 min post-TNFα stimulation prior to immunoblot 
analysis of bisphosphorylated ERK, JNK, and p38. B) 100 pM TNFα was added to PAs 
and ADs in parallel. Cell lysates were collected over time post-TNFα and 
immunoblotted for phospho-ERK, JNK, and p38 as well as total p38. 
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Figure 4.2. MAPK dephosphorylation is regulated by mechanisms 
involving de novo mRNA synthesis. PAs were stimulated with 100 pM TNFα 
over time pretreated in the absence or presence of 1 ng/ml Actinomcyin D 
(AD). Cell lysates were collected over time post-TNFα and protein expression 
of bisphosphorylated ERK, JNK, and p38 along with total p38 analyzed via 
immunoblotting.  
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Figure 4.3. DUSPs are phenotypically regulated in PAs versus ADs. Total RNA was 
harvested from untreated PAs (d0) and mature ADs (d8) prior to mRNA analysis of A) group 
I, B) group II, and C) group III DUSPs via qRT-PCR. Data were normalized to 18S rRNA and 
expressed relative to untreated PAs. Statistical significance was determined by Student’s t-
test (* p<0.05).   
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Figure 4.4. Several DUSPs are induced in PAs and 
ADs in response to TNFα. Total RNA was harvested 
from PAs and ADs stimulated in parallel with 100 pM 
TNFα over time and gene expression of A) group I, B) 
group II, and C) group III DUSPs analyzed with qRT-PCR. 
All data were normalized to 18S rRNA and expressed 
relative to untreated cells. Genes were selected as 
‘inducible’ when upregulated above a 2.5-fold criterion 
indicated by the dashed line, while genes were considered suppressed that fell below a 0.5 
criterion indicated by the dotted line on the graph.   
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Figure 4.5. Individual DUSPs modulate MAPK signaling in 3T3-L1 PAs in response to 
TNFα. PAs were transfected with DharmaFect 3 transfection reagent in the presence of non-
targeting control siRNA or siRNA specific for dusp1, dusp8, or dusp16 for 72 hrs prior to 
stimulation with 100 pM TNFα. Cell lysates were then harvested for RNA at 0h, 1h, or 2h 
post-TNFα stimulation and mRNA expression of A) dusp1, C) dusp8, and E) dusp16 
analyzed via qRT-PCR. Data were normalized to 18S rRNA and changes in gene expression 
measured as fold differences relative to untreated control siRNA (0h). Statistical differences 
were determined by ANOVA. Tukey's post-hoc analysis was performed when the p value for 
the respective parameter was statistically significant (p < 0.05). In addition, cell lysates were 
collected over time post-TNFα stimulation for control siRNA and B) dusp1, D) dusp8, or F) 
dusp16 specific siRNA and protein expression of bisphosphorylated ERK, JNK, and p38 
along with total JNK and GAPDH examined via immunoblotting.  
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Figure 4.6. Combination DUSP knockdown modulates MAPK signaling magnitude and 
duration in PAs in response to TNFα. PAs were transfected with DharmaFect 3 transfection 
reagent in the presence of non-targeting control siRNA or siRNA specific for dusp1, dusp8, 
and dusp16 for 72 hours prior to stimulation with 100 pM TNFα. A) Total RNA was harvested 
at 0hr, 1hr, or 2hr post-TNFα stimulation and mRNA expression of dusp1 (1h), dusp8 (1h), 
and dusp16 (2h) analyzed via qRT-PCR. Data were normalized to 18S rRNA and changes in 
gene expression measured as fold differences relative to untreated control siRNA (0h). 
Significance differences were determined by ANOVA. Tukey's post-hoc analysis was 
performed when the p value for the respective parameter was statistically significant (p < 
0.05).  B) Cell lysates were collected over time post-TNFα stimulation for control siRNA or 
combination DUSP siRNA and protein expression of bisphosphorylated ERK, JNK, and p38 
along with α-Tubulin examined via immunoblotting.  
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Figure 4.7. MAPK-dependent regulation of proinflammatory genes in response to 
TNFα. A) Total RNA was harvested over time from PAs stimulated with 100 pM TNFα and 
gene expression of MCP-1, IL-6, Cox-2, and TNFα mRNA expression examined via qRT-
PCR. B) PAs were pretreated for 1hr in the presence of inhibitors for ERK (U0126, 10 µM), 
JNK (SP600125, 20 µM), or p38 (SB203850, 10 µM) prior to TNFα stimulation. Total RNA 
was harvested at 2hr post-TNFα and mRNA expression analyzed for the above mentioned 
genes. Nomenclature related to the graph is assigned: T (TNFα), T+E (TNFα + ERK), T+J 
(TNFα + JNK), T+P (TNFα + p38), or TEJP (TNFα +ERK+JNK+p38). Data were expressed 
relative to untreated cells and normalized to the 18S rRNA. Statistical significance was 
determined by ANOVA with Dunnett’s post-hoc analysis conducted to assess differences 
from control (TNFα) when p<0.05.  
 
137 
 
 
 
 
 
 
Figure 4.8. DUSPs modulate MAPK-dependent proinflammatory gene expression 
in response to TNFα. PAs were transfected with 3 µl DharmaFect 3 transfection 
reagent in the presence of non-targeting control siRNA or siRNA specific for dusp1, 
dusp8, and dusp16 for 72 hours prior to stimulation with 100 pM TNFα. Total RNA was 
collected at 0h or 2h post-TNFα stimulation and mRNA expression of A) MCP-1, B) IL-6, 
C) Cox-2, and D) TNFα analyzed via qRT-PCR. Data were normalized to 18S rRNA and 
changes in gene expression measured as fold differences relative to untreated control 
siRNA (0h). Statistical differences were determined by ANOVA. Tukey's post-
hoc analysis was performed when the p value for the respective parameter was 
statistically significant (p < 0.05). 
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Figure 4.9. JNK activation is essential for 
dusp8 gene expression. A) 3T3-L1 PAs were 
pretreated for 1hr in the presence of inhibitors for 
ERK (U0126, 10 µM), JNK (SP600125, 20 µM), 
or p38 (SB203850, 10 µM) prior to 100 pM TNFα 
stimulation. Total RNA was harvested at 1 hr and 
2 hr post TNFα stimulation and assessed for 
dusp1, dusp8, and dusp16 mRNA expression via 
qRT-PCR. Nomenclature related to the graph is 
assigned: T (TNFα), T+E (TNFα + ERK), T+J 
(TNFα + JNK), T+P (TNFα + p38), or TEJP (TNFα +ERK+JNK+p38). B) In addition, PAs 
were pretreated for 1hr with increasing doses of JNK inhibitors A) SP600125 or B) JNK 
inhibitor VIII prior to stimulation with 100 pM TNFα. Total RNA was harvested at 1 hr post 
TNFα stimulation and assessed for dusp8 expression via qRT-PCR. Data were expressed 
relative to untreated cells and normalized to 18S rRNA. Statistical significance was 
determined by ANOVA with Dunnett’s post-hoc analysis conducted to assess differences 
from control (TNFα) when p<0.05.  
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CHAPTER V 
ROLE FOR DUAL-SPECIFICITY PHOSPHATASES REGARDING CHEMOKINE 
EXPRESSION IN ADIPOCYTES IN RESPONSE  
TO INFLAMMATORY STRESS 
Abstract 
Obesity is an independent risk factor for heart disease, stroke, insulin resistance (IR), 
and diabetes. Early evidence demonstrated an essential role for the proinflammatory 
chemokine monocyte chemoattractant protein-1 (MCP-1) in macrophage recruitment, 
adipose tissue (AT) inflammation, and obesity-induced IR. However, it is now clear that 
other proinflammatory chemokines are induced in AT with obesity and are associated 
with obesity-induced IR. Moreover, reports have elucidated that the modulation of 
mitogen-activated protein kinase (MAPK) signaling by upstream kinases and 
downstream phosphatases plays a central role in linking inflammation to obesity-induced 
IR. This study investigated the role of MAPK-specific dual-specificity phosphatases 
(DUSPs) on MAPK-regulated CC chemokine expression under conditions of 
inflammatory stress in 3T3-L1 adipocytes. We report that all CC chemokines (i.e., CCL2, 
CCL3, CCL4, CCL5, CCL8, CCL9, CCL12, and CCL20) examined were expressed in 
preadipocytes (PAs) and adipocytes (ADs), where expression for most CC chemokines 
was greatest in PAs compared to ADs. Additionally, we demonstrated that all CC 
chemokines examined were induced in response to inflammatory stress (i.e., TNFα). 
While nuclear factor kappa B (NF-κB) partially regulated the expression of select 
chemokines, all CC chemokines examined were downstream targets of MAPK signaling. 
Finally, this report demonstrated that increased MAPK signaling duration and magnitude 
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via DUSP RNA interference (RNAi) resulted in significant amplification of nuclear MAPK-
dependent processes involving CC chemokine expression. Collectively, these data 
present empirical evidence that timely modulation of MAPK signaling via DUSPs is 
essential in the regulation of biological processes involving MAPK-dependent CC 
chemokine expression and AT inflammation. 
 
Introduction 
 Obesity plays a causal role in IR where increased adiposity in humans and 
animals highly correlate with decreased insulin sensitivity (1-4). Excessive expansion of 
AT in obesity triggers inflammatory stress, disrupting adipocyte function that leads to 
localized and systemic IR (5-10). The emergence of inflammation as a central mediator 
involved in adipocyte dysfunction and IR developed from observations that tumor 
necrosis factor α (TNFα) increased during obesity, while genetic attenuation of TNFα or 
its receptor protects mice fed a high-fat diet from developing IR (11-16). While it is now 
apparent that obesity is associated with chronic, low-grade inflammation, initiation of the 
inflammatory response in AT has not been fully elucidated. 
Observations of macrophage accumulation and activation in AT of obese 
humans and animals revealed an important source for TNFα expression in obesity that 
disrupts adipocyte function and impairs insulin signaling (17). Moreover, reduction of AT 
macrophage infiltration observed in diet-induced obese (DIO) mice deficient in MCP-1/ 
chemokine (C-C motif) ligand 2 (CCL2) or its cognate receptor CCR2 demonstrated a 
decreased expression of inflammatory adipose cytokines (i.e., TNFα) and improved 
insulin sensitivity (18,19). In contrast, transgenic mice expressing MCP-1/CCL2 have the 
reverse phenotype (18). MCP-1 is a CC chemokine that belongs to the β-chemokine 
145 
 
family that includes monocyte chemoattractant proteins (MCP), macrophage 
inflammatory proteins (MIP), and regulated upon activation, normal T cell expressed and 
secreted (RANTES), among others. These chemokines attract most monocytes, 
eosinophils, basophils, and lymphocytes under inflammatory conditions (20) including 
obesity (21). While MCP-1/CCL2 appears essential for obesity-induced IR, it has 
become increasingly clear that other CC chemokines play an essential role in AT 
inflammation (21). As reports demonstrate that AT inflammation involves the secretion of 
TNFα derived from activated AT macrophages (22), adipocyte-secreted CC chemokines 
may play a key role in the development of chronic AT inflammation.  
Two major signaling pathways that have been identified as upstream regulators 
of TNFα-mediated inflammatory signaling include nuclear factor kappa B (NF-κB) and 
MAPKs, consisting of extracellular signal-regulated kinase (ERK), p38, and c-Jun N 
terminal kinase (JNK) (1,23). All four pathways are activated in AT in response to 
macrophage-mediated TNF stimulation and serve as mediators of localized IR through 
transcriptional mechanisms involving adipocyte gene expression as well as the 
expression and secretion of other proinflammatory molecules (1,24-27). Compared to 
lean counterparts, AT of obese animals display markedly increased expression of ERK, 
p38, and JNK (27-30), while genetic loss-of-function studies demonstrate that deletion of 
these kinases protects against AT inflammation and IR in animals challenged with 
obesity or high fat diet (HFD) (27,31). For example, deletion of JNK in dietary and 
genetic (ob/ob) mouse models of obesity led to decreased adiposity, improved insulin 
sensitivity, and enhanced insulin receptor signaling (27). Moreover, phosphorylated JNK 
has been shown to regulate nuclear events involving cytokine (e.g., TNFα) and 
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chemokine (e.g., MCP-1) expression in 3T3-L1 adipocytes that promote macrophage 
recruitment and AT inflammation  (32,33). 
Activation of MAPK signaling is regulated by sequential and concerted 
phosphorylation of upstream kinases where phosphorylation of both the threonine and 
tyrosine residues of the (T-X-Y) motif within the activation loop by upstream MAPK 
kinases is essential and sufficient for MAPK activation (25,34,35). While upstream 
kinases were traditionally viewed as major regulators of MAPK signaling, many 
phosphatases are now recognized as key modulators and even controllers of MAPK 
activation and MAPK-dependent processes involving inflammation (25,33,36-38). 
MAPK-specific DUSPs constitute a group of ten protein tyrosine phosphatases that 
specifically inhibit MAPK activity through dephosphorylation of both threonine and 
tyrosine residues. These 10 known DUSPs are MAPK-specific as they contain a MAP 
kinase-binding (MKB) domain that selectively imparts catalytic activity toward ERK, JNK, 
or p38 (34,37,38,38,39). DUSPs have recently been identified as potential targets in the 
regulation of MAPK-mediated inflammation and IR (37,40), where dusp1 was observed 
to regulate inflammatory protein expression in macrophages in response to 
lipopolysaccharide (LPS) challenge as well as mitigate IR and MCP-1 expression within 
ADs (41-44).  
Considering the role for CC chemokines on obesity-associated AT inflammation 
and IR, we examined the impact of DUSPs on MAPK-dependent CC chemokine 
regulation during TNFα-mediated inflammatory stress in 3T3-L1 adipocytes. This cell line 
consists of nearly pure populations of undifferentiated PAs as well as mature ADs 
representing cellular effectors of AT dysfunction without macrophage contamination. 
This study demonstrated that DUSPs act as key regulators of MAPK-dependent CC 
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chemokine expression under conditions of TNFα-mediated inflammatory stress in 
adipocytes, highlighting a potential therapeutic role for DUSPs on macrophage infiltration 
and chronic AT inflammation. 
   
Materials and Methods 
Materials: Dulbecco’s Modified Eagle’s Medium (DMEM), calf bovine serum (CS), 
and trypsin-EDTA were purchased from Invitrogen. Fetal bovine serum (FBS) was 
obtained from HyClone. Antibodies used for immunoblotting include phospho-ERK, 
phosho-p38, phospho-JNK, total p38, and α-tubulin purchased from Cell Signaling. 
U0126, SP600125, SB203580, and Helenalin were purchased from CalBiochem. 
Enhanced chemiluminescence (ECL) reagents were obtained from Perkin-Elmer Life 
Sciences. All Taqman primer probes (Table 5.1) used in this study were purchased from 
Applied Biosystems. The murine 3T3-L1 cell line was purchased from Howard Green, 
Harvard Medical School (45).  
Cell Culture: 3T3-L1 preadipocytes were propagated in DMEM supplemented 
with 10% CS until density-induced growth arrest, as previously described (46). At 2 days 
post-confluence, growth medium was replaced with DMEM supplemented with 10% 
FBS, 0.5mM 1-methyl-3-isobutylxanthine, 1 µM dexamethasone, and 1.7 µM insulin 
(MDI). Throughout the study, ‘time 0’ refers to density arrested cells immediately before 
the addition of MDI to the culture medium. Experiments described herein were 
conducted in density-arrested preadipocytes (d0) and mature adipocytes (d8) stimulated 
in parallel with 100 pM TNFα. All experiments were repeated at least 3 times to validate 
results and ensure reliability. 
148 
 
Immunoblotting: Cell monolayers were washed with phosphate-buffered saline 
(PBS) and scraped into ice-cold lysis buffer containing 1.0 M Tris, pH 7.4, 150 mM NaCl, 
1% Triton X, 0.5% Nonidet P-40 (NP40), 1 mM EDTA, 1 mM EGTA, and 10 mM N-
ethylmaleimide. Phosphatase (20 mM ß-glycerophosphate, 10 mM NaFl, and 2 µM 
sodium vanadate), as well as protease (0.3 µM aprotonin, 21 µM leupeptin, 1 µM 
pepstatin, 50 µM phenanthroline, and 0.5 µM phenylmethylsulfonyl fluoride) inhibitors 
were added to lysis buffer prior to cell harvest. Cell lysates were sonicated, centrifuged 
(13,000 x g, 10 min, 4°C), and the supernatant transferred to a fresh tube. Bicinchoninic 
acid assay (Pierce, Rockford, IL) was used to determine protein concentration. Cell 
lysates were resuspended in loading buffer containing 0.25 M Tris, pH 6.8, 4% sodium 
dodecyl sulfate (SDS), 10% glycerol, 10% dithiothreitol, and 0.01% bromophenol blue 
and heated for 5 min at 80°C. Proteins were resolved on SDS-polyacrylamide gel 
electrophoresis gels (PAGE) and transferred to polyvinylidene fluoride membranes 
(Millipore Corp., Billerica, MA). After transfer, membranes were blocked with 4% milk and 
probed with indicated primary antibodies overnight at 4°C. Membranes were 
subsequently probed with horseradish peroxidase-conjugated secondary antibodies for 1 
hr at room temperature. Immunoblots were immersed in ECL and visualized by 
autoradiography using CL-XPosure film (Pierce). 
Real-Time RT-PCR: Total RNA was extracted and genomic DNA contamination 
was removed using the RNeasy Plus Mini Kit (Qiagen) following the manufacturer’s 
protocol. Total RNA was quantified with a Nanodrop ND-1000 spectrophotometer and 
reverse-transcribed to cDNA in a 10 µl reaction volume using a high capacity cDNA 
reverse transcription kit (Applied Biosystems). The reverse transcription (RT) master mix 
containing RT buffer, deoxyribonucleotide triphosphate (dNTP) mix, RT random primers, 
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RNase inhibitor (1.0 U/µl), and MultiScribe RT was added to 1 µg RNA and RNase-free 
water. Reverse transcription reaction conditions followed the protocol (25°C for 10 min, 
37°C for 120 min, 85°C for 5 sec, followed by 4°C indefinitely/ RT complete) and utilized 
the Gene Amp PCR System 9700 thermal cycler (Applied Biosystems) for cDNA 
synthesis. 
PCR amplification was run utilizing the 7500 fast system (Applied Biosystems) 
that consisted of enzyme activation at 95°C for 20 sec, followed by 40 cycles of 
denaturation at 95°C for 3 sec combined with annealing/extension at 60°C for 30 sec. All 
data were analyzed with the ABI 7500 real time PCR system (Applied Biosystems). Data 
were recorded and analyzed with Sequence Detector Software (Applied Biosystems) 
and graphs visualized with SigmaPlot software. All data were presented as mean  
standard error of the mean (SEM) and representative of at least two experiments 
performed in duplicate. Data were normalized to 18S previously validated in this lab as a 
suitable reference gene under these experimental conditions (47). Relative differences 
between treated and untreated control samples were analyzed by the 2-ΔΔCT method as 
previously described (47,48).  
Statistical analyses were conducted using SPSS v18. Phenotypic differences in 
mRNA expression were determined via student’s t-test where a p-value of <0.05 was 
considered significant. Knockdown data were analyzed using ANOVA, with Tukey's post-
hoc analysis used when the p value for the respective parameter was statistically 
significant (p < 0.05). Inhibitor data were analyzed using analysis of variance, with 
Dunnett’s post-hoc analysis conducted to assess differences from controls (TNFα) when 
p<0.05.  
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RNA Interference. SMARTpools containing four different short interfering RNAs 
(siRNAs) for dusp1, dusp8, and dusp16 specific sequences as well as non-targeting 
sequences were transfected using DharmaFect 3 transfection reagent according to 
manufacturer’s (Dharmacon) protocol. Briefly, 3T3-L1 preadipocytes were propagated in 
6-well culture dishes until reaching density-induced growth arrest. Growth medium was 
then replaced with DMEM supplemented with 10% CS, 3 µl DharmaFect 3 reagent and 
either 100 nM dusp1, dusp8, and/or dusp16 specific siRNA or non-targeting siRNA for 
72 hr. Growth medium was subsequently switched to differentiation medium containing 
MDI as described above. 
 
Results 
Phenotypic differences between preadipocytes and adipocytes regarding 
TNFα-mediated changes in inflammatory signaling. AT is comprised of insulin-
sensitive adipocytes (ADs) and a stromal vascular fraction containing numerous 
metabolically relevant cell types including undifferentiated adipocyte precursor cells 
known as preadipocytes (PAs). The onset of obesity is associated with marked AT 
recruitment of macrophages that likely represent the major source of elevated TNFα that 
imparts AT dysfunction by increasing proinflammatory signaling that leads to cytokine 
and chemokine gene expression in PAs and insulin resistance in ADs (17). Therefore, 
we examined the effect of TNFα stimulation on MAPK and NF-κB signaling in these 
functionally diverse cell types of adipocyte lineage. The 3T3-L1 murine adipocyte cell 
line was used to assess phenotypic differences, as this cell line yielded undifferentiated, 
quiescent PAs prior to differentiation and greater than 90% conversion to mature ADs 
following differentiation. Moreover, phenotypic differences in inflammatory signaling were 
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cell type specific as this well-established cell line is devoid of other cell types (e.g., 
macrophages) that comprise AT.  Cells were differentiated by established protocol for 8 
days to yield functionally mature ADs and compared to undifferentiated, density-arrested 
PAs of similar passage. To compare phenotypic difference in MAPK and NF-κB 
signaling, PAs and ADs were stimulated with 100 pM TNFα in parallel and lysates 
harvested over time and immunoblotted for ERK, JNK, and p38 bisphosphorylation. This 
concentration of TNFα was chosen, as it was previously determined that inflammatory 
signaling was increased in a concentration-dependent fashion in both PAs and ADs, with 
an estimated ED50 of approximately 100 pM (data not shown; Ch.4). Furthermore, this 
dose closely approximates the concentration of TNFα in human and animal models of 
obesity and has been shown to suppress insulin signaling in culture (11). As shown in 
Fig.5.1, TNFα stimulation resulted in a rapid, transient activation of all three MAPKs in 
PAs where robust phosphorylation was observed at 15 min with complete 
dephosphorylation by 60 min post-TNFα. Conversely, the same concentration of TNFα 
produced markedly lower magnitude, but sustained duration of JNK and ERK with no 
phosphorylation observed for p38 in mature ADs. Likewise, degradation of Iκ-Bα, an 
indicator of increased NF-κB activity, was rapid and transient in PAs where complete 
degradation was observed at 15 min with return expression by 60 min post-TNFα. In 
contrast, Iκ-Bα degradation was delayed in ADs where complete degradation was 
observed at 30 min with a return in expression by 60 min post-TNFα. As the abundance 
of total p38 protein was not affected by TNFα, phenotypic differences observed 
regarding magnitude and duration of MAPK phosphorylation and Iκ-Bα degradation 
suggest that PAs were more responsive to inflammation. 
152 
 
Cell type specific induction of CCL chemokine gene expression following 
TNFα stimulation. Data presented above demonstrated phenotypic differences in 
inflammatory signaling. Thus, we examined phenotypic differences between PAs and 
ADs regarding chemokine expression. We initially screened unstimulated PAs for mRNA 
abundance of eight chemokines previously shown to be regulated under conditions of 
genetic and diet-induced obesity, using qRT-PCR. As illustrated in Table 5.1, all 
chemokines were easily measurable within the detectable limits of 36 threshold cycles 
(CT) with CCL2, CCL5, CCL8, and CCL9 most abundantly expressed and CCL3, CCL4, 
CCL12, and CCL20 least abundantly expressed. Additionally, this screen was extended 
to examine differences in basal chemokine expression between unstimulated PAs and 
ADs. Chemokine mRNA abundance was normalized to 18S ribosomal RNA and 
expressed as relative differences to unstimulated PAs. As illustrated in Fig.5.2, relative 
mRNA abundance of CCL3 and CCL4 was significantly elevated in ADs compared to 
PAs. CCL2, CCL5, CCL8, CCL12, and CCL20 were significantly elevated in PAs 
compared to ADs, while CCL9 showed no marked differences in basal expression 
between cell types.  
Data presented above demonstrated that chemokine expression and 
inflammatory signaling was more prominent in PAs compared to ADs. Therefore, we 
next examined which chemokines were induced at the level of gene expression during 
inflammatory stress in PAs stimulated with 100 pM TNFα using qRT-PCR. Kinetic 
determinations for chemokine expression were examined over time to establish which 
chemokines were induced as well as whether the induction was transient versus 
sustained to gain potential insight into functional roles. As illustrated in Fig.5.3, CCL3, 
CCL4, and CCL12 were induced rapidly and transiently in PAs with an inducible peak 
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occurring at 2h post-TNFα, returning to baseline by <6h post stimulation. In addition, 
CCL2 and CCL20 were rapidly induced in PAs, but in contrast to the above chemokines, 
mRNA levels remained elevated ≥12h following TNF stimulation suggesting the 
possibility of divergent roles in inflammation and macrophage recruitment (Fig.5.3). 
Conversely, induction of CCL5, CCL8, and CCL9 was delayed in PAs stimulated with 
TNFα where CCL5 peaked at 12h, CCL8 peaked at 24h, and CCL9 peaked at 6h post-
TNFα. While the early activation from the above chemokines suggests a direct role for 
TNFα signaling, late phase induction of CCL5 and CCL8 may be in response to 
autocrine or paracrine activation by TNFα-induced inflammatory mediators. 
 Role for MAPK activity regarding chemokine gene expression in response 
to TNFα. As data presented above suggested that all chemokines were induced under 
these conditions of inflammatory signaling, we next examined the role of MAPK and NF-
κB activity on chemokine regulation in PAs under conditions of inflammatory stress. To 
address this question, PAs were pretreated with specific, pharmacological inhibitors of 
ERK (U0126), JNK (SP600125), p38 (SB203580), and NF-κB (Helenalin) for 1h prior to 
TNFα stimulation. Total RNA was harvested from PAs at 2h, 4h, or 18h post-TNFα 
stimulation and mRNA abundance assessed by qRT-PCR comparing treated cells to 
untreated controls. Inhibition of ERK signaling significantly suppressed TNFα-induced 
CCL5 and CCL9 mRNA accumulation (Fig.5.4). In addition, inhibition of p38 signaling 
significantly suppressed CCL2, CCL3, CCL4, CCL8, CCL9, CCL12, and CCL20 mRNA 
accumulation, while JNK inhibition significantly suppressed CCL3, CCL4, CCL5, and 
CCL9. Suppression of CCL3 and CCL4 by JNK and p38 accounted for the effects seen 
with the combination of all three MAPK inhibitors. Likewise, suppression of CCL5 by 
ERK and JNK accounted for the combined effects of all three MAPK inhibitors, while 
154 
 
suppression of CCL8, CCL12, and CCL20 by p38 signaling accounted for the effects of 
all three MAPK inhibitors combined. The diverse regulation of chemokines by MAPK 
signaling suggested specificity of pharmacological inhibitors. Interestingly, CCL3, CCL4, 
CCL5, CCL8, and CCL9 were also significantly suppressed in the presence of NF-κB 
inhibition by helenalin suggesting that multiple signaling pathways were involved in the 
regulation of these inflammatory genes. While MAPKs were essential for the 
upregulation of all the chemokines examined, it played no role in the regulation of 
interleukin-7 (IL-7).  
 Role for DUSPs regarding MAPK-dependent chemokine gene expression in 
response to TNFα.  We demonstrated above that all the CC chemokines examined 
were induced in response to TNFα and downstream of MAPK signaling. Previous 
observations from our lab (data not shown; Ch.4) demonstrated that dusp1, dusp8, and 
dusp16 were induced in PAs following transient phosphorylation of all three MAPKs in 
response to TNFα, while individual knockdown via RNAi led to increased MAPK 
signaling magnitude and duration. Therefore, we focused additional effort in this study 
toward understanding a cooperative role of these DUSPs in PAs in response to TNFα. 
For this, PAs were transfected with pools of oligonucleotides containing siRNAs for 
dusp1, dusp8, and dusp16 for 72 hrs prior to TNFα stimulation. Pooled siRNAs 
attenuated TNFα-mediated mRNA induction for each DUSP (Fig.5.5A). Combined 
targeted knockdown of all three phosphatases resulted in a marked increase in the 
magnitude and duration of ERK, JNK, and p38 phosphorylation when compared to non-
targeting control siRNA (Fig.5.6B).  
Data presented above demonstrated that all the proinflammatory CC chemokines 
examined were MAPK-dependent targets. Therefore, we hypothesized that alterations in 
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MAPK status observed with DUSP knockdown would exacerbate inflammatory status via 
upregulation of these proinflammatory genes. To address this question, we examined 
chemokine expression in the presence of combination DUSP knockdown via qRT-PCR. 
As DUSP knockdown was essential for early MAPK activity, we chose to focus on those 
CC chemokines that were rapidly induced (<2h) in response to TNFα. Thus, CCL5 and 
CCL8 were not examined in the presence of DUSP knockdown as TNFα-mediated 
induction of gene expression was markedly delayed (Fig.5.3). While TNFα robustly 
induced the expression of all inflammatory genes, TNFα-induced CCL2, CCL3, CCL4, 
CCL9, CCL12, and CCL20 were significantly elevated in the presence of DUSP 
knockdown (Fig.5.6). However, TNFα-induced IL-7 mRNA expression was not increased 
with DUSP knockdown (Fig.5.4). As IL-7 was not a downstream target of MAPK 
signaling, these data suggests that DUSPs modulate MAPK-dependent biological 
processes involving AT inflammation.  
 
Discussion 
This study presents empirical evidence that modulatory actions of DUSPs on 
MAPK signaling has a profound influence on biological processes involving MAPK-
dependent regulation of CC chemokine expression under conditions of inflammatory 
stress. First, we show phenotypic differences in inflammatory signaling and basal 
chemokine expression, where MAPK and NF-κB signaling and chemokine mRNA 
expression were markedly greater in PAs compared to ADs. Second, we demonstrate 
that stimulation of PAs with TNFα resulted in the induction of all chemokines examined, 
where most chemokines were inducible in a manner consistent with direct actions of 
TNFα-mediated signaling. Third, we show that inhibition of NF-κB activity partly 
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suppressed select chemokines, while all chemokines were downstream targets of MAPK 
phosphorylation. Finally, we report that increased MAPK signaling duration and 
magnitude with DUSP knockdown resulted in amplification of TNFα-inducible chemokine 
gene expression. Collectively, these data demonstrate an important biological role for 
select DUSPs in the modulation of MAPK signaling and MAPK-dependent biological 
outcome involving CC chemokine expression, highlighting potential therapeutic targets 
regarding decreased macrophage infiltration that links obesity with metabolic 
inflammatory diseases. 
It is well established that TNFα plays a critical role in AT inflammation linking 
obesity with IR (11,12). Cells within AT including PAs, ADs, and macrophages share 
many functions, including the production and secretion of various cytokines and 
chemokines in response to TNFα (5,49,50). Moreover, traits primarily attributed to 
macrophages, such as phagocytosis, have also been shown in PAs (51), while others 
have shown that PAs can trans-differentiate into macrophage-like cells (51). As 
transcriptional profiling studies suggest that macrophages and PAs are genetically 
related (52), other reports demonstrate that the development of new PAs may originate, 
in part, from AT macrophages (53). Data presented in this investigation demonstrate that 
MAPK and NF-κB signaling magnitude was markedly greater in PAs compared to ADs, 
while duration of ERK and JNK signaling was prolonged in ADs in response to TNFα. 
Moreover, the increase in TNFα-mediated p38 phosphorylation in PAs was not observed 
in ADs stimulated under the same conditions. While MAPK signaling magnitude 
highlights the responsiveness of PAs to inflammatory stimulation, the extent of MAPK 
signaling in ADs may be equally important, as others have shown that both JNK 
signaling magnitude and duration influence inflammation and insulin signaling (17). 
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Phenotypic examination of CC chemokine expression further highlights the inflammatory 
nature of PAs, as five of the eight chemokines examined were significantly higher in PAs 
compared to ADs. Collectively, these data demonstrate that PAs are more responsive to 
external inflammatory cues and have a greater inflammatory potential as chemokine 
expression was markedly greater in this cell type. However, prolonged signaling duration 
of JNK and ERK as well as high levels of CCL3 and CCL4 mRNA expression in ADs 
suggests that diverse inflammatory regulation between the different cell types may be 
equally important in AT inflammation and obesity-induced IR.  
Evidence now demonstrates that PAs and hypertrophied ADs secrete increased 
amounts of the chemokine MCP-1/CCL2 (54) that results in macrophage infiltration, 
increased AT inflammation, and IR (3,55). Consistently, macrophage accumulation in AT 
of lean individuals (5-10%) is substantially less than that of obese patients, in which 
macrophage accumulation can make up to 50% of the total number of cells (22). While 
chemokine receptor CCR2 deficient mice have severely impaired macrophage 
accumulation, MCP-1 deficient mice have partial impairment of macrophage 
accumulation (56), suggesting a role for other CC chemokines in macrophage 
recruitment. As other CC chemokines can bind to CCR2, it is plausible that increased 
secretion of MCP-1 and/or other CC chemokines from adipocytes maintain a state of 
chronic AT inflammation (1). This appears evident as several CC chemokines are 
upregulated in genetic and dietary models of obesity, while fractionation of adipose 
tissue from DIO mice demonstrates that CC chemokine expression is primarily secreted 
from isolated adipocytes (21). In this investigation, we showed that five of the eight CC 
chemokines examined were expressed more abundantly in PAs compared to ADs. As 
AT recruitment of macrophages likely represents the major source of elevated TNFα that 
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imparts AT dysfunction by increasing proinflammatory chemokine gene expression in 
PAs and insulin resistance in ADs (17), we further show that all eight CC chemokines 
are induced in response to TNFα-mediated inflammatory stress in PAs. Moreover, we 
report that TNFα-mediated regulation of CC chemokines resulted in different kinetic 
profiles of early (i.e., CCL3, CCL4, and CCL12), prolonged (i.e., CCL2 and CCL20), and 
late (i.e., CCL5, CCL8, and CCL9) induction that may have biological consequences 
regarding chronic AT inflammation. Collectively, these data suggest a cyclical pattern of 
macrophage infiltration and adipocyte inflammation resulting in the chronic inflammation 
associated with obesity.  
The rapid mRNA accumulation observed for early, inducible CC chemokines 
suggests a direct role for TNFα-mediated inflammatory signaling potentially involving 
MAPKs and NF-κB, while the late induction of CCL5 and CCL8 suggest secondary 
mechanisms possibly involving autocrine/paracrine feedback from TNFα-induced 
inflammatory mediators. While cellular signaling cascades play a pivotal role in linking 
external environmental cues like inflammation to cellular outcome such as IR, MAPKs 
are recognized for their innate ability to couple inflammation to macrophage recruitment 
and obesity-induced IR (17). Evidence supports the hypothesis that all three MAPK 
family members may be activated in response to external stress from proinflammatory 
cytokines (24-26). Furthermore, reports demonstrate that MAPK signaling is essential for 
select CC chemokine expression in 3T3-L1 adipocytes stimulated with free fatty acids 
(21). While we demonstrate that pharmacological inhibition of NF-κB significantly 
suppressed select CC chemokines gene expression, we further show that all 
chemokines examined were downstream targets of MAPK phosphorylation. Thus, 
regulation of select CC chemokines by both MAPK and NF-κB pathways suggest that 
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multiple signaling pathways can regulate chemokine expression. However, regulation of 
IL-7 was predominantly downstream of NF-κB and not MAPK signaling, suggesting that 
pharmacological inhibition was target-specific. As macrophages primarily contribute to 
TNFα secretion (57,58), these data suggest that MAPK signaling couples TNFα to CC 
chemokine expression creating a feedback loop involving PA recruitment of 
macrophages, ultimately contributing to chronic AT inflammation.  
Until recently, upstream kinases rather than phosphatases were traditionally 
viewed as major regulators of MAPK signaling. However, evidence now demonstrates 
that DUSPs can modulate and even control MAPK signaling in response to inflammation 
(37). Since the initial identification of dusp1, various DUSPs have been examined as a 
feedback control mechanism governing the production of proinflammatory chemokines 
and cytokines by limiting MAPK activity (37,59-61). DUSP knockout animals lend further 
support to the critical need for these phosphatases in the restraint of the immune 
response during infection, where animals present with an increased proinflammatory 
profile and susceptibility to infection (37,42,43,62). In adipocytes, suppression of dusp1 
and increased activation of ERK leads to increased secretion of MCP-1, while 
adenoviral-mediated overexpression of dusp1 markedly decreased MCP-1, suggesting 
that down-regulation of dusp1 plays a critical role in macrophage recruitment within AT 
(44). In this report, we demonstrate that knockdown of select DUSPs (i.e., dusp1, dusp8, 
and dusp16) significantly increased mRNA expression of CCL2, CCL3, CCL4, CCL9, 
CCL12, and CCL20, concomitant with increased MAPK signaling magnitude and 
duration under conditions of TNFα-mediated inflammatory stress. Moreover, we report 
that DUSP knockdown did not affect TNFα-induced IL-7 mRNA expression. As inhibitor 
data presented above demonstrates that IL-7 was not downstream of MAPKs, these 
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data suggest that DUSP-mediated effects on chemokine expression were MAPK-
specific. Collectively, these data demonstrate that DUSPs act as key regulators of 
inflammatory stress in adipocytes, potentially influencing AT macrophage accumulation 
and inflammation. 
In summary, data outlined here and elsewhere (37,39) demonstrate the 
importance of MAPK phosphorylation/dephosphorylation in the regulation of 
inflammatory signaling and inflammatory status. We show that all CC chemokines were 
induced in adipocytes in response to TNFα, suggesting a role for PAs in macrophage 
recruitment contributing to chronic AT inflammation. As all CC chemokines were 
downstream targets of MAPK signaling, loss of DUSP function resulted in amplification 
of TNFα-induced MAPK-dependent CC chemokine expression. As work on DUSP 
regulation and function continues, elucidation into the function of these phosphatases 
may provide therapeutic targets for the treatment and prevention of obesity-mediated 
inflammatory diseases. 
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Table 5.1.  DUSP and chemokine genes analyzed in this study. 
 
 symbol name/alias     accession ABI number CT 
dual-specificity 
phosphatases 
GP MKB NLS NES    
 Dusp1 
MKP-1, 
hVH1 
I ● ●  NM_013642.3 Mm00457274_g1 24 
 Dusp8 M3/6, hVH5 III ● ● ● NM_008748.2 Mm00456230_m1 32 
 Dusp16 
MKP-7, 
MKP-M 
III ● ● ● NM_130447 Mm00459935_m1 26 
‘CC’ chemokines    
 Ccl2 MCP-1, Scya2 NM_011333 Mm00441242_m1 21 
 Ccl3 MIP-1α, Scya3 NM_011337 Mm99999057_m1 36 
 Ccl4 MIP-1β, Scya4 NM_013652 Mm00443111_m1 34 
 Ccl5 Rantes, Scya5, TCP228 NM_013653 Mm01202428_m1 29 
 Ccl8 MCP-2, Scya8, HC14 NM_021443 Mm01297184_g1 28 
 Ccl9 MIP-1γ, MRP-2, Scya9 NM_011338 Mm00441260_m1 24 
 Ccl12 MCP-5, Scya12 NM_011331 Mm01617100_m1 34 
 Ccl20 MIP-3A, Scya20, exodus-1 NM_106960 Mm00444228_m1 32 
 Ccl20  NM_001159738   
reference gene    
 18S 18 ribosomal RNA X03205.1 4342930E 9 
 
 
 
 
 
 
 
 
 
 
Table 5.1. DUSP and chemokine genes analyzed in this study. DUSPs that contained 
the MAPK binding domain (MKB) were assigned to groups (GP) based on structural 
differences involving the presence or absence of a nuclear localization sequence (NLS), 
nuclear export sequence (NES), or both that may dictate subcellular localization to the 
nucleus (group I), cytosol (group II), or could localize to either compartment (group III).  
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Figure 5.1. Phenotypic differences in MAPK signaling and IkBα 
degradation in response to TNFα. Cell lysates were harvested over 
time from 3T3-L1 preadipocytes (PA) and mature (d8) adipocytes 
(AD) stimulated in parallel with 100 pM TNFα. Phosphorylated state of 
ERK, JNK, and p38 along with degradation of IkBα was assessed in 
both cell lineages by immunoblotting. 
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Figure 5.2. Basal chemokine expression in PAs versus 
ADs. mRNA expression of select CC chemokines was 
measured in untreated PAs (d0) and mature ADs (d8) using 
qRT-PCR. Data were normalized to 18S rRNA and expressed 
relative to untreated PAs (d0). Statistical significance was 
determined by Student’s t-test (* p<0.05).   
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Figure 5.3. TNFα-mediated regulation of chemokine mRNA expression in 
PAs. Total RNA was harvested from preadipocytes stimulated in parallel with 
100 pM TNFα over time and gene expression of select CC chemokines 
analyzed with qRT-PCR. All data were normalized to 18S rRNA and expressed 
relative to unstimulated PAs.   
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Figure 5.4. MAPK and NF-κB signaling mediate TNFα induced chemokine mRNA 
expression. Total RNA was harvested at 1h, 2h, 4h, and 18h post TNFα stimulation in the 
absence or presence of inhibitors for ERK (U0126; 10 µM), JNK (SP600125; 20 µM), p38 
(SB203850; 10 µM), or helenalin (HLN; 10 µM). Nomenclature related to the graph is 
assigned: T (TNFα), T+E (TNFα + U0126), T+J (TNFα + SP600125), T+P (TNFα + 
SB203850), TEJP (TNFα +U0126+SP600125+SB203850), or T+HLN. mRNA was 
assessed for select CC chemokine and IL-7 expression using qRT-PCR and values 
expressed as fold differences relative to untreated PAs. All data were normalized to 18S 
rRNA and statistical significance determined by ANOVA, with Dunnetts post-hoc analysis 
performed to assess differences from control (TNFα) when  p < 0.05. 
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Figure 5.5. Combination DUSP knockdown amplifies MAPK signaling magnitude 
and duration. Preadipocytes were transfected with DharmaFect 3 transfection reagent in 
the presence of 100 nM non-targeting control siRNA or 100 nM siRNA specific for dusp1, 
dusp8, and dusp16 for 72 hours prior to stimulation with 100 pM TNFα. A) Total RNA 
was harvested at d0, 1h, or 2h post-TNFα stimulation and mRNA expression of dusp1 
(1h), dusp8 (1h), and dusp16 (2h) analyzed via qRT-PCR. Data were normalized to 18S 
rRNA and changes in gene expression measured as fold differences relative to untreated 
control siRNA (d0). Statistical differences were determined by ANOVA. Tukey's post-
hoc analysis was performed when the p value for the respective parameter was 
statistically significant (p < 0.05). B) Cell lysates were collected over time post-TNFα 
stimulation for control siRNA or combination DUSP siRNA and protein expression of 
bisphosphorylated ERK, JNK, and p38 along with α-Tubulin examined via 
immunoblotting.  
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Figure 5.6. Combination DUSP knockdown 
significantly enhanced chemokine gene expression. 
Preadipocytes were transfected with DharmaFect 3 
transfection reagent in the presence of 100 nM non-
targeting control siRNA or 100 nM siRNA specific for 
dusp1, dusp8, and dusp16 for 72 hours prior to stimulation 
with 100 pM TNFα. Total RNA was collected at 0h or 2h 
post-TNFα stimulation and mRNA expression of select CC 
chemokines and IL-7 analyzed via qRT-PCR. Data were 
normalized to 18S rRNA and changes in gene expression 
measured as fold differences relative to untreated control 
siRNA (0h). Statistical significance was determined by 
ANOVA, with Tukey's post-hoc analysis performed when 
the p value for the respective parameter was statistically 
significant (p < 0.05). 
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CHAPTER VI 
EPILOGUE 
Data presented in this dissertation represent the first empirical evidence 
demonstrating that regulation of the extent of MAPK signaling by inducible MAPK-
specific DUSPs impacts biological processes downstream of MAPK activation in 3T3-L1 
adipocytes. Findings presented in Ch.2 collectively demonstrated that DUSPs were 
abundantly expressed in adipose tissue (AT) and divergently regulated under conditions 
of genetic and diet-induced obesity that is associated with AT inflammation and insulin 
resistance (IR). Furthermore, data from Ch.3 demonstrated kinetic differences in DUSP 
regulation throughout adipocyte differentiation concomitant with the timely modulation of 
MAPK signaling and adipogenesis, suggesting a role for DUSPs in the development of 
obesity. Finally, findings from Ch.4 and Ch.5, demonstrated an essential role for DUSPs 
on the extent of MAPK signaling and subsequent regulation of MAPK-dependent 
proinflammatory genes involved in macrophage recruitment, AT inflammation, and IR 
under conditions of inflammatory stress. Collectively, data presented in this dissertation 
provide seminal evidence for the regulatory actions of DUSPs on MAPK-dependent 
biological processes within the adipocyte lineage, potentially linking obesity with 
metabolic inflammatory diseases.  
While this dissertation established a role for DUSPs on MAPK signaling, findings 
from the previous chapters, along with other observations made by our lab, have 
generated additional questions for future investigation. These preliminary findings and 
potential areas of focus will be discussed in detail in this chapter. Data presented in this 
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dissertation demonstrated that dusp4 was only induced during early genetic obesity, 
absent of TNFα-mediated inflammation (Ch.2). Consistent with this observation, we 
further observed that that mRNA expression of dusp4 was markedly upregulated during 
mid-stage adipocyte differentiation (Ch.3), concomitant with ERK dephosphorylation and 
peroxisome proliferator-activated receptor γ (PPARγ) induction. Preliminary findings 
from our lab further demonstrated that regulation of dusp4 required the same activators 
of adipocyte differentiation as that of PPARγ. PPARγ is a master regulator of adipocyte-
specific gene expression (1-3). As ERK dephosphorylation is required for PPARγ activity 
and adipocyte differentiation (4), it is plausible that dusp4 modulates ERK 
dephosphorylation critical for adipogenesis. Furthermore, we demonstrated that dusp4 
was suppressed in preadipocytes (PAs) and adipocytes (ADs) under conditions of TNFα-
mediated inflammation (Ch.4). In addition to its role in adipogenesis, suppression of 
PPARγ expression and activity in response  to inflammatory stress results in adipocyte 
dysfunction, consequently leading to decreased triglyceride storage, increased fatty acid 
release, and IR (5). Thus, inflammatory-mediated suppression of dusp4 potentially alters 
MAPK-dependent regulation of PPARγ activity and adipocyte function. An interesting 
addition to the story would be to examine a role for dusp4 on MAPK signaling and 
PPARγ activity in differentiating and fully differentiated adipocytes as well as examine a 
role for this phosphatase under these conditions in response to inflammatory stress. As 
loss of dusp4 may negatively affect PPARγ activity and adipocyte function, in vivo 
investigations of dusp4 knockout animals under conditions of obesity may highlight 
phenotypic changes regarding inflammation and insulin signaling. Future examination of 
dusp4 would ultimately expand our knowledge regarding adipogenesis and adipocyte 
function.      
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We also presented data that demonstrated a role for early inducible DUSPs on 
MAPK signaling during adipocyte differentiation (Ch.3). However, time constraints 
prohibited loss-of-function studies investigating the direct role of these DUSPs 
individually and cooperatively on timely modulation of MAPK signaling and preadipocyte 
replication and differentiation. As transient MAPK signaling during early adipocyte 
differentiation is essential for adipogenesis (6), future examination of the regulatory 
actions of early DUSPs would add to our understanding of early signaling processes 
involved in adipocyte differentiation. In addition to the studies addressing a role for early 
inducible DUSPs during differentiation, examination of the late-stage inducible dusp9 
(Ch.3) also poses interesting questions regarding MAPK signaling and adipocyte 
differentiation. Observations from this dissertation showed that dusp9 was upregulated 
with genetic and diet-induced obesity (Ch.2) and not affected by TNFα-mediated 
inflammation in ADs (Ch.4). While MAPK signaling is suppressed in mature ADs (Ch.3), 
it is conceivable that induction of dusp9 maintains MAPK suppression and therefore 
maintains the adipocyte phenotype. Loss-of-function studies examining dusp9 under 
conditions of differentiation, obesity, and inflammation in vitro and in vivo would add to 
our understanding of the regulatory actions of these phosphatases on MAPK-dependent 
physiological outcomes (e.g., metabolic dysfunction).  
Data highlighted in Ch.3 further showed that dusp1 increased the extent of 
MAPK signaling during early adipocyte differentiation. Preliminary observations from our 
lab demonstrated that mRNA induction of dusp1 during early adipocyte differentiation 
occurred in the presence of methyl-isobutylxanthine (MIX), a component of our 
differentiation cocktail that primarily regulates cAMP/PKA activity and its downstream 
transcription factors, cAMP-response element binding protein (CREB) and 
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CCAAT/enhancer-binding protein β (C/EBPβ) (7,7,8). Subsequently, we observed that 
treatment with the cAMP/PKA inhibitor H-89 led to a marked and significant decrease in 
dusp1 during early adipogenesis, suggesting that cAMP/PKA regulates dusp1 mRNA 
expression. While C/EBPβ is a downstream transcription factor regulated by the 
cAMP/PKA signaling pathway, others report that C/EBPβ regulates dusp1 in other cell 
types (9). However, we observed that loss-of-function did not attenuate dusp1 
expression, suggesting that C/EBPβ does not regulate dusp1. Similar to C/EBPβ, CREB 
is a downstream target of cAMP signaling (7) and a regulator of dusp1 in other cell types 
(10). Preliminary observations from our lab demonstrated that CREB loss-of-function 
significantly increased dusp1 mRNA and protein expression, suggesting that CREB 
indirectly regulates MAPK signaling via dusp1 suppression during early adipocyte 
differentiation. As others report a critical role for CREB in the early regulation of 
adipogenesis (7), future examination of CREB-mediated dusp1 regulation may highlight 
a role for transcription factors on feedback regulation of signaling cascades essential for 
differentiation. Thus, elucidating functional CREB binding sites within the dusp1 
promoter, as well as examining CREB and dusp1 loss- and gain-of-function studies 
would delineate a role for CREB-mediated suppression of dusp1 on MAPK-dependent 
adipogenesis.   
While data presented above generated questions regarding dusp1 mRNA 
expression, other observations from our lab led to questions regarding dusp1 protein 
stability. Preliminary findings from our lab demonstrated that MIX was sufficient to induce 
dusp1 mRNA expression, but protein accumulation only occurred when dexamethasone 
or insulin was present. As ERK has been shown to phosphorylate dusp1 on S359 and 
S364 and stabilize the protein from degradation (11), we examined the role of MAPKs on 
178 
 
dusp1 protein stability. Inhibition with all three MAPK inhibitors, SB203850 (p38), UO126 
(ERK), or SP600125 (JNK) demonstrated a potential role for p38 in the regulation of 
dusp1 protein stability (Fig.6.1), where inhibition led to decreased protein independent of 
gene suppression. Using cyclohexamide to inhibit protein synthesis, we further observed 
that dusp1 half-life markedly decreased with ERK or p38 inhibition during early adipocyte 
differentiation, suggesting that kinase-mediated phosphorylation of DUSPs is essential 
for protein stability. While ERK phosphorylation has been previously shown to stabilize 
dusp1 protein, investigations of p38 remain unknown. Thus, investigations examining 
p38-mediated phosphorylation of dusp1 would increase our understanding of dusp1 
regulation. For instance, is p38 needed for dusp1 stability, and if so, which phospho-
specific site(s) on dusp1 are essential to prevent protein degradation?  
Observations presented above highlight future studies involving DUSPs on 
MAPK signaling during adipogenesis. In this dissertation, we have also identified 
individual DUSPs that markedly increased MAPK signaling and MAPK-dependent 
nuclear events involving cytokine and chemokine gene expression in PAs in response to 
inflammation (Ch.4&5). However, a role for inducible DUSPs on MAPK signaling and 
biological outcome remains unknown in ADs. Loss-of-function examination of DUSPs on 
MAPK signaling and MAPK-dependent processes involving inflammation and IR in ADs 
would prospectively highlight therapeutic targets linking obesity with inflammatory 
diseases. Furthermore, as MAPK activation can influence cellular fate involving the 
regulation of cytosolic or nuclear events, examination of compartmentalized DUSP 
actions in both PAs and ADs would highlight potential therapeutic targets that uncouple 
MAPK signaling in the cytosol (i.e., insulin signaling) from those events in the nucleus 
(i.e., inflammatory gene expression).  
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While we showed that TNFα-mediated inflammation induced individual DUSPs in 
PAs and ADs, we further showed that several DUSPs were suppressed in response to 
inflammation (Ch.4). This observation generated additional questions regarding the role 
of DUSP suppression on MAPK activation and cellular outcome in PAs and ADs in 
response to inflammation. While this dissertation was limited to investigations of 
inducible DUSPs, gain-of-function studies involving suppressed DUSPs would contribute 
to our understanding how phosphatases participate in the balanced regulation of 
phosphorylation/dephosphorylation that is critical in determining cellular outcome. 
Moreover, recent research has shown that the anti-inflammatory potential of 
phytochemicals is mediated in part through the suppression of MAPK signaling in 
response to inflammatory stress (12), while others have shown that DUSPs contribute to 
the MAPK-dependent actions of these phytochemicals (13). Therefore, investigation of 
bioactive food components on the regulation of induced and suppressed DUSPs will 
potentially link anti-inflammatory actions of phytochemicals with MAPK suppression and 
improved inflammatory status and insulin signaling in ADs. 
While most of our future questions developed from observations related to this 
dissertation, other questions regarding DUSPs have developed from other studies 
undertaken in our lab. Recent focus in our lab has begun to address the role of histone 
deacetylases (HDACs) on the epigenetic regulation of MAPK signaling and 
inflammation. Anti-inflammatory actions have been ascribed to HDAC inhibitors in vitro 
and in vivo, mediated in part through select class I and II HDACs (14,15). While many of 
these anti-inflammatory properties appear to be driven by epigenetic regulation of gene 
transcription (16), new evidence suggest that lysine acetylation-deacetylation contributes 
to signaling regulation in part through acetylation-mediated increases or decreases in 
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phosphorylation (17). Furthermore, reports are emerging involving HDAC regulation of 
select DUSPs, where HDACs regulate dusp1 and dusp16 expression in response to 
inflammation (18,19). Preliminary findings from our lab demonstrated that pretreatment 
of PAs with trichostatin A (TSA), an HDAC class I and IIb inhibitor, for 24 hrs markedly 
attenuated p38 and ERK signaling, but not JNK. We further observed that TSA 
pretreatment of <24 hrs did not attenuate MAPK signaling, suggesting a role for new 
mRNA/protein synthesis in the regulation of phosphorylation. Moreover, pretreatment 
with TSA was sufficient to ablate TNFα induction of proinflammatory chemokines and 
cytokines that are downstream targets of MAPK-dependent as well as MAPK-
independent pathways, suggesting that anti-inflammatory actions of TSA are mediated in 
part by MAPK signaling. Based on these preliminary findings, we developed the 
following working model (Fig.6.1), where HDACs mediate MAPK signaling and MAPK-
dependent inflammation through epigenetic regulation of DUSP transcription in response 
to inflammatory stress. 
Data presented in chapters II-V have significantly contributed to the limited body 
of knowledge regarding DUSPs in adipocytes. Use of the murine 3T3-L1 cell line 
provided an excellent model to study DUSP regulation and function, as this cell line does 
not consist of a heterogeneous population of cells (e.g. macrophages, endothelial cells, 
preadipocytes, adipocytes, etc.) allowing us to delineate signaling events in  a 
homogenous population of PAs or ADs. Moreover, our findings have led to ample 
questions for future studies related to DUSPs in adipocytes. It is expected that continued 
examination of DUSPs will provide researchers with a better understanding of signaling 
networks involved in obesity, inflammation, and IR potentially providing therapeutic 
targets for the treatment of obesity-related metabolic inflammatory diseases.  
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Figure 6.1. Working model examining the role of HDACs on MAPK signaling 
through epigenetic regulation of DUSP transcription. 
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